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ABSTRACT  
The main topic of this thesis was to evaluate the relevance of immune-
tolerance dysregulation in the pathogenesis of some haematopoietic disorders 
and for the occurrence of immune pathological complications in chronic 
infection models.  
In Paroxysmal Nocturnal Haemoglobinuria model, we described the 
occurrence of Treg reduction and NKTi increase in untreated PNH patients as 
well as the ability of the Complement blocking monoclonal antibody 
Eculizumab to selectively restore B and NKTi peripheral concentration 
without significant interference on NK and Treg numbers.  
In MyeloDysplastic Syndromes model, the study focused on HLA-E and 
HLA-I molecules, key elements for NK and Cytotoxic T cell recognition. We 
consistently found that a subgroup of Low and Int-1 Risk MDS patients, 
categorised according with their altered immune profile, (low Treg level and 
high CD54 expression on CD8 T cell effectors in BM) showed significant 
decrease of HLA-I expression on peripheral PMN. This observation indicate 
the occurrence of CD8-dependent selection in BM. In addiction, the presence 
of polyclonal NK expansion bearing an activating receptor able to recognise 
HLA-E in BM has been observed to associate with the selection of dysplastic 
precursors lacking HLA-E expression. 
In chronic infection model, as represented by natural infection by 
Leishmania Infantum in dogs we described a significant increase of CTL and 
TH1 cells accompanied by reduction of Tregs. The possibility that such 
condition might be relevant for the occurrence of autoimmune platelet 
deficiency, frequently observed in Leishmania infected dogs has been 
hypothesised. In this model, pharmacological treatment associated with 
administration of a diet supplemented with nutraceuticals selected for their 
potential immune modulating properties and rich in essential fatty acids was 
observed to induce restoration of Treg and a progressive decrease of TH1 CD4+ 
T cells. The possibility that such immune-modulating effects could affect the 
occurrence of immune-mediated platelet deficiency is currently under 
investigation. 
In SOD1 model, we suggested that SOD-1 is part of the network of 
molecules involved in antigen-dependent T cell response. Indeed, we described 
that antigen-dependent activation of human T lymphocytes significantly 
increased extracellular SOD-1 levels in lymphocyte cultures. This effect was 
accompanied by the synthesis of SOD-1-specific mRNA and by the induction 
of microvesicle SOD-1 secretion. Moreover, confocal microscopy showed that 
antigen-dependent activation was able to modify SOD-1 intracellular 
localization in T cells, allowing association of the enzyme with the intracellular 
network of signalling molecules involved in TCR-dependent signal 
transduction processes. The possibility that such observation might indicate the 
involvement of peroxide/superoxide balance in fine tuning of TCR triggering, 
needs further investigation. 
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INTRODUCTION  
 
The Immune System 
The immune system is constituted by cells, tissues and organs and has the 
fundamental role to protect and defend the organism from the disease: this 
occurrence is usually defined as “immunity” and, in more complex point of 
view, such condition is not only related to the defence against infections, but 
also as ability to preserve the homeostasis and health in several non infectious 
disease, like tumours. Therefore, the immunity could be defined as the process 
leading to the preservation of the integrity of an individual from all those 
substances potentially dangerous for the organism, the antigens. The antigen 
may originate from the same organism (self) or from the external environment 
(non-self). 
In order to consent the immunity status, the immune system exerts two 
principal functions in the different species: the humoral and the cellular 
responses. The humoral function is mediated by soluble substances (i.e. 
complement proteins, antibodies, natural compounds, etc), while the cellular 
response is based on the direct activity of immune cells (i.e. macrophage, poly-
morpho-nucleated cells, B and T lymphocytes, Natural Killer cells, etc). Both 
responses have different characteristics and complexities between living 
species.  
In this regard, the immune system can be classified into subsystems or phases: 
the innate and acquired (or adaptive) responses.  
The innate immunity is present in vertebrates and in non-vertebrates and is a 
non-specific immune system that represents the first defence-line in the species 
and is based on cells and some mechanisms, mediated by soluble substances, 
that defend the plants and animals from infections. The cells of the innate 
response recognize and respond to pathogens by using several generic 
mechanisms, whose do not confer a long-lasting protective immunity to the 
host. The recognition of the infectious agents is mediated by several receptors 
encoded by genes that do not undergo any rearrangement to generate variants.  
Adaptive immunity is present only in vertebrates and is a host defence related 
to several specific that specifically recognize the antigens.  
These receptors are encoded by genes that undergo rearrangement to generate 
great diversity, and are expressed by the B and T lymphocytes. This 
rearrangement process is not driven by the infectious agent, but happens by 
genetic programming. 
 
Previously thought to be crude and nonspecific, innate immunity is now know 
to involve a range of receptor families that recognize diverse microbial 
products. Importantly, these receptors program gene expression changes in 
target cells. The products of these genes drive inflammation and are also 
required for adaptive immunity. These protein include cytokines that promote 
activation of B and T cells. Other innate immune proteins have direct 
antimicrobial effects or act as opsonins, coating bacteria and promoting 
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phagocytosis. Innate immunity has therefore gone from being viewed as a 
process lacking sophistication, to a key element for both inflammation and 
adaptive immunity (Paul 2012).  
 
The major principles of the immune response are: 
o Elimination of many microbial agents through the non specific 
protective mechanisms of the innate immune system. 
o Ability of the innate immune system to inform the cells of the adaptive 
counterpart about the appropriateness to make a response and the type 
of response to make. 
o Capability of the cells of the adaptive immune system to display 
exquisitely specific recognition of foreign antigens and mobilize 
potent mechanisms for elimination of microbes bearing such antigens. 
o Memory of its previous responses. 
o Tolerance of self-antigens. 
 
Innate Immune System 
Powerful nonspecific defences prevent or limit infections by most 
potentially pathogenic microorganisms. The epithelium provides both a 
physical barrier to the entry of microbes and produces a variety of 
antimicrobial factors. Agents that penetrate the epithelium are met with 
macrophages and related cells possessing "microbial sensor" that recognize 
key molecules characteristic of many microbial agents. These "pattern 
recognition receptors" include several families of molecules, of which the 
most studied are the Toll-Like Receptors (TLRs) and the Nucleotide 
Oligomerization Domain-like receptors (NOD). Each TLR recognizes a 
distinct substance (or set of substances) associated with microbial agents; for 
example, TLR4 recognizes lipopolysaccharides, TLR3, double-stranded 
ribonucleic acid, and TLR9, unmethylated CpG-containing DNA. The 
interaction of a TLR with its ligand induces a series of intracellular signaling 
events, mainly represented by activation of the NF-kB system. Macrophage 
activation with enhancement of phagocytic activity and induction of 
antimicrobial system aid in the destruction of the pathogen. The induction of 
an inflammatory response as a result of the activation of the innate immune 
system recruits other cell type, including neutrophils, to the site (Paul 2012). 
The main components of this response are: 
o physical and chemical barriers, such as epithelia, mucosal membranes 
and antimicrobial substances they secrete. 
o blood proteins such as the complement system, consisting of plasma 
proteins capable of promoting the killing of microbes and induce a 
inflammatory response . 
o phagocytic cells such as neutrophils and macrophages. 
o natural killer (NK) cells, a subpopulation that recognizes infected 
and/or damaged cells and kills them releasing perforin, a protein that 
creates a pore-channel in the target cells, and granzyme, which induce 
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apoptosis. NK cells also activate the microbial activity of macrophages 
by secreting interferon γ (IFN-γ). 
Innate immunity, mainly due to the activity of NK lymphocytes, also 
contribute to maintenance of tissue integrity. Indeed, according to the 
"missing self" hypothesis, NK are able to recognize the genetically altered or 
damaged cells evaluating the expression of key molecules, related to the 
health status, such as the MHC Class I. 
 
NK Lymphocytes 
NK are a subpopulation of lymphocytes which represents 5-10% of 
circulating lymphocytes: are characterized by the ability to exercise cytotoxic 
functions against virus infected or transformed cells. 
NK cells are larger than B and T lymphocytes and are characterized by 
intracytoplasmic azurophilic granules: for this reason are also called "large 
granular lymphocytes" (LGL). Phenotypically they constitutively express: 
o CD16: low-affinity receptor for the Fc segment of IgG1 and IgG3 
antibodies. 
o CD56 and CD2: adhesion molecules. 
o CD7: signal transduction molecule, also present in haematopoietic 
stem cells and thymocytes. 
There is no antigen that characterizes only NK cells, such as the TCR for T 
lymphocytes or the BCR for the B lymphocytes, in fact, the CD56+ antigen is 
also expressed by a number of cells like neurons, muscles and by a subset of T 
lymphocytes double positive for CD3 and CD56. 
NK activity is governed by two main receptors families: 
Activating receptors 
o Ly49 (homodimers), relatively ancient, belonging to the C-type lectin 
family receptors; represent the receptor for classical (polymorphic) 
MHC I molecules. 
o NCR (natural cytotoxicity receptors), upon stimulation, mediate NK 
killing and IFN-γ release. 
o CD94: NKG2 (heterodimers), a C-type lectin family receptor, is 
conserved in both rodents and primates and identifies nonclassical 
(also nonpolymorphic) MHC I molecules such as HLA-E. Expression 
of HLA-E at the cell surface is dependent on the presence of nonamer 
peptide epitope derived from the signal sequence of classical MHC 
class I molecules, which is generated by the sequential action of signal 
peptide peptidase and the proteasome. Though indirect, this is a way to 
survey the levels of classical (polymorphic) HLA molecules. 
o CD16 (FcγIIIA) playing a role in antibody-dependent cell-mediated 
cytotoxicity; 
Inhibitory receptors 
o Killer-cell immunoglobulin-like receptors (KIRs) belong to a 
multigene family of Ig-like extracellular domain receptors; they are 
present in nonhuman primates and are the main receptors for both 
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classical MHC I (HLA-A, HLA-B, HLA-C) and nonclassical HLA-G 
in primates. Some KIRs are specific for certain HLA subtypes. Most 
KIRs are inhibitory and dominant. Normal cells express MHC class I, 
so are recognised by KIR receptors and NK-dependent killing is 
inhibited. 
o ILT or LIR (leukocyte inhibitory receptors); are recently discovered as 
members of the Ig receptor family. 
o Ly49 (homodimers) have both activating and inhibitory isoforms. 
They are highly polymorphic on the population; Ly49s are receptor for 
classical (polymorphic) MHC I molecules. 
NK effectors represent the guardians of tissue integrity. This condition is 
mainly associated with the expression, on the cell membrane, of high levels of 
MHC class I antigens, especially of non classical MHC molecules, as 
represented by HLA-E. MHC molecules, are mainly involved in antigen 
presentation to T lymphocytes and have been also associated with the control 
of transplant compatibility.  
NK cells are able to recognize virus infected cells, that normally are 
opsonized with antibodies. The Fc portion of the antibodies (IgG1 and IgG3) 
that bind to antigens can be recognised by FcϒRIIIa(CD16) receptors 
expressed on NK cells, resulting in NK activation, release of cytolytic 
granules and consequent cell apoptosis. This mechanism, called Antibody 
Dependent Cell-mediated Citotoxicity (ADCC), is the major killing 
mechanism of some monoclonal antibodies, currently used for therapeutic 
purpose.  
In addition to the cytotoxic activity, the NK cells are critical elements to 
establish a pro-inflammatory environment; indeed, they produce IFN-γ that 
activates macrophages and directs the response of T cells towards a TH1 
profile (Paul 2012). 
 
Adaptive Immune System 
The adaptive immune system, is mainly devoted to sterilize infectious 
environment. It also creates immunological memory after an initial response 
to a specific pathogen; memory response is usually rapid and efficient; it 
controls the pathogen before the establishment of a clinical disease. This 
process of acquired immunity is the basis of vaccination. Adaptive system 
includes both humoral immunity components (mediated by antibody produced 
by B lymphocytes) and cell-mediated immunity components (dependent on 
the T lymphocytes). 
Acquired immunity is triggered in vertebrates when a pathogen evades the 
innate immune system and generates a threshold level of antigen. At this stage 
there is the recruitment, expansion and differentiation of high specific 
lymphocyte clones that modulate their effector activity sterilizing the 
infectious outbreak. 
The major functions of the acquired immune system include: 
o Recognition of specific "non-self" antigens. 
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o Generation of responses that are tailored to maximally eliminate 
specific pathogens or pathogen-infected cells. 
o Development of immunological memory, in which pathogens are 
"remembered" through memory B and T cells. 
Adaptive immunity is characterized by two functional categories, humoral and 
cell mediated response. B lymphocytes recognize native antigens; in this way 
are recruited, proliferate and differentiate into antibody-producing plasma 
cells. 
T lymphocytes are not able to recognize native antigens; they recognize only 
peptides derived from antigen processing by Antigen Presenting Cells (APC) 
such as macrophages, B lymphocytes, dendritic cells, cells of Langerhans, and 
vascular endothelial cells. These peptides, exposed on APC in association 
with MHC molecules, are recognized specifically by the T Cells Receptor 
(TCR). To activate naїve T lymphocytes, are needed, in addition to the 
antigen recognition by TCR (I signal), also a series of signals sent by APC (II 
signal) only after binding of the pathogen with a TLR. Costimulatory 
molecules CD80/CD86 expressed by APC are recognized by CD28 molecule 
expressed by T lymphocytes. This interaction determines the activation of 
cytotoxic (CTL) or helper T lymphocytes (TH).  
MHC molecules are integral membrane proteins highly polymorphic, whose 
NH2-term extracellular region form a pocket in which is located the antigenic 
peptide. These molecules are divided into two classes: the MHC class I and 
MHC class II, which differ in structure and function and are recognized by 
different subpopulations of T cells. Indeed, the cytotoxic lymphocytes (CD8+) 
recognize peptides expressed in association with MHC class I molecules; 
derived by processing of endogenous antigens, such as viral proteins, 
synthesized within the same cell or derived from bacteria and protozoa 
penetrated into the cell cytoplasm. Instead, the helper T cells (CD4+) recognize, 
in association with MHC class II, exogenous antigens that are internalized by 
pinocytosis or endocytosis, processed and finally exposed as peptides on the 
APC. Different types of effector responses can be generated by CD4+ helper T 
cells: TH1, TH2 and TH17 are the most common. The TH1 response is 
characterized by the production of Interferon-gamma (IFN-γ) which optimizes 
the bactericidal macrophages capability, induces the production of opsonizing 
(coating) and complement-fixing antibodies, favours the establishment of an 
optimal CTL response. The TH2 response is characterized by the release of 
Interleukin 4, IL-5, IL-10, IL-13 which results in the activation of B cells to 
make neutralizing non-cytolytic antibodies, leading to "humoral immunity" 
(Paul 2012).  
 
Major Histocompatibility Complex (MHC) 
The major histocompatibility complex (MHC) is a set of cell surface 
molecules encoded by a large gene family which controls recognition ability 
of adaptive compartment in all vertebrates. The major function of MHC  is to 
bind peptide fragments derived from pathogens and display them on the cell 
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surface for recognition by the appropriate T-cell. In humans, the MHC is also 
called the Human Leukocyte Antigen (HLA). 
The MHC gene family is present in the short arm of chromosome 6 and 
extends for 3500 kb thus occupying a large segment of DNA. The frequencies 
of recombination are around 4%. The MHC genes are highly polymorphic and 
have co-dominant expression: each individual expresses both alleles inherited 
from parents, allowing you to express the highest number of MHC 
polymorphisms available. Many different alleles exist in the different 
individuals inside a population. 
The polymorphic regions in each allele are located in the region for peptide 
contact. Of all the peptides that could be displayed by MHC, only a subset 
will bind strongly enough to any given HLA allele, so by carrying two alleles 
for each gene, a much larger set of peptides can be presented. 
On the other hand, inside a population, the presence of many different alleles 
ensures there will always be an individual with a specific MHC molecule able 
to load the correct peptide to recognize a specific microbe. The evolution of 
the MHC polymorphism ensures that a population will not succumb to a new 
pathogen or mutation, because at least some individuals will be able to 
develop an adequate immune response to win over the pathogen. The 
variations in the MHC molecules (responsible for the polymorphism) are the 
result of the inheritance of different MHC molecules and they are not induced 
by recombination, as it is the case for the antigen receptors. 
MHC genes are divided into three subgroups: class I, class II, and class III. 
The latter encoding for molecules other than those which expose the peptide. 
The region of Class I contains the loci that encode for HLA Class I  molecules 
classic (HLA-A, HLA-B, HLA-C) and non-classical (HLA-E, HLA-F, HLA-
G, HLA-H, MIC-A), characterized by limited polymorphism. The HLA class 
II region is in turn divided into 3 loci HLA-DP, HLA-DQ, HLA-DR encoding 
the α and β chains of each molecule of Class II. This region contains genes 
encoding TAP (Transporter Associated with Antigen Processing), the ATP-
dependent transporter of peptides, important for the correct biosynthesis of 
MHC class I molecules. 
The two classes of molecules are expressed differently from the cells of the 
organism: 
o MHC Class I on almost all nucleated cells 
o MHC Class II on antigen-presenting cells, dendritic cells, 
macrophages and B cells; on thymic epithelial cells; on activated 
human T lymphocytes. 
 
The MHC molecules expression is finely modulated during the immune 
response. Several cytokines, such as IFN-α, IFN-β and IFN-γ, induce the 
MHC I increase. The IFN-γ is able to increase the MHC Class II expression 
on macrophages and to induce of MHC class II on cell populations that 
normally do not express them. Cytokines increase expression of MHC 
molecules by gene transcription. 
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Antigen processing is an immunological process allowing antigen presentation 
to T lymphocytes. This process involves two distinct pathways for processing 
of endocellular and extracellular antigens. Both MHC class I and II are 
required to bind peptides to be stably expressed on a cell surface. MHC I 
antigen presentation typically involves the endogenous pathway of antigen 
processing, and MHC II antigen presentation involves the exogenous pathway 
of antigen processing. 
Usually, old or defective endocellular proteins become ubiquitinated and 
marked for proteasome degradation and binding to Class I molecules; in virus 
infected cells, viral proteins gain such pathway allowing the immune system to 
recognize and kill the infected cells. Briefly, proteasome breaks the proteins 
into peptides around nine amino acids long (suitable for fitting within the 
peptide binding cleft of MHC class I molecules). Transporter associated with 
antigen processing (TAP) transports the peptides into the lumen of the rough 
endoplasmic reticulum (ER). Here, a series of chaperone proteins, including 
calnexin, calreticulin, ERp57 and Binding immunoglobulin protein (BiP) 
facilitates the proper folding of MHC class I and its association with β2 
microglobulin. The partially folded MHC class I molecule then interacts with 
TAP via tapasin (the complete complex also contains calreticulin and Erp57). 
Once the peptide is transported into the ER lumen it binds to the cleft of the 
MHC Class I molecule, stabilizing the MHC and allowing it to be transported 
to the cell surface by the Golgi pathway. 
The exogenous pathway is utilized by specialized antigen presenting cells 
(APC) to present peptides derived from proteins that the cell has endocytosed. 
The peptides are presented on MHC class II molecules. Proteins are 
endocytosed and degraded by acid-dependent proteases in endosomes. 
The nascent MHC class II protein in the rough ER have peptide-binding cleft 
blocked by Ii (the invariant chain) to prevent it from binding cellular peptides 
or peptides from the endogenous pathway. The invariant chain also facilitates 
MHC class II export from the ER in a vesicle. This fuses with a late endosome 
containing the endocytosed, degraded proteins. The invariant chain is then 
broken down in stages, leaving only a small fragment called CLIP which still 
blocks the peptide binding cleft. An MHC class II-like structure, HLA-DM, 
removes CLIP and replaces it with a peptide from the endosome. The stable 
MHC class-II is then expressed on the cell surface (Paul 2012). 
 
Immune Tolerance  
The innate immune cells have a Pattern recognition receptors (PRRs), 
broadcast inherited with chromosomes, able to selectively recognize 
molecules  expressed by pathogens (PAMPs). Adaptive cells express a clonal 
receptor (TCR and BCR), generated by processes of gene rearrangement, 
extremely variable, but substantially incapable of directly discriminate "self" 
from "non-self". Therefore, in order to maintain the "self tolerance", the 
immune system have a series of mechanisms to eliminate or inactivate self-
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reactive clones. These processes occur both during lymphocyte development 
and in periphery (Alpdogan and van den Brink, 2012). 
 
T cell development and (central tolerance)  
Lymphoid precursors from the BM migrate to the thymus and then undergo 
differentiation under the control of multiple factors including Interleukin-7 (IL-
7) and Notch-1. Thymocytes develop TCR β- and α- locus rearrangements and 
then start to express CD4 and CD8. This process is controlled by Recombinant 
Activator Gene (RAG) expression. After generation of a complete TCR all 
thymocytes, in order to avoid the occurrence of not functional (unable to bind 
MHC presented peptides) or dangerous self reactive clones, undergo positive 
and negative selection. Thus, the fate of each T cell precursor depends upon the 
ability of its newly rearranged TCR to properly interact with MHC molecules. 
Most MHC molecules display self-peptides and positive selection involves the 
recognition of the MHC-self peptide complex. More than 95% of thymocytes 
do not have any specificity to an MHC ligand and die by neglect. Only the 
small proportion of cells able to bind an MHC ligand with mild avidity will 
complete its maturation process.  
Intra-thymic T cell tolerance occurs via deletion of auto-reactive T cell clones. 
If the TCR has high affinity to self-antigens (self MHC and peptide complex), 
this leads to the deletion of thymocytes by apoptosis. Thymocytes that express 
a low affinity TCR survive and continue to the next maturation step. In the 
last decade a new transcriptional regulator was discovered in the thymus, 
named Autoimmune Regulator (AIRE). AIRE is primarily expressed in 
medullary thymic epithelial cells. It promotes self-tolerance by inducing 
transcription of a wide array of tissue-specific antigens (TSAs) in the thymus 
and plays a critical role in negative selection. In the absence of functional 
AIRE, medullary TECs express a severely restricted array of self-antigens 
which results in severe autoimmune disease (Alpdogan and van den Brink, 
2012).  
 
Peripheral Immune Tolerance 
Negative selection in the thymus effectively deletes thymocytes that have 
high affinity TCR to self-peptide-MHC complexes. Peripheral immune 
tolerance mechanisms are critical for controlling mature T cells with 
low/moderate affinity TCRs to self MHC/peptide complexes. Indeed, small 
amounts of T lymphocytes escape selection in the thymus; these can be 
eliminated in the periphery by deletion, induced anergy and/or suppression by 
other immunologically active cells (regulatory cells/suppressor cells) 
(Alpdogan and van den Brink, 2012).  
 
Peripheral Deletion 
Varying levels of antigenic stimulation of mature T cells in the periphery 
can result in T cell clonal deletion. Moreover, small amount of antigenic 
stimulation can induce T cell tolerance by partial down-regulation of T cell 
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receptors (TCR) on self-reactive CD8+ cells (Alpdogan and van den Brink, 
2012).  
 
T cell Anergy and Costimulatory Signals  
T cell activation requires two signals: i) TCR signal ii) costimulatory 
signal. T cells are not able to mount an immune response without a second 
costimulatory signal. CD28 is the main co-stimulatory receptor and has two 
ligands, B7.1 (CD80) and B7.2 (CD86), that are expressed on APCs (Figure 
1A). CD28 signals are critical for T cell activation, proliferation and survival 
after T cell interaction with APCs. CD28 activation results in increased 
expression of cyclins and cyclin dependent kinases (cdk), downregulation of 
cdk inhibitor cdk27kip1 and upregulation of glucose metabolism through 
phosphoinositol 3-kinase (PI3K) and Akt activation. CD28 controls T cell 
survival by enhancing BCLXL expression in T cells, which prevents T cell 
death from apoptotic signals such as Fas activation or IL-2 withdrawal. 
Activation of T cells in the absence of CD28 results in an anergic state . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Main mechanisms of T regulatory cell function. Treg suppress effector T cell 
function through cell contact (Figure 1A) and inhibitory cytokine and granzyme secretion 
(Figure 1B). T Eff; effector T cells, IDO; indoleamine 2,3-dioxygenase, Trp; Tryptophan, Kyn; 
kynurenines, IFNs; interferons 
 
Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Inhibition of CD28 
Costimulatory Signal 
CTLA-4, a member of the immunoglobulin superfamily has a similar 
structure to CD28. Both molecules bind to CD80 and CD86 on antigen-
presenting cells. CTLA-4 inhibits CD28 dependent T cell activation, cell cycle 
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progression and IL-2 production of T cells. Interestingly, CTLA-4 inhibition 
is more pronounced after initiation of T cell activation and anti-CTLA-4 
antibody activity is optimized with continuous CD28 signaling, suggesting 
that upregulation of CTLA-4 is CD28 dependent. CTLA-4 has a significantly 
higher binding affinity for the B7 molecules than that of CD28 and acts as a 
competitive antagonist of CD28. This inhibitory function of CTLA-4 is 
mediated by its cytoplasmic tail (Alpdogan and van den Brink, 2012).  
 
Programmed Death-1 (PD-1)/PD-1 Ligands 
PD-1 (CD279) is a member of the CD28 family that is expressed on 
activated T, B, and myeloid cells. PD-1 ligands (PD-L1 and PD-L2) are 
expressed on T cells, B cells, antigen-presenting cells, endothelial cells, and 
tumor tissues. PD-L1 (CD274, B7-H1), a transmembrane glycoprotein 
belonging to the immunoglobulin (Ig) superfamily plays an integral role in the 
regulation of immune tolerance and homeostasis. PD-1/PD-L1 interactions 
lead to inhibitory signals, and ligation of PD-1 occurs during autoimmunity, 
allergy, allograft rejection, antitumor immunity, and chronic virus infection. 
PD-1 is expressed on T cells after activation and delivers co-inhibitory signals 
via an immunoreceptor tyrosine-based switch motif in the cytoplasmic domain. 
The ability of PD-1 to block T cell activation requires receptor ligation, 
suggesting that co-localization of PD-1 with CD3 and/or CD28 may be 
necessary for inhibition of T cell activation. PD-1 signals interfere with CD28 
mediated activation of phosphatidylinositol-3-kinase (PI3K) and subsequently 
inhibit interleukin-2 production resulting in an anergic state in T lymphocytes. 
 
CD40/CD40L Pathway 
CD40 and its ligand CD154 (CD40L) are members of the tumor necrosis 
factor (TNF)/TNF-receptor family. CD40 is constitutively expressed on APCs 
such as B cells, macrophages, dendritic cells, and thymic epithelium, but can 
also be found on endothelial cells and fibroblasts. CD154 (CD40L) is 
expressed on activated T cells and NK cells. Signaling through CD40/CD154 
is critical for activation of B and dendritic cells. CD40 ligation leads to 
secretion of IL-1, TNF-α, and IL-12, and to endothelial cell secretion of 
monocyte chemotactic factors. Signaling downstream of the CD40 molecules 
is mediated by TRAFs and leads to the activation of NFκB, which results in 
the upregulation of MHC molecules and co-stimulatory molecules in B cells. 
CD154 is rapidly induced on CD4+ and some CD8+ T cells following T cell 
activation after stimulation with cognate antigen. 
 
Suppression of immune responses: Regulatory Cells 
The suppressive functions of T cells on the immune system has been 
known since the 1970s, but a clear definition of T regulatory cells was not 
achieved until the mid 90s. Regulatory T cells (Treg) play a major role in the 
development of tolerance by suppression of immune responses. Other 
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immunologically active cells can also suppress immune responses including 
NK-T cells, double negative (CD4-CD8-), CD8+CD28- cells, and veto cells. 
 
Regulatory T Cells 
Regulatory T cells were first defined as CD4+CD25+ double positive cells 
with suppressive functions on immunological response in rodents. 
Approximately 5-10 % of peripheral CD4+ cells express IL-2 receptors on 
their surface. The depletion of CD4+CD25+ cells results in development of 
autoimmune disease. 
Normally, the thymus produces immunoregulatory CD4+CD25+ T cells that 
are anergic to TCR stimulation and are able to suppress proliferation of other 
T cells. They might have intermediate affinity to MHC/peptide resulting in an 
escape from negative selection in the thymus. 
Naturally occurring Treg specifically express a transcription factor (Foxp3), 
which is the main inducer, regulator, and survival factor in Treg development 
and function. Only CD4+CD25+ single positive thymocytes exhibit expression 
of Foxp3 in the thymus. Naïve T cells in the periphery can also acquire Foxp3 
expression and suppressive function in conditions such as chronic antigenic 
stimulation in the presence of transforming growth factor (TGF)-β1. TGF-β1 
signaling is required for the maintenance of immune suppressive activity and 
expansion of regulatory T cells. Interestingly TGF-β1 deficient mice have a 
reduced number of peripheral Treg while preserving normal thymic Treg 
development. A defect in TGF-beta-mediated signaling in Treg is associated 
with a decrease in Foxp3 expression and suppressor activity. Other types of T 
regulatory cells can be induced in the periphery in the presence of interleukin-
10 (IL-10), called Tr1 cells. Tr1 cells secrete IL-10 and TGF-β1 and their 
suppressive activities are independent of Foxp3 expression. Both naturally 
occurring Treg cells and Tr1 cells are hyporesponsive to stimulation of their 
TCR but can slowly proliferate in presence of IL-2. Recently, CD8+ Foxp3+ 
Treg have been shown to have a suppressive function in autoimmune 
disorders and after allergen immunotherapy as well as in GVHD. 
 
Function of regulatory T cells 
CD4+CD25+ T cells suppress the proliferation of CD4+ as well as CD8+ T 
cells, which requires direct cell contact with Treg. Survival and function of 
Treg is dependent on presence of IL-2; IL-2 deficient mice develop 
lymphoproliferation and severe autoimmune disease. Expression of IL-2R 
(CD25) on their surface and signaling through IL-2R is required for optimal T 
regulatory function. Treg are anergic after stimulation and therefore, IL-2 
secretion from conventional T cells is critical for development of suppressive 
activity of Treg. The crosstalk between T cell effector and T regulatory cells is 
shown in Figure 1B. On the other hand CD4+CD25+ Treg can secrete IL-10 in 
vivo and autoimmunity can be suppressed by regulatory cells through IL-10 
secretion. Treg interaction with CD80/CD86 through the CTLA-4 molecule 
may lead to suppression of effector T cells. Interaction of CTLA-4 expressing 
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Treg with APCs induces the activation of indoleamine 2,3-dioxygenase (IDO), 
which results in both a local deprivation of tryptophan and the production of 
inhibitory molecules known as kynurenines. CTLA-4 expressing CD4+CD25+ 
regulatory cells show a stronger suppressive activity than their CTLA-4 
counterparts. Moreover, blocking CTLA-4 on Treg can abrogate the 
suppression of T effectors. CD28-deficient CD25+ CD4+ T cells can also 
suppress activation of normal T cells, indicating that CD28 is not required as a 
costimulatory molecule for activation of the regulatory T cells. Treg may also 
act as cytotoxic T cells that expresses granzyme A after activation and are 
able to kill activated CD4+ and CD8+ T cells by a perforin dependent 
mechanism (Alpdogan and van den Brink, 2012).  
 
NKT cells 
These are T cells that recognize highly hydrophobic antigens associated 
with CD1d, a non polymorphic molecule belonging to the conserved family of 
MHC class I-like CD1 genes. NKT cells secrete high levels of IL-4 and IFN-γ 
and their prompt cytokine secretion has been suggested as a key element in 
pursuing specific T cell cytokine profile (Alpdogan and van den Brink, 2012).  
In mice and humans, NKT cells can express a restricted TCR repertoire with 
an invariant TCR alpha and beta chain, V apha 14 and V alpha 24, 
respectively. Recent reports suggest that NKT cells might promote immune 
tolerance through an interaction with Treg, by increasing expression of 
negative costimulatory molecules (like PD-1) on Treg, which is mostly 
dependent on enhanced IL-4 secretion by NKT cells. Their involvement in 
citotoxic mechanisms has been also suggested (Alpdogan and van den Brink, 
2012).  
 
Immune system is involved in tissue homeostasis control. In order to manage 
damage recognition and tolerance maintenance, multiple mechanisms have 
been observed to regulate immune activation processes. Perturbation of such 
complex network might be associated with autoimmune reactions and/or 
damage of tissue homeostasis maintenance.  
 
Bone Marrow failure syndromes 
Syndromes of Bone marrow failure are a heterogeneous group of disorders 
characterized by alterations of the haematopoietic stem cells. These alterations 
deeply compromise the physiological haematopoiesis.  
These syndromes may have a primary ethiopatho-genesis that is dependent on 
genetic alterations intrinsic to haematopoietic stem cell and due to inherited 
germ-line mutations. However, majority of the bone marrow failure, are 
acquired. In this context, the occurrence of damages of the bone marrow stem 
cell, progressively alters its ability to generate a physiological haematopoiesis 
(Figure 2). These disorders are characterized by the inappropriate production 
of peripheral blood cells. The stem cell defect could affect single 
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haematopoietic cell lineage or involve more lineages generating a pan-
cytopenia. 
Several experimental evidences indicates that immune-mediated processes 
may be relevant in fostering the bone marrow failure. In particular, the ability 
to escape immune-mediated attacks could be a determining factor in the 
selection of pathologic haematopoietic precursors, as frequently observed in 
bone marrow failure conditions. (Maciejewski et al. 2007; Luzzatto et al. 
1997; Barrett 2004); syndromes of the bone marrow failure most 
representative are: aplastic anemia (AA) due to widespread bone marrow 
failure; Paroxysmal Nocturnal Hemoglobinuria (PNH) and Myelodysplastic 
Syndromes (MDS) characterized instead by the emergence and dominance of 
mutated or dysplastic haematopoietic clones. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Healthy BM (A) hosts a number of precursors mutated (indicated by circular 
elements green, red, blue) that normally are not used in the processes physiological polyclonal 
haematopoietic. The immune-mediated damage at precursors healthy brings out the 
pathological haematopoiesis (mutated) able to resist the attack immune . In the three cases 
mentioned (B-D) emerge precursors characterized by different genetic defects (red, green or 
blue) , based on the ability of specific resistance to auto-immune damage occurred . 
 
 
Paroxysmal Nocturnal Hemoglobinuria (PNH) 
Paroxysmal Nocturnal Haemoglobinuria (PNH) is a complex acquired 
haematological disorder characterised by the emergence of a haematopoietic 
precursor bearing somatic mutations of the phosphatidyl-inositol glycan-A 
(PIG-A) gene (Rotoli and Luzzatto 1989; Luzzatto and Bessler 1996; Bessler 
et al. 1994; Takeda et al. 1993; Kinoshita et al. 1995).  
This gene codifies for the glycosil-phosphatidil-inositol (GPI) structure and the 
cells carrying these PIG-A mutations lack the expression of proteins needing 
this molecule for their membrane anchoring (Miyata et al. 1993; Rosse and 
 19 
Ware 1995). Defective clonal haematopoiesis develops trough several lineages, 
along with a residual normal haematopoiesis thus accounting for the mixed 
(GPI+ and GPI-) phenotype commonly present in the peripheral blood of PNH 
patients (Rotoli and Luzzatto 1989; Bessler et al. 1994; Rosse 1993; Hillmen et 
al. 1995).  
PNH is characterized by clinical manifestations such as severe haemolytic 
anemia, thrombophilia and cytopenia, with increased susceptibility to 
infections (Rotoli and Luzzatto 1989; Rosse and Ware 1995; Rosse 1992 ; 
Ortolan et al. 2006). The disease is associated with serious complications 
usually represented by thrombosis involving hepatic, abdominal and brain 
vessels. Mortality is highly frequent (Luzzatto and Bessler 1996; Luzzatto 
2006). 
The lack of the GPI-linked molecules CD55 (DAF) and CD59 (MIRL), 
involved in the protection of red cells from the lytic attack of activated 
complement fractions (Wilcox et al. 1991), causes a chronic haemolysis with 
capricious exacerbations. Platelet surface activation by small amounts of 
complement and urokinase plasminogen activator receptor (uPAR) deficiency 
(Gralnick et al. 1995; Hall et al. 2002) might explain thrombophylia. However, 
the origin of the underlying bone marrow failure is still unknown (Rotoli and 
Luzzatto 1989; Luzzatto et al. 1997; Karadimitris et al. 2000; Risitano et al. 
2002).  
GPI-defective clones have been identified in healthy individuals (Rosti et al. 
1997; Araten 1999; Karadimitris et al. 2000) and Pig-a KO chimeric mice are 
unable to mimic a PNH syndrome (Risitano et al. 2002; Greenberg et al. 2002). 
These observations strongly suggest that an isolated PIG-A mutation is 
insufficient to account for the clonal dominance of the GPI-defective clone and 
for the development of PNH. The possibility that some extrinsic selective 
pressure could favour the preferential expansion of the GPI-defective clone has 
been hypothesised (Luzzatto et al. 1997; Karadimitris et al. 2000; Guidetti et al. 
2004). In this context, the absence of GPI-linked proteins might provide the 
GPI-defective clone with a survival advantage in a background that impairs 
normal haematopoieis. A relationship between PNH and Aplastic Anaemia 
(AA), whose autoimmune origin is generally accepted, has been reported, 
(Rotoli 1998; Luzzatto 2000) while other and our data suggest the critical 
involvement of immune–mediated mechanisms for the clonal dominance of the 
GPI-defective compartment (Terrazzano et al. 2005),  
 
PNH onset may be characterized by fatigue, pallor and occasional 
emission of dark urine in the morning, while thrombosis, infections and bone 
marrow failure are the clinical features of advanced disease. 
Therapy is based on blood transfusion  to correct anemia. Anticoagulant drugs 
are frequently used to control the thrombophilia. Highly hypoplastic disease is 
treated with immuno-suppressive approach and bone marrow transplantation. 
Clinical management of PNH has been completely revolutionized by the 
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introduction of drugs to suppress the activity of the complement (Hillmen 
2006). 
The complement system is an essential element in the defense against 
infectious agents. It is constituted by several circulating proteins and cell 
membrane ligands, each other interacting and leading to the microrganism 
lysis and to the optimization of the inflammatory processes. The bactericidal 
function of complement is expressed by the formation of a peculiar "pore-
channel", namely membrane attack complex or MAC, at the surface of cell 
membrane of the target: it generates the colloid-osmotic collapsing of the 
target cell , and, therefore, the cell destruction (Ricklin D et al. 2010). 
 
Complement activation is a cascade sequentially activating the various 
complementary components that circulate in an inactive form. There are three 
distinct pathways of complement activation: the classical pathway, which is 
stimulated by the binding of antibodies to the pathogen surface;, the lectin 
pathway and the alternative pathway. Pathways converge in the formation of 
an enzyme, the C3 convertase, which cleaves the complement component C3 
into C3b and C3a. Several proteins on normal host cells inhibit complement 
activation and this event minimizes the harmful effect that the complement 
could have against self (cells, tissues and organs). The CD55 and CD59 
proteins are involved in regulating complement activation. They are linked to 
cell membrane via a GPI anchor. Therefore, CD55 and CD59 are defective in 
the cells derived from haematopoietic stem cell, carrying a mutation 
inactivating the PIG-A gene. 
The two pathways, classical and alternative, convey to the formation of two 
different complexes, C4b-C2b and C3b-Bb, but with an identical function: to 
cleave C3 into two fragments, C3a and C3b, and to bind to C3b constituting 
the C5 convertase. C5 convertase cleave the C5 into two fragments, C5a 
which remains in solution by carrying out important functions pro-
inflammatory and C5b that binds to the cell membrane. The remaining 
components of the complement cascade (C6, C7, C8, C9) devoid of 
enzymatics activity, bind to the cell membrane set in the lipid layer of the cell 
wall. The last component of the cascade, the C9, has the ability to polymerize 
at the point where it is inserted by forming pores in the cell membrane of 
about 100A°. Through the pores produced by the polymerization of C9, the 
water and the ions have free access to the inside of the cell by determining 
first the colloid-osmotic collapsing and then lysis. The molecule GPI-linked 
CD59 or MIRL is able to regulate the formation of MAC. 
 
Traditionally, the complement system has been considered as a first line of 
defense against microorganisms, able to contain rapidly growth, in order to 
give time adaptive immunity to act appropriately, sterilizing the infectious 
outbreak. The current acquisitions highlighted that the complement is able to 
orchestrate the immune response as a whole, extending its activities far 
beyond the simple elimination of the pathogen. Indeed, the complement 
 21 
system participates to several process as, the antigen-antibody complexes 
elimination , angiogenic processes regulation , the haematopoietic precursors 
mobilization, the lipid metabolism modulation as well as the modulation of 
the adaptive response both humoral and cell-mediated. 
A new therapeutic approach for patients with PNH involves the use of the 
humanized monoclonal antibody Eculizumab, produced by recombinant DNA 
technology. Eculizumab is an anti-C5 and therefore blocks the cleavage of C5 
into C5a and C5b, preventing the formation of the terminal complex C5-9 on 
GPI- cells devoid of CD55 and CD59, insensitive to complement-dependent 
lysis. 
Considering its large size is neither eliminated by renal filtration or urine, but 
it breaks down into small peptides and amino acids by lysosomal enzymes. 
In the evaluation of the effectiveness, several clinical studies have shown that 
this therapy reduces or eliminates the need for transfusion and determines a 
significant improvement in quality of life in PNH patients (Risitano et al. 
2010). 
Given the extremely broad role that the complement plays in the regulation of 
physiological status, a study of the effects of a therapeutic block of 
complement is of great importance. 
Complement functions are not limited to amplification of inflammatory 
process, it also acts in the apoptotic cells removal, in inhibiting fibrinolysis, in 
regulating B and T lymphocytes interactions and differentiation (Ricklin et al. 
2010). 
  
In this context, we examined the effect of Eculizumab treatment on innate and 
adaptive immune effectors in a cohort of 34 PNH patients also investigating 
whether complement inhibition might interfere with the selection/expansion of 
the GPI-defective haematopoiesis. (Alfinito et al. 2012) 
 
Myelodysplastic syndromes (MDS) 
Myelodysplastic Syndromes (MDS) are clonal haematopoietic disorders 
characterised by ineffective haematopoiesis accompanied by 
expansion/dominance of dysplastic haematopoietic clones and frequent 
development of Acute Myeloid Leukaemia (Heaney and Golde 1999). They are 
a heterogeneous group of diseases mainly characterised by an active but 
ineffective, often clonal haematopoiesis. Peripheral blood cytopenias combined 
with dysplastic changes in a hyper-cellular bone marrow represent the hallmarks 
of MDS (Corey et al. 2007). In this regard, there is a very significant clinical 
variability in MDS.  
The presence of normal polyclonal precursors able to maturate in vitro is 
accompanied by the emergence of the dysplastic population. Aetiology of MDS 
is still unclear. Genetic changes have been suggested to cause stem cell 
alteration with perturbation of the multistep processes involved in the control of 
cell proliferation, differentiation and apoptosis induction.  
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Moreover the growth advantage of the dysplastic, often clonal 
haematopoiesis, could be hypothesised to be also dependent on damaging 
mechanisms preferentially affecting the normal counterpart in the bone marrow 
microenvironment.  
Stem cell defects, cellular and cytokine-mediated stromal lesions and 
immune-mediated mechanisms have been suggested to be involved in the 
pathogenesis of MDS and in their clinical evolution. Multiple parameters like 
chromosomal changes, bone marrow blast cells number and the presence of 
multiple cytopenias appear to be useful in predicting the survival and 
transformation rate in MDS patients.  
The possible relevance of immune-dependent mechanisms for the 
selection/shaping of the dysplastic stem precursor in MDS needs to be 
addressed. 
A number of data have been suggesting that immune-dependent mechanisms 
are relevant for the selection, expansion and dominance of dysplastic clone/s, at 
least in a subgroup of MDS patients (Stern et al. 2007; Sloand et al. 2008; 
Ruggiero et al. 2009). Aberrantly activated, likely auto-reactive, oligoclonal T 
cell populations have been suggested to suppress polyclonal haematopoiesis by 
direct damage of stem progenitors as well as by releasing cytokines (IFN-γ, 
TNF-α) and other factors inducing extensive apoptotic response in stem cells 
and progenitors. Thus, it is possible to hypothesise that, in such group of 
patients, a defect in tolerance control could be relevant in the selection of 
pathological clones and in fostering their leukaemia progression.  
Several trials of immune-suppressive therapy have been performed in the 
last ten years, based on the evidence concerning the involvement of immune-
mediated events in MDS pathogenesis. Majority of them employed anti-T 
lymphocyte sera (ATG) with or without Cyclosporine A. Response rate varied 
widely (0-66%), rarely exceeding 30%. Younger age, Low Risk group of IPSS 
classification and presence of the HLA-DR15 allele were proposed as useful 
criteria to predict clinical response to immune-suppression in MDS (Sloand et al. 
2008). Identification of the mechanisms underlying the immune-mediated MDS 
pathogenesis is expected to be of critical relevance to propose new biological 
targets for innovative immune modulating approaches in MDS.  
 
Characteristics, Classification criteria and Therapeutic approach in MDS 
In order to classify MDS patients the French American British Group 
(FAB) has suggested criteria that takes account of the different morphological 
features found in the periphery and the BM. This group proposed the division 
into five subgroups of the disease: refractory anemia with ring sideroblasts 
(RARS); refractory anemia with excess blasts (RAEB; 5-20% marrow blasts); 
refractory anemia with excess blasts in transformation/RAEB-t; 21-30% 
marrow blasts); chronic myelomonocytic leukemia (CMML). 
The grading of MDS is defined by the WHO classification 2008 that includes 
five groups nosographical also characterized by a different prognosis: 
refractory cytopenia with unilineage dysplasia (RCUD); refractory anemia 
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with ring sideroblasts (RARS); refractory cytopenia with multilineage 
dysplasia (RCMD) with or without ring sideroblasts; refractory anemia with 
excess blasts (RAEB 1-2; 5-20% marrow blasts); myelodyplastic syndromes-
unclassified (MDS-U); MDS associated with isolated del(5q). 
A proper assessment of the probability of leukemic evolution can be obtained 
by calculating the IPSS which is a "prognostic score" based on three variables 
(number of marrow blasts, cytogenetic abnormalities, number of cytopenias); 
this assessment allows splitting the MDS in four risk categories (low, int-1, 
int-2, high) (Malcovati et al. 2007; Garcia-Manero 2012). Recently a more 
detailed classification of recurrent cytogenetic abnormalities in MDS has led 
to the redefinition of "prognostic score" (RIPSS); currently it recognizes five 
categories of risk (very low, low, intermediate, high, very high) in which are 
also better defined the "cut off" for the evaluation of cytopenias. 
The therapy is based on the index of risk and considers two groups of 
patients: those with low risk (low and Int1) and those at high risk (Int2 and 
high). In the first group the therapeutic aim is the correction of cytopenias: the 
increase of the cell number is achieved through the use of erythropoietin and 
when you lose the effect of the cytokine by regular transfusion therapy; 
currently the use of growth factors for granulocytes and platelets is not yet 
allowed, thus it is recommended a careful prophylaxis against infectious for 
neutropenia and appropriate supportive treatment for thrombocytopenia. 
Patients with 5q-syndrome represent a separate category because they show 
good response to lenalidomide, an immune-modulating agent. Immuno-
suppressive therapy with anti-lymphocyte serum and/or cyclosporine is 
reserved for those cases where it is most obvious he occurrence of a 
autoimmune noxa (young patients with MDS hypoplastic, HLA-DR15 
positive). In patients in the high risk group the therapeutic goal is the 
elimination or containment of the dysplastic clone; therapies are: the 
allogeneic bone marrow transplantation (only in patients under the age of 
sixty years, with family donor), methylating agents and cell growth inhibitors 
(Fenaux et al. 2009). 
 
Pathogenic mechanisms in PNH and MDS: the immune-mediated 
hypothesis 
Different data suggest that common pathogenic mechanisms can underlie 
hematopoietic disorders characterized by emergence and dominance of 
defective or dysplastic clones, as PNH and MDS. 
In this regard, the pathogenic role of an immune-mediated attack directed 
against autologous hematopoietic stem cells and/or bone marrow 
mesenchymal elements has been suggested. This attack, resulting in 
destruction of physiological polyclonal haematopoiesis, could exercise a 
significant selective pressure for the emergence of resistant clones, also 
fostering their leukaemia progression. The research team I joined in order to 
develop my PhD project has been investigating such hypothesis.  
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Main results obtained by our research Team: the Hematopoiesis disorder 
model 
Regarding the PNH model, data obtained by our group (Terrazzano et al. 
2005) have shown that clonal expansion of GPI-defective precursors is 
accompanied by an altered GPI+ T lymphocyte counterpart. Indeed, the GPI+ 
T lymphocytes show clear signs of hyperactivity with significant functional 
persistence of CD154 after TCR triggering. Such an attitude, already observed 
in autoimmune diseases, as Systemic Lupus Erythematosus (Koshy et al. 
1996) suggests that dysregulation of immune-mediated mechanisms, able to 
control the self-reactive response, is relevant for the expansion and dominance 
of the GPI- defective clones in PNH (Terrazzano et al. 2005). 
These observations were further confirmed by the study of HLA gene 
expression, widely considered as an important factor for susceptibility to auto-
immune diseases (Spurkland and Sollid 2006). The hypothesis is that certain 
HLA alleles are able to preferentially bind peptides derived from autologous 
proteins, allowing their T cell recognition. In this context, our studies 
(Lombardi et al. 2008) have shown, in PNH patients, a significant increase in 
the frequency of alleles of class I A*0201 (p<0.05), B*1402 (p<0.001) and 
Cw*0802 (p<0.005), the alleles of class II DRB1*1501 (p<0.01) and 
DRB1*01 (p<0.05) and an increase of more than four times of the frequency 
of the Class I haplotype B*1402, Cw*0802 (p<0.0005), and fifteen times of 
the ancestral Mediterranean haplotype A*33, B*1402, Cw*0802, DRB1*0102, 
DQB1*0501 (p<0.005). These data suggest the presence of multiple 
associations that engage both T helper cells (association with class II alleles 
DRB1*1501 and DRB1*01), as well as cytotoxic T cell presentation 
(association with alleles of class I A*33, B*1402, Cw*0802). 
NK cells are critical components of innate immune response. The 
possibility that NK cells might directly participate in PNH pathogenesis has 
been proposed, but it is still controversial. Indeed, it was suggested that the 
inability by GPI- cells to express (GPI-linked) stress-related molecules might 
protect the PNH progenitors from NK effectors recognition, raising the 
question of the mechanisms underlying the interdependence of T and NK-
mediated selection of GPI-defective clone(s) (Luzzatto et al. 1997; 
Karadimitris et al. 2000; Gargiulo et al. 2007; Terrazzano et al. 2005; Poggi et 
al. 2005). 
NK activity is dependent on dynamic balance between activating and 
inhibiting signals. A key component of such regulatory network is represented 
by KIR. KIR genes are highly polymorphic, with individual genes exhibiting 
allelic variability and individual haplotypes differing in gene content. 
Combination of KIR and HLA genes has been associated with autoimmunity, 
viral infections, reproductive failure and cancer.  
A number of data indicate that NK cells can drive, shape and regulate 
adaptive immune compartment. In a study (Cosentini et al. 2012) done by our 
group has been investigated the frequency of KIR genes and of their known 
human leukocyte antigen (HLA) ligands in 53 PNH Italian patients (almost 
 25 
the half of all the Italian PNH patient population). The results showed an 
increased frequency of genotypes characterized by ≤2 activating KIR and by 
the presence of an inhibitory/activating gene ratio ≥3.5. In addition, a better 
match between KIR-3DL1 and its ligand HLA-Bw4 has been found. These 
genotypes may be associated with a lower NK-dependent recognition of self 
molecules related to stress. This is conceivable with the hypothesis that 
increased availability of specific molecular targets, not eliminated by NK cells, 
for T cell effectors could be involved in the pathogenesis of PNH. 
 
In MDS model, the study also focused on the hypothesis that immune-
mediated mechanisms may be pathogenetically relevant to the expansion and 
dominance of dysplastic clones being MDS. For this purpose, were recruited 
50 MDS patients, classified according to WHO and IPSS criteria in Low Risk 
(N = 27, Int-1 Risk (N = 16, Int-2-High Risk (N = 7), and 12 healthy donors. 
The study allowed us to: 
A. To identify a single clinical case, in which dysregulation of the NK 
response was related to the selection and progression of a myeloid dysplastic 
clone characterized by a severe deficiency in the expression of the molecule 
HLA-E, a critical element in regulating the cytotoxic NK response (Ruggiero 
et al. 2009) In this patient, NK effectors, which expressed high levels of the 
receptor CD94/NKG2C (an activating receptor recognizing HLA-E) were able 
to lyse PMNs, but not autologous monocytes (both defective for HLA-E) due 
to highe expression of HLA Class I molecules on dysplastic monocytes.  
 
B. To identify subgroups of MDS patients, in stage Low Risk and Int-1 Risk, 
in which a peculiar immune profile was correlated with the intensity of bone 
marrow impairment of polyclonal physiological erythroid compartment 
(Alfinito et al. 2010). Indeed, the analysis of the patient cohort allowed the 
identification of a subgroup of MDS patients characterized by low Treg levels 
and high CD54 expression on the CD8+ T population in Bone Marrw (BM). In 
these patients the pathogeneic relevance of immune-mediated mechanisms 
might be inferred. In the later stages of the disease, the leukemic progression 
was observed to result in an increase of Treg cells in BM, likely able to inhibit 
anti-tumor cytotoxic response. In this context, the measurement of the levels 
of Treg in BM could represent, in groups Low Risk and Int-1 Risk patients, a 
useful addition to the pathogenetic classification of the patients. Moreover, the 
possibility that the criteria described by us can contribute to the selection of 
sub-groups of patients likely susceptible to immune-modulating therapies 
represents an intriguing experimental hypothesis.  
 
Infectious Disease Model: Leishmania infantum natural infection and 
immune profile of infected host 
Canine Leishmaniosis (CL) is a zoonotic disease potentially fatal to humans 
and very common in dogs that are the main reservoir of infection for humans. 
CL is caused by the protozoan parasite Leishmania infantum in the 
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Mediterranean area (Baneth et al. 2008) and is usually transmitted by blood-
feeding phlebotomine. Several immune responses and clinical manifestations 
have been described in CL (Ciaramella et al. 1997). In this regard, clinical 
appearance and evolution of leishmaniosis appear to be the consequence of 
complex interactions between the parasite and both the genetic and 
immunological backgrounds of host animals (Baneth et al. 2008; Maia and 
Campino, 2011).  
Several studies pointed out that lymphocyte level in sick dogs is decreased 
but returns to normal values after treatment (Moreno et al., 1999; Guarga et 
al.,2002; Guerra et al., 2009); an increased number of CD4+T cells in dogs with 
low parasitism (Reis et al., 2006) has been also referred. Furthermore, the 
number of CD4+ T cells in peripheral blood was observed to be similar in dogs 
with leishmaniasis and in healthy dogs while there was no correlation between 
the clinical status or response to therapy and CD4+ T cell counts (Miranda et al. 
2007). The results obtained highlight the complexity of the immune response to 
L. infantum infection.  
Control of the immune response in human and murine leishmaniasis has 
been observed to largely depend on the production of interleukin-10 (IL-10), 
which can come from several different cell types (Kaye and Scott, 2011). In 
human visceral leishmaniasis (VL) reports on the frequency and function of 
Tregs are not conclusive. Recently, Maurya et al. (2010) reported that active 
CL is not associated with increased frequencies of peripheral Foxp3 Treg or 
accumulation at the site of infection. In veterinary medicine, Tregs have been 
observed to significantly increase in dog tumour models (Biller et al., 2007; 
Houriuchi et al., 2009; O’Neill et al., 2009; Rissetto et al., 2010). Few studies 
addressed the level of regulatory cytokines interleukin-10 (IL-10) and the 
transforming growth factor beta (TGF-β) (Strauss-Ayali et al., 2007; Boggiatto 
et al., 2010) in CL. The study of Treg involvement in the regulation of dog 
immune-response against Leishmania needs further investigation. Indeed, IL-
10 producing regulatory T cell subsets have been described to be relevant in 
the early phase of visceral leishmaniasis in mouse model of L. infantum 
infection (Rodrigues et al., 2009), while a reduction in lymphnode Treg was 
described to significantly correlate with immune protection consequent to 
Leishmune vaccination (de Lima et al., 2010). 
Different treatment protocols and prognoses have been suggested for the 
clinical stages of CL (Solano-Gallego et al., 2009). The combination of N-
methylglucamine antimoniate (75–100 mg/kg/SID or 40-75 mg/kg/BID) for 4–
8 weeks, S.C. with allopurinol (10 mg/kg/BID) is considered as the most 
effective therapy and constitutes the first line protocol against the disease. 
Therapy with allopurinol alone should be continued for 6 months (Mirò et al., 
2009) or for one year, as currently recommended (Solano-Gallego et al., 2009; 
Torres et al., 2011; Paradies et al., 2012). The association of Miltefosine with 
allopurinol and Amphotericin B represents the second and the third lines in CL 
therapy (Solano-Gallego et al., 2009). Clinical response varies from poor to 
good, depending on the animal’s overall initial clinical status and on its 
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individual response to therapy. Dogs with renal insufficiency could manifest a 
lower recovery rate in comparison to the animals without kidney impairment or 
with mild proteinuria. Therapy with anti-leishmaniosis drugs often leads to 
clinical recover (Noli and Auxilia, 2005), although treated dogs may continue 
to harbour the parasite (Ribeiro et al., 2008; Mirò, Galvez, Fraile, Descalzo, & 
Molina, 2011). Majority of sick dogs obtain clinical amelioration within the 
first month of therapy (Pennisi et al., 2005). The clinical parameters to be 
monitored during treatment depend on the individual abnormalities (Solano-
Gallego et al., 2009).  
The critical relevance of host immune response in CL outcome has been 
largely demonstrated (Baneth, Koutinas, Solano-Gallego, Bourdeau, & Ferrer, 
2008; Reis et al., 2009; Solano-Gallego et al., 2009; Alexandre-Pires et al., 
2010; Coura-Vital et al, 2011). The involvement of Tregs is of critical 
relevance in the presence of infectious agents usually associated with chronic 
diseases, as in CL. Occurrence of Treg modulation represents an useful 
mechanism to optimise immune response against the infection, since Treg 
regulate the recruitment and activation of immune effectors (Sakaguchi, 2005).  
During CL, Treg activity could hamper inflammatory responses required for 
infection clearance. This occurrence exacerbates the risk that the unbridled 
parasite growth could lead to a severe disease. However, Treg recruitment is 
necessary to prevent the onset of severe immune-mediated mechanisms in 
infected tissues, particularly for the presence of autoimmune processes highly 
frequent in CL (Kharazmi et al. 1982; Ferrer, 1992; Terrazzano et al., 2006; 
Solano-Gallego et al., 2009; Cortese et al., 2009 and 2011). 
It is worth noting that the unbalanced diet and malnutrition represent 
primary causes of immune suppression and has been demonstrated to be a 
major risk factor for the development of visceral leishmaniosis in human and 
animal models (Anstead et al., 2001; Malafaia, 2009; Carrillo et al., 2014; 
Mengesha et al., 2014). Energetic/metabolic status has been described to 
regulate immune response and immune tolerance in human and animal models 
(Matarese et al. 2005; Gerriets & Rathmell, 2012). Furthermore, the pathways 
that control immune cell function and metabolism are intimately linked and 
this relationship might intriguingly provide new strategies to modulate immune 
functions in several infectious diseases.  
In this regard, the role of some biological principles (mainly derived from 
plants), referred as “nutraceuticals”, in modulating the immune system 
homeostasis (Andlauer & Furst, 2002) needs to be investigated. In this context, 
Cucumis melo, Aloe vera, Punica granatum, Piper nigrum, Camellia sinensis, 
Ascophyllum nodosum, Grifola frondosa, Glycine max, Echinacea purpurea, 
Poligonum spp, Carica papaya and Curcuma longa have been described to 
mediate several immune-modulating effects (Mujumdar et al. 1990; Barak et al. 
2002; Inoue et al. 2002; Kodama et al. 2002; Barrett 2003; Lee et al. 2008; Butt 
and Sultan, 2009; Dhasarathan et al. 2010; Liu et al. 2010; Buttle et al. 2011; 
Kim et al. 2011; Sakarkar and Deshmukh 2011; Halder et al. 2012; Kim et al. 
2013; Senthikumara et al. 2013). Anti-oxidant properties have been described 
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for Cucumis melo, Carica papaya and Curcuma longa, astaxanthin from 
Haematococcus pluvialis as well as for poly-unsaturated fatty acids derived 
from fish oil. Piper nigrum, polyphenols from Camellia sinensis, β-glucans 
from Grifola frondosa and Glicine max extract have been associated with the 
modulation of inflammatory pathways (Devasagayam and Sainins 2002; 
Vouldoukis et al. 2004a,b; Galli and Calder, 2009; Barros et al. 2012). 
Punicalagin, the most important active substance contained in the fruit of 
Punica granatum, exerts an immune suppressant activity (Lee et al. 2008). 
Poligonum cuspidatum extract, source of Resveratrol, in humans induced a 
significant reduction in the generation of reactive-oxygen species and can 
suppress plasma concentrations of pro inflammatory factors like TNF-α, IL-6, 
and C-reactive protein (Ghanim et al. 2010). 
In order to investigate the immune regulatory networks involved in CL 
control, we focused the immune profile of dogs naturally infected by L. 
infantum. In particular, lymphocyte T cell subsets, peripheral Treg levels and 
the presence of pro-inflammatory T cells have been assessed, in a cohort of 45 
Leishmania infected dogs (LD), compared with 30 sex/age matched healthy 
animals, by using immune fluorescence and flow cytometry detection. In this 
study, Leishmaniotic dogs have been categorised according to their clinical-
pathological status and their serological anti specific-Leishmania antibody titer. 
Subsequently, we focused on the potential immune-modulating activities 
of specific nutraceutical pet food containing anti-inflammatory and anti-
oxidant nutrients, described above. In this study, was analyzed the immune 
profile of a cohort of 40 Leishmania infected dogs treated with conventional 
therapy associated with standard diet (20 animals) or a diet enriched with 
essential fatty acids and nutraceuticals with described immuno-
stimulatory/antioxidants characteristics, mainly derived from medicinal plants 
(20 animals). A cohort of 20 healthy animals age/sex matched with the 
infected dogs has been also included in the study as control population. 
(manuscript submitted for publication).  
 
T lymphocyte activation and Super Oxide Dismutase (SOD)1 
involvement: ROS and adaptive immune response regulation 
T lymphocytes play a critical role in the orchestration of both the immune 
response and immune tolerance. Their activation is a complex phenomenon in 
which intracellular signals mediated by the TCR engagement are integrated by 
accessory signals able to finely tune antigen-dependent triggering. In this 
context, TCR-mediated signalling is a critical event for proper channelling the 
immune response and to obtain pathogen control and self-tolerance (Fraser I 
D and Germain R N 2009). Several studies have suggested that the production 
of small amounts of Reactive Oxygen Species (ROS) characterizes many 
receptor systems of human cells. In this context, TCR-dependent T cells 
activation has been associated with the production of ROS. This phenomenon 
involves several enzymatic sources as the mitochondrial respiratory chain 
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(Sena et al. 2013), lipooxygenases, NADPH oxidase NOX2 and DUOX1 (Los 
et al. 1995; Jackson et al. 2004). 
TCR stimulation generates both H2O2 and superoxide anion and 
antioxidant enzymes specific for H2O2 enhance and/or prolong TCR-
dependent ERK activation (Jackson et al. 2004; Devadas et al. 2002). ROS are 
highly reactive chemical species with a very short life; for example H2O2 (1 
minute half-life). They are constituted by an atom with an unpaired electron 
which makes the extremely reactive radical, as capable of binding to other 
radicals or subtract an electron to other neighboring molecules. ROS include 
superoxide oxygen (O2-), hydrogen peroxide (H2O2), hydroxyl radical and 
peroxides. Generally ROS production in mammalian cells is associated with 
the presence of metabolic products or apoptotic signals. In some cells of the 
innate immunity ROS produced by NADPH oxidase (NOX), are used in the 
defense against pathogens. 
Recent studies have shown that the ROS generation is relevant for a series 
of physiological systems, interactions receptor/ligand such as TGF-β 
(Thannickal et al. 2000), insulin (Mahadev et al. 2001), angiotensin (Ushio-
Fukai et al. 1998) and EGF (Bae et al. 1997). ROS formation has proved 
essential to optimize the signal transduction pathways by acting as a second 
messenger regulating several crucial cellular responses, as protein kinase 
activation, gene expression and cell proliferation/apoptosis rate (Burdon 1996). 
Ros are able to cause cellular damage of various nature; in fact, may act on 
the fatty acids, on proteins and nucleic acids. Oxidative damage is controlled 
by a series of enzymatic mechanisms scavenger capable of interfering with 
the mechanisms of the cascade of reactions activated by the radicals: 
o superoxide dismutase which converts superoxide anion into hydrogen 
peroxide and molecular oxygen 
o catalase which converts the hydrogen peroxide into water and molecular 
oxygen 
o glutathione peroxidase which eliminates peroxides at the expense of 
glutathione. 
Superoxide dismutase molecules belongs to a large family of isoenzymes 
oxido-reductases. The type of metal which binds SOD identifies the different 
enzymatic forms. The form is constituted by the enzyme cytosolic SOD bound 
to copper (Cu) and zinc (Zn) and is known as SOD1. SOD-1 is a homodimer 
of molecular weight 32,500 Da, in which the sub-units are linked via 
hydrophobic interactions and electrostatic while the two cofactors are linked 
to de side chains. The Mn SOD (SOD-2) is localized at the level of the 
mitochondrial matrix; tetrameric Cu,Zn SOD (SOD-3) is localized 
extracellularly. 
ROS production has been observed to be involved in the physiological 
regulation of antigen-dependent signal transduction. At light of this, the 
availability of SOD-1, that is able to modulate cytosolic superoxide and 
peroxide level could behave as a possible adjustment for specific targeting of 
proliferation and/or apoptosis in immune effectors.  
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SOD-1 may be relased in vitro by fibroblasts, hepatocytes (Mondola et al. 
1996), human neuroblastoma cells (Mondola et al. 1998) and Sertoli cells 
(Mruk et al. 1998). The extracellular release of such enzyme is related to 
specific stress conditions (Ookawara et al. 1998). ER/Golgi involvement in 
SOD-1 secretion has been described (Turner et al. 2005; Urushitani et al. 
2006; 2008), while it is unclear how this cytosolic protein con be targeted into 
the ER/Golgi network.  
Studies conducted by our research group showed that SOD1 plays a key 
role in mediating the response to oxidative stress in primary lymphoid organs 
such as the thymus, where were detected significant levels of SOD-1 
especially in medullary area, critical for the selection of T lymphocyte 
repertoire (Cimini et al. 2002). In the study of 2002 was also detected the 
ability of human epithelial thymic cells of releasing the SOD1 by a 
mechanism of active secretion, in response to mild stress represented by the 
deprivation of nutrients. Further, the group has focused on the possibility that 
SOD-1 may be involved in paracrine control of oxidative stress in other 
human biological systems particularly susceptible to oxidative damage, such 
as neurons. In the work of 2003, it has been characterized SOD-1 role in the 
neuronal secretion mechanism, using the human neuroblastoma cell line SK-
N-BE. The data obtained have revealed that the SOD-1 is secreted by a 
microvesicular pathway sensitive to pharmacological block from Brefeldin-A, 
2-deoxy-D-glucose and sodium azide. Thus, the SOD-1 secretion could 
represent a significant phenomenon for the neuronal maintenance, probably 
able to influence the excitability of cells extremely sensitive to perturbations 
(Mondola et al. 2003). 
In order to highlight a possible paracrine role of SOD-1, (Mondola et al. 
2004) the ability of the enzyme to directly interfere with human 
neuroblastoma cell line SK-N-BE has been analysed. Data indicate that SOD-
1 may interact specifically with the membrane of SK-N-BE cells, mobilizing 
intracellular calcium and protein kinase C (PKC). The SOD-1 activity seems 
to depend to phospholipase C (PLC) pathway, since the effects are sensitive to 
block by U73122, a specific inhibitor of PLC. Some experimental data 
indicate that SOD-1 is not constitutively expressed: in fact, in the cell line SK-
N-BE derived from neuroblastoma, it is possible to observe the increase of the 
intracellular SOD-1, after exposure to oxidative stress.  
Taken in all, these results suggest the involvement of SOD-1 in the 
regulation of complex biological events. The possibility that the enzyme might 
be involved in multiple regulatory pathways involving adaptive immune 
response and its functional effectiveness needs to be investigated in different 
physiological and pathological models. 
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AIMS  
The aim of this work is to investigate whether immune-tolerance 
dysregulation might be involved in the pathogenesis of haematopoiesis 
disorders and in the immune-pathological effects consequent to chronic natural 
infections. The mechanisms underlying such involvement and the possibility to 
specifically modulate such effects by targeting immune-metabolic pathways 
and ROS production has been also addressed. 
The first model allowed us to identify some immune-mediated mechanisms 
underlying emergence, expansion and dominance of pathological 
haematopoietic precursors in PNH and MDS patients. 
In this model we are proposing that specific alterations of immune profile 
in BM could identify a subgroup of MDS patients in which an immune-
mediated pathogenesis of the disease might be inferred. Indeed, low Treg 
levels and high expression of CD54 on CD8 effectors in BM has been 
consistently associated with the selection of dysplastic precursors expressing 
low level of MHC Class I molecules, the key recognition element for cytotoxic 
T cells. 
In addiction, in selected patients the expansion of NK effectors expressing 
high levels of NKG2C receptors has been associated with the selection of 
dysplastic precursor lacking HLA-E expression. 
The above described studies indicate the key role of Treg population for 
immune tolerance control in MDS model as well the possible involvement of 
polyclonal NK expansion in some specific conditions.  
A number of studies has been suggesting that mTOR (mammalian Target of 
Rapamicine), a key sensor of nutrient availability in the extra-cellular 
microenvironment, plays a major role in orchestrating immune cell 
differentiation and haematopoietic Proliferation/Quiescence transition. A 
specific involvement of mTOR-dependent mechanisms in the expansion of 
Treg population has been also largely demonstrated. (Battaglia et al. 2012; 
Procaccini et al. 2010). The possibility to specifically target such pathways by 
metabolic (diet) and/or pharmacological approaches has been also addressed 
taking advantage from a chronic infection model represented by Leishmania 
Infantum natural infection in dogs, usually complicated by the occurrence of 
autoimmune platelet deficiency.  
The immune response regulation includes the ability to integrate signals. 
This integration is physiologically exerted by the availability of accessory 
molecules capable of finely tune the plasticity of T lymphocytes response. 
Superoxide dismutase (SOD) belongs to a family of isoenzymes involved in 
the scavenging of oxygen radicals to hydrogen peroxide (H2O2) and molecular 
oxygen. TCR stimulation has been observed to generate balanced production of 
H2O2 and superoxide anion. In this context, the possible involvement of 
cytosolic SOD-1 in intracellular signalling network regulating TCR-dependent 
immune response in both physiological and pathological settings (Terrazzano, 
Rubino et al. 2014) might be hypothesized. The possibility that SOD1 targeting 
might allow specific modulation of T cell response needs further investigation. 
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MATERIALS AND METHODS  
 
Paroxysmal Nocturnal Haemoglobinuria (PNH)  
Patients 
The study was conducted in 34 Italian PNH patients. Diagnosis was made 
according to International PNH Interest Group Criteria (Parker et al. 2005). All 
patients showed primary haemolytic PNH with a large GPI-defective 
granulocyte population (CD66b− and/or CD59− granulocytes >50%). No 
patients showing bone marrow failure with emergence of PNH clones (i.e. 
Aplastic Anaemia/PNH syndrome or Hypoplastic PNH) were enrolled in the 
study (Brodsky 2008). Notably, some of the patients were on Eculizumab 
treatment for more than 48 months. Biological samples were collected by 
venipuncture according to standard procedures and used within the 3 h from 
the collection. Informed consent was obtained in accordance with the 
Declaration of Helsinki, as approved within the study protocol by the 
Institutional Review Board at the Federico II University of Naples. Patients 
were studied at diagnosis, before any treatment; 17 of them were retested after 
at least six months of Eculizumab therapy; 14 patients were tested at least three 
times before and after Eculizumab treatment. None of PNH patients received 
immune-suppressive therapies or other treatments potentially interfering with 
immune responses. 
 
Immunofluorescence and flow cytometry 
Blood samples from patients and controls were analyzed by 
immunofluorescence and flow cytometry by using a two laser equipped 
FACScalibur apparatus and the CellQuest analysis software (Becton 
Dickinson). FITC, PE, Cychrome and APC labelled mAbs against CD3, CD4, 
CD25, FoxP3, CD45, CD8, CD16, CD56, NKTi, CD19, CD20, CD45 and 
isotype-matched controls were purchased from Becton Dickinson PharMingen, 
San Jose, CA. All phenotypes referred to flow cytometry analysis of the 
lymphocyte population gated by using FSC and SSC parameters, as well as 
CD45 labelling. We choose to evaluate T, B, NK, NKTi and Treg populations.  
 
Statistical analysis 
Statistical evaluation of data, by using software InStat 3.0 (GraphPad Software 
Inc., San Diego, CA, USA), has been performed by means of the Mann-
Whitney test. Comparisons in the paired samples were evaluated by means of 
the Wilcoxon matched-pairs signed-rank test. Two-sided p values of less than 
0.05 were considered to indicate statistical significance and were not adjusted 
for multiple testing. 
 
MyeloDysplastic Syndromes (MDS) 
Patients and controls 
We examined whole BM and peripheral blood (PB) specimens of 30 MDS 
patients belonging to Low Risk and Int-1 Risk groups. BM and PB sample 
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collection, haematological investigation, cytogenetics were performed 
according to the WHO recommendations and IPSS score (Greenberg F  et al. 
1997; Malcovati L et al. 2005). 17 patients belonged to Low Risk Group (4 
refractory anaemia, RA, 8 refractory cytopenia with multilineage dysplasia, 
RCMD, 2 refractory neutropenia, RN, 3 refractory thrombocytopenia, RT), and 
13 to Intermediate-1 (Int-1) Risk Group (2 RA, 8 RCMD, 3 RN). BM and PB 
samples from MDS patients were obtained during routine diagnostic 
procedures. Informed consent was obtained from each individual patient. Local 
Ethical Committee approved the study. None of the patients has been receiving 
medical treatments that could have an impact on their immune condition. 
Patients were devoid of immune-mediated diseases and acute or chronic viral 
infections to avoid any interference on immuneregulatory mechanisms. A 
group of 26 healthy blood donors were recruited in the study as controls. All 
the MDS patients were clustered in two sub-groups, according to their BM 
Treg levels and CD54 expression on BM CTL, as described (Alfinito F et al. 
2010). Briefly, 14 MDS patients showing a Treg percentage in BM ≥ 2% of the 
lymphocyte population or a ratio <10 between the mean intensity fluorescence 
(MIF) for CD54 on BM CD8 T cells and the control MIF value, obtained after 
staining of the same cell population with the isotype control mAb, were 
considered with normal immune profile (NIP). At variance, 16 MDS patients 
showing a Treg percentage in BM<2% of the lymphocyte population or a 
ratio≥10 between the mean intensity fluorescence (MIF) for CD54 on BM CD8 
T cells and the control MIF value obtained after staining of the same cell 
population with the isotype control mAb, were considered with altered immune 
profile (AIP). 
 
mAb, immunofluorescence, and flow cytometry 
FITC, PE, Cychrome and APC labelled mAb against CD3, CD4, CD8, CD56, 
CD19, CD10, CD25, CD45, CD54 and isotype-matched controls were 
purchased from BD PharMingen (San Jose, CA). Biotin labelled HLA-E mAb 
clone MEM-E/07, FITC labelled MHC-I mAb clone W6/32 and PE labelled 
avidin, were purchased from Sigma–Aldrich, Milan, Italy. To analyse Foxp3 
expression, intracellular staining was performed by anti-human Foxp3 kit 
(eBioscience San Diego, USA), following the manufacturer’s instructions. 
Treg subset was identified as the high CD25 expressing CD4+CD3+ 
population appearing as a tail, with a slightly but reproducible lower CD4 
expression, distinct from the major CD4 population containing both the CD25 
low and negative cells (Alfinito F. et al., 2010). These cells were observed to 
express Foxp3 at a percentage >98%, as described (Alfinito F. et al., 2010). All 
phenotypes referred to flow cytometry analysis of the lymphocyte population 
gated by using forward scatter (FSC) and Side Scatter (SSC) parameters, as 
well as CD45 labelling. Flow cytometry and data analysis were performed by a 
two laser equipped FACScalibur apparatus and CellQuest software (Becton 
Dickinson). 
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Statistical analysis 
BM and PB values were compared in the paired samples by means of the 
Wilcox on matched-pairs signed-rank test. Comparisons between MDS patients 
and controls were performed by Mann–Whitney test. The corrected p value (pc) 
was calculated by applying Bonferroni adjustment for multiple comparisons. 
 
Case report 
An 85-year-old man presented with thrombocytopenia, whose first record was 
referred to few months before. Hb was 12.9 g/dL, MCV 67fl, white blood cell 
count 4.4 X 109/L with 0.15 X 109/L neutrophils, 0.096 X 109/L monocytes, 
and 0.166 X 109/L lymphocytes. PMN appeared hypogranular and monocytes 
highly dysmorphic. Platelet count was 80 X 109/L. BM aspirate was 
characterized by good cellularity with erythroid and granulocytic dysplasia, 
numerous micromegakaryocyte and 5% of blast cells. Patient received 
diagnosis of refractory cytopenia with multilineage dysplasia according to 
WHO classification (Mufti GJ et al. 2004). Microcytosis was due to beta 
thalassemia, and no organomegaly was present. Patient showed a normal 
karyotype (46,XY). Patient has been not receiving medical treatment, which 
may impact his immune response. Informed consent was obtained from the 
patient and the controls. 
 
mAb, immune fluorescence and flow cytometry 
Anti-CD3, -CD8, -CD4, -CD54, -CD25, -CD56, -CD14, -CD45, -CD33,-
CD127, -p140 (Q66 clone) and isotypematched labeled controls mAbs 
(Becton-Dickinson, Los Angeles, CA, USA), anti-HLA-I (W6/32 clone) mAb 
(SIGMA, Milan, Italy), anti-HLA-E mAb (MEM-E/08 clone) (Immunological 
Sciences, Rome, Italy); anti-CD158e1/e2 (p58.1/2), -CD244 (2B4), -CD335 
(NKp46), -CD337 (NKp30), anti-NKG2A (Z199), -Vb14, -Vb12, -Vb7.2, -
Vb20, -Vb18, -Vb7.1, -Vb22, -Vb13.2, -Vb1, -Vb17, -Vb5.3, -Vb5.1 -Vb23, -
Vb4, -Vb2, -Vb13.1, -Vb5.2, -Vb8, -Vb9, -Vb11, -Vb3, -Vb13.6, -Vb21.3F, -
Vb16 mAbs (Beckman-Coulter, Paris, France), and -NKG2C (134591 clone) 
mAb (R&D System, Minneapolis, MN, USA). Flow cytometry was performed 
by FACSCalibur and CellQuest analysis software (Becton Dickinson), as 
described (Ruggiero G et al. 2009; Alfinito F et al. 2010; Terrazzano G et al. 
2013). Three sex- and age-matched healthy donors were used as controls. 
 
Statistical analysis 
Statistical analysis for p calculation was performed by using Student’s t-test. 
Results were considered significant with a p value < 0.05. 
 
L. infantum.chronic natural infection in dog model 
First study 
Animals 
Forty-five dogs naturally infected by L. infantum (20 males and 25 females, 5-9 
years old) from the Campania region (South Italy) were enrolled with the 
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owner’s consent. Ten dogs were pure breed, while 35 were mongrels. Also, 30 
healthy dogs (12 males, 18 females, 5–7 years old) with no clinical signs of CL, 
which were also being negative for serological, parasitological and molecular 
examinations, were considered as healthy control group. 
This work has been reviewed by Ethical Animal Care and Use Committee of 
the University of Naples Federico II and received institutional approval (Prot. 
2011/0043885). 
 
Clinical parameters and diagnostic procedure 
For all dogs, the history (none of dogs received a specific treatment for CL) 
and the clinical examination were performed. Leishmania infected dogs were 
classified according to (Solano-Gallego et al. 2009). The LD cohort has been 
categorised in two groups: LD-A dogs (n =23), presenting neither clinical signs 
on physical examination nor clinical-pathological abnormalities by routine 
laboratory tests (CBC, biochemical profile and urinalysis) but with a confirmed 
L. infantum infection and LD-S dogs (n=22) with clinical leishmaniasis, 
presenting clinical signs and/or clinical-pathological abnormalities and a 
confirmed L. infantum infection. Diagnosis of CL has been confirmed by 
detection of amastigotes in stained cytological smears of aspirates from lymph 
nodes or bone marrow, serologically by a positive indirect fluorescent antibody 
test (IFAT ≥1:80) and by a polymerase chain reaction (PCR). Animals 
presenting IFAT titers ≥1:80 and positive molecular diagnosis were included in 
the study as infected animals. 
The relevance of humoral immune response on susceptibility/resistance 
mechanism during ongoing canine visceral leishmaniasis has been recognized 
throughout ex vivo and in vitro investigations (Oliva G et al. 2006; Reis AB et 
al. 2006). Thus, in order to analyse the immune profile in Leishmania infected 
animals showing different degree of specific immune activation, Leishmania 
infected dogs were further sub-classified as Low IFAT titer animals (LD-L) 
when showing a IFAT titer 1:80–1:160 or High IFAT Title animals (LD-H) 
when showing a IFAT titer >1:160. 
Animals presenting neither clinical signs on physical examination nor 
clinical-pathological abnormalities by routine laboratory tests, and with IFAT 
negative (≤1:40) and negative PCR, were considered non-infected and included 
as healthy control group. Occurrence of other infectious diseases was always 
excluded in all dogs. No Ehrlichia canis nor Anaplasma phagocytophilum 
morulae, Babesia canis trophozoites and microfilariae were observed in 
peripheral blood smears. These infections were also excluded using IFAT 
and/or PCR. Finally, Dirofilaria immitis infection was ruled out using the Snap 
Canine Combo Heartworm Antigen Antibody Test (IDEXX). 
 
Blood sample collection 
Ten millilitres of peripheral blood was collected from the jugular vein into 
tubes containing ethylene diamine tetraacetic acid (EDTA). A complete cell 
blood count was performed in each sample within 30 min from the collection 
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by using a semi-automatic cell counter (Genius S; SEAC Radom Group, 
Florence, Italy). All samples were maintained at room temperature up to 5–6 h 
prior to processing. In addition, serum aliquots were obtained from all the dogs 
enrolled for the study of their biochemical profile and serological examination. 
Serological diagnosis Detection of anti-Leishmania IgG antibodies was 
performed by an in-house IFAT assay using L. infantum promastigotes (WHO 
reference strain MHOM/TN/1980/IPT-1) as antigen and following the protocol 
recommended by the Office International des Epizooties (Gradoni L and 
Gramiccia M, 2008). Samples were classified as positive if promastigote 
cytoplasmatic or membrane fluorescence was observed at a serum dilution of 
1:80 or higher. 
 
Molecular diagnosis 
To perform a nested-PCR assay for Leishmania spp. DNA was obtained from 
bone marrow. In 4 animals, due to lack of bone marrow specimens, lymph 
nodes aspirates and peripheral blood were used as DNA source for nested-PCR 
assay.  
 
Monoclonal antibodies, immunofluorescence and flow cytometry 
Peripheral blood from each dog was employed as whole blood sample to 
evaluate the number of CD3+CD4+, CD3+CD8+ and CD4+- Foxp3+ T cells 
by immune-fluorescence technique and flow cytometry analysis. Fluorescein 
isothiocyanate (FITC), Phycoerythrin (PE), Cy-chrome and Allophycocyanin 
(APC) labelled monoclonal antibodies (mAb) against dog CD3, CD4, CD8, 
and isotype-matched controls were purchased from Serotec Ltd, London, UK. 
Intracellular detection of Foxp3 was performed using a cross-reactive, directly 
conjugated murine Foxp3 antibody (Clone FJK-16s, eBioscience, San Diego, 
CA) and the permeabilisation buffer provided by the detection Kit (Foxp3 
Staining Set, eBioscience), as described (Biller B.J. et al., 2007). Foxp3 
staining was carried out on Peripheral Blood Mononuclear Cells (PBMC) 
purified by Ficoll (Sigma–Aldrich, St. Louis, MO) density gradient 
centrifugation, as described (Biller BJ et al. 2007). CD8+ and CD4+ T cell 
subsets were always identified by a combination of canine specific anti-CD3 
together with anti-CD4 or anti-CD8 mAbs. A typical phenotype analysis 
strategy is shown in Figure 8. 
To analyze the production of IFN-γ and IL-4, purified PBMC were cultured 
overnight (ON) in presence of Phorbol 12-Myristate 13-Acetate (PMA) and 
Ionomycin, all purchased from Sigma–Aldrich. This approach has been widely 
described as useful in the study of established cytokine profile in human and 
animal models (Terrazzano G et al. 2005; Papadogiannakis EI et al. 2009; 
Olsen I and Sollid LM, 2013). Intracellular staining with the mAbs recognising 
dog IFN-γ, IL-4 or isotype-matched controls (Serotec) was performed by a 
fixing/permeabilization kit (Caltag, Burlingame, CA), following the 
manufacturer’s instructions. To avoid extracellular cytokine export, the 
cultures were incubated in the presence of 5 µg/ml of Brefeldin-A (Sigma–
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Aldrich), as described (Terrazzano G et al. 2005; Papadogiannakis EI et al. 
2009). 
All phenotypes referred to flow cytometry analysis of the lymphocyte 
population gated by using Forward Scatter (FSC) and Side Scatter (SSC) 
parameters, as well as CD45 labelling. Flow cytometry and data analysis were 
performed by using a two laser equipped FACScalibur apparatus and the Cell 
Quest analysis software (Becton Dickinson, Mountain View, CA). 
 
Statistical analysis 
Statistical analysis was performed by Mann–Whitney test (GraphPad Prism, 
San Diego, CA, USA). Results were considered significant at p < 0.05. 
 
Second study 
The diets. 
Two groups of dogs (see next paragraph) were fed with two industrial dry pet 
foods. Both diets were based on the same receipt and completely fulfil the 
recommendations for protein, carbohydrate and fat in order to obtain a 
complete food for a daily ration in dog (as reported in Nutritional Guidelines 
for complete and complementary pet food for cats and dogs by The European 
Pet Food Industry Federation). In particular, the two foods reported similar 
analytical composition in nutrients (24% of crude protein, 12% of crude oils 
and fats, 3.7%, of crude fibre 5% of crude ash, 9% of moisture) and, as a 
consequence, similar Metabolised Energy (ME) of 3.477 kcal/kg corresponding 
to 14.6 MJ/kg. Both foods are commercial and in the form of kibbles 
industrially produced with extrusion technique. The potential immune-
modulating diet was composed by two mixed components: kibbles, included in 
the ideal percentage of 93-94% in weight, and cold-pressed tablets at the 6-7% 
in weight of complete food (European patent n.EP 2526781). Overall nutrient 
profile of the product was obtained by the sum of a first nutrient profile of the 
kibbles, for feeding purpose, and a second nutrient profile of the tablets for 
both nutrient and therapeutic purposes. Tablets were composed by 60-80% of 
protein hydrolisated (fish and vegetable ones), 20-40% of minerals used as 
glidants and were added by therapeutical substances (Ascophyllum nodosum, 
Cucumis melo, Carica papaya, Aloe vera, Astaxanthin from Haematococcus 
pluvialis, Curcuma longa, Camellia sinensis, Punica granatum, Piper nigrum, 
Poligonum spp, Echinacea purpurea, Grifola frondosa, Glycine max, Omega 3 
and Omega 6 un-saturated fatty acids from fish oil). The dry pet food used as 
control diet did not contain the above-mentioned active substances. 
The standard and the nutraceutical supplemented dietary administration 
were carefully adjusted to provide similar caloric animal food intake and to 
satisfy the nutritional requirement of adult dogs. In this regard, the food was 
administered twice a day according to the specific requirements for the nutrient 
amount. To guarantee the maintenance energy requirement, food dosage was 
established using a daily dietary table based on the equation 130 kcal ME/kg of 
Body Weight0.75 as recommended by the National Research Council Committee 
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on Animal Nutrition, USA. The coefficient used referred to a moderate activity. 
The two commercial products used in this trial completely respect the 
nutritional guidelines established by European Pet Food Industry Federation to 
provide all nutrients necessary for a canine diet.  
 
Animals and study design 
Forty dogs naturally infected by L. infantum (20 males and 20 females, 5-9 
years old) from the Campania region (South Italy), which is a CL endemic area, 
were enrolled with the owner consent. Ten dogs were pure breed (4 German 
Shepherds, 4 Rottweilers and 2 Labrador Retrievers), while 30 were mongrels 
(15 females and 15 males, between 20 and 35 kg in weight). The study was 
performed on household dogs under the biweekly supervision of the 
veterinaries from the Department of Veterinary Medicine and Animal 
Productions. Animals were allocated to two groups. Group 1 was composed of 
20 dogs treated with meglumine antimoniate (50 mg/kg, subcutaneous, twice 
daily, for 1 month), allopurinol (10 mg/kg, oral, twice daily, for 6 months) and 
fed with standard diet. Group 2 included 20 dogs subjected to the same 
therapeutic treatment combined with the administration of a diet with potential 
immune-modulating activity (see previous paragraph). Animals were equally 
distributed for breed, sex, weight and clinical signs in the two groups. 
Immune profile evaluation was performed at diagnosis (T0) and after three 
(T3), six (T6) and twelve (T12) months of trial in all the animals. As controls, 
20 healthy dogs (12 males, 18 females, 5-7 years old) were enrolled. The full 
blood count, total proteins, albumin/globulin ratio, urea and creatinine value 
determinations and immune profile analysis were evaluated at T0, T3, T6 and 
T12. In addition, at T0 and T12, both indirect fluorescence antibody test 
(IFAT) and sternal bone marrow aspirate for Leishmania DNA detection by n-
PCR were performed.  
 
Clinical evaluation of dogs  
History and clinical examination were performed with the accuracy of 
guideline criteria for CL diagnosis and classified according to Solano-Gallego 
et al. (2009). No dog received a specific treatment for CL before the enrolment. 
Dogs were monitored for clinical signs correlated to other illnesses potentially 
occurring during the trial. Clinical recovery was evaluated at T3, T6 and T12 
and was based on the reduction/disappearance of clinical signs listed in the 
inclusion criteria. At the beginning of the study (T0) and during the follow-up 
(T3, T6 and T12), the dogs were evaluated for their weight by five-point body 
condition score (BCS). Enrolled dogs were of medium body weight of 27+2 kg 
while the BCS, which assesses the nutritional status, ranged from 2.75 to 2.90. 
 
Monoclonal antibodies, immunofluorescence and flow cytometry 
See above in the same session referred to the first study. 
 
Statistical analysis  
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Statistical analysis was performed by One-way Analysis of Variance 
(ANOVA) Tukey-Kramer Test for Multiple Comparisons using GraphPad 
Prism Software (GraphPad Prism Inc, San Diego, CA, USA). Results were 
considered significant at p<0.05. 
 
T lymphocyte activation and SOD1 involvement 
Cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from 10 healthy 
donors, after informed consent, by centrifugation of peripheral blood on Ficoll-
Paque cushion (GE Healthcare, Uppsala, Sweden) gradient. T cells have been 
isolated from PBMC by using a negative isolation kit (Invitrogen Corporation, 
Carlsbad, CA, USA) and following the manufacturer's instructions. PBMC or T 
cells (1×106/ml) were cultured in 96 well flat-bottomed plates (Falcon) in 
RPMI 1640 medium with 2% FCS (Invitrogen, Carlsbad, CA, USA). TCR 
triggering was performed by anti-CD3 mAb (Becton Dickinson, Mountain 
View, CA, USA) at 5 ng/ml or by using anti-CD3/anti-CD28 beads 
(Invitrogen), at 0.3 bead/cell. This activation strategy has been largely 
demonstrated to mimic antigen-dependent T cell triggering. To analyze TCR-
dependent SOD-1 T cell export, distinct experiments were performed in the 
presence of Brefeldin-A, (BFA) at 5 µg/ml or of 1 mM methylamine, all 
purchased from Sigma-Aldrich (Milan, Italy), as described (Mondola P et al. 
2003). Cell viability was evaluated by using PropidiumIodide (PI) (Sigma-
Aldrich) labeling and flow cytometry detection (Mondola P et al. 2003) as well 
as by analyzing lactate dehydrogenase (LDH) activity in culture supernatants 
by using the Roche Molecular Biochemical LDH kit (Mannheim, Germany). 
Written informed consent (model n. 5526 of Azienda Ospedaliera Universitaria 
“FEDERICO II”) was obtained from each donor at the time of venous 
peripheral blood donation. All the experiments done by using blood donations 
were performed and analyzed anonymously, without any biographical 
reference to donors.  
 
ELISA 
The quantitative detection of human SOD-1 in medium of cultured PBMC was 
carried out using the Bender Med System kit (Bender Med System Diagnostic, 
Vienna, Austria), as described (Mondola P et al. 2003). Results were always 
normalized for total protein content of the tested sample. SOD-1 ELISA 
detection has been always performed on culture supernatants immediately 
frozen at −80 °C. Protein concentrations were determined according to the 
method of Lowry et al. 1951 using BSA, as standard. 
 
RNA preparation, semi-quantitative RT-PCR and DNA sequencing. 
Analysis of SOD-1 specific RNA has been performed, as described (Russo M 
et al. 2011). Briefly, total RNA was extracted with High Pure RNA isolation 
kit (Roche Italia, Milano, Italia), according to the manufacturer's instructions. 
Traces of contaminated DNA were removed with DNAse I treatment. 
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Quantification was achieved in a single reaction by using the housekeeping β-
actin gene as internal standard. To rule out genomic DNA contamination we 
performed a negative control that contained RNA instead of cDNA. The signal 
intensities of PCR products were separated on a 1.2% agarose gel and were 
visualized by ethidium bromide staining. The products' signal intensitieswere 
determined by computerized densitometric analysis using Fotoplot software. 
The expression of SOD-1 was normalized to β-actin mRNA levels. To check 
the specificity of the amplified products, DNA bands were eluted from the gel 
and purified; sequence analysis was determined by the Big Dye Terminator 
Cycle Sequencing method (ABI-PRISM Sequencer 310 Perkin-Elmer). 
 
Microvesicle isolation and western blotting for SOD-1 detection 
To purify the membrane microvesicle-containing fraction, supernatants were 
collected immediately after culture and treated, as described (Thery C et al. 
2006). Briefly, they were sequentially centrifuged at 500 g for 15 min to 
remove cellular debris and again at 10,000 g for 20 min. The obtained 
supernatant was collected and further centrifuged at 100,000 g for 2 h. The 
resulting pelletwas then collected and considered to represent the enriched 
membrane vesicle fraction. Western blotting analysis of the purified material 
was performed as previously described (Mondola P et al. 2003). Comparative 
analysis of SOD-1 was performed by using 40 µg of total 
proteins. 
 
Immunofluorescence and flow cytometry analysis 
Intracellular SOD-1 contentwas evaluated anti-SOD-1mAb and FITC labeled 
anti-mouse IgG secondary antiserum (Sigma-Aldrich) staining of 
permeabilized cells and immunofluorescence technique. A commercial 
fixing/permeabilization kit, purchased from Becton Dickinson was always 
employed, following the manufacturer's instructions. For the analysis of SOD-1 
content in distinct cell subsets and to evaluate T cell activation after TCR 
triggering, co-staining with FITC, PerCP or APC labelled anti-CD3, anti-CD45 
and anti-CD69 mAb was performed. Labeled antibodies and isotype-matched 
controls were purchased from Becton Dickinson. T cell staining and activation 
were performed by anti-CD3 mAb recognizing different CD3 epitopes. Cell 
death was always less than 5% as evaluated by using PI (Sigma-Aldrich) 
staining. Immunofluorescence, flow cytometry and data analysis were 
performed by using a two laser equipped Becton–Dickinson FACSCalibur flow 
cytometer and the Cell Quest analysis software. 
 
Fluorescence microscopy 
PBMC or purified T cells (0.5 × 106) were adhered to polylysine coated glass 
slides for 16–18 h at 37 °C. When indicated, the above populations were 
stimulated with anti-CD3 mAb CLB-CD3/4E at 1:100 ascites dilution or 
antiCD3/anti-CD28 beads (at 0.3 bead/cell) and 1 mM NAC (Karlsson H et al. 
2011). Cells were incubated at 37 °C and immediately fixed with 3% 
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paraformaldehyde solution. Fixed cells were incubated with FITC labelled anti-
CD3 and anti-human Cu,Zn SOD-1 rabbit antibody (Santa Cruz Biotechnology, 
CA, USA) for 45 min in a humidified chamber, washed three times with PBS 
and incubated with Alexa Fluor 594- conjugated goat anti-rabbit secondary 
antibody (Molecular Probes, 
Life Technologies) for additional 45 min at 37 °C in the same conditions. After 
3 washes with PBS the glass slides were mounted using a 50% solution of 
glycerol in PBS and examined with a Zeiss LSM 510 confocal microscope with 
a 63× oil immersion objective (N.A. 1,4) at room temperature. Pictures were 
taken from selected fields of control and treated samples. 
 
Cell to cell aggregate evaluation 
To evaluate cell aggregation, PBMCs were cultured in 96 wells flat bottomed 
microtiter plates (Falcon) in the presence of Medium, anti-CD3 and 1 mM 
NAC (Sigma-Aldrich), as indicated. This NAC concentration was 
demonstrated in preliminary experiments to completely block ROS formation, 
as described (Orci L et al. 1991). Contrast phase microscopy analysis was 
performed with a Leitz DIAVERT microscope with a 10× objective at room 
temperature. Pictures were taken from selected fields by using a digital Nikon 
Coolpix Camera. NAC treatment was unable to significantly affect T cell 
viability and proliferation, as evaluated by PI staining after 1 to 5 h of culture 
and 3H thymidine incorporation after 72 h of culture. Quantification has been 
performed by counting the number of cell aggregates (identified by the 
presence of at least 8 clustered cells) in the cell culture of 1 × 105 PBMC 
plated on the flat bottomed microtiter wells. 
 
Statistical analysis 
Statistical evaluation of data, by InStat 3.0 software (GraphPad Software Inc., 
San Diego, California, USA), has been performed by means of the Mann-
Whitney test or Paired t test, as indicated. Two-sided p values of less than 0.05 
were considered to indicate statistical significance. 
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RESULTS  
 
Immune tolerance in bone marrow failure syndromes. 
 
Paroxysmal Nocturnal Haemoglobinuria (PNH)  
PNH was our first research model to study the impact of immune tolerance-
dysregulation in bone marrow failure syndromes. 
In particular, we analysed the effects of the Eculizumab treatments on innate 
and adaptive immune effectors in a cohort of 34 PNH patients (Alfinito et al. 
2012).  
To investigate whether complement inhibition might interfere with the 
selection/expansion of the GPI-defective haematopoiesis, comparative analysis 
of immuno-phenotypic profile was performed among PNH patients before  
(PNH BT) and during (PNH OT) Eculizumab treatment. In Figure 3, a decrease 
in levels of B cells, NK cells and Treg accompanied by an increase in 
lymphocytes NKTi was observed in PNH patients BT compared to controls. 
Eculizumab therapy was able to selectively restore B and NKTi peripheral 
concentration without significant interference on NK and Treg numbers. 
 
 
 
Figure 3. Analysis of B, NK, NKTi and Treg lymphocytes in PNH patients before and on 
Eculizumab treatment. As indicated, panels A-D refer comparative analysis of B, NK, NKTi 
and Treg lymphocytes in PNH patients before (BT) and on (OT) at least six months of 
Eculizumab treatment. The analysis has been performed by considering the values obtained in 
the same patients before and after Eculizumab therapy. For the patients, each value represents a 
mean obtained in at least three independent evaluations before and after treatment. Statistical 
analysis has been performed by Wilcoxon matched-pairs signed-rank test.  
A
C D
B
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MyeloDysplastic Syndromes (MDS) 
In a subset of MDS patients (Low/Int-1 risk) with low levels of Treg and high 
expression of CD54 on cytotoxic T lymphocytes (CD8+) (CTL) in BM, in 
which the involvement of immune-mediated mechanisms in the pathogenesis 
of the espansion of the dysplastic precursor might be inferred, were analyzed 
the expression of HLA-I and HLA-E, as key elements for the regulation of 
CD8+ T cells and NK effectors (Terrazzano et al. 2013). 
Therefore, we evaluated the HLA-E expression on Granulopoietic 
compartment (GC) versus PMN in peripheral blood (PB) in paired samples. As 
shown in Panel A of the Figure 4, HLA-E levels on peripheral PMN are 
significantly higher than GC in BM, while no significant differences have been 
observed between peripheral PMN from patients and healthy controls (not 
shown).  
In the light of this result, we hypothesize that the higher HLA-E 
characterises mature PMN effectors in the peripheral blood. Such higher HLA-
E expression could be the result of a specific up-regulation of the molecule on 
circulating PMN or it could be dependent on a preferential selection of a BM 
precursor showing higher HLA-E expression. To investigate on this issue, we 
also analysed the staining profile of HLA-E on GC in BM. As showed in panel 
B of the Figure 4, two distinct populations with different HLA-E expression 
levels are present in the GC of BM.  
Since HLA-E molecules are believed to preferentially regulate NK-dependent 
cytotoxicity, these data suggest the role for NK cells in the selection of PMN in 
all MDS patients regardless the occurrence of an altered immune profile. 
 
 
Figure 4. HLA-E expression on PB and BM cells. (A) Mean of immunofluorescence (MIF) 
graph for HLA-E on BM GC and on PB PMN in Low, Int-1, AIP and NIP patients. A p value < 
0.05 has been considered significant and (B) staning profiles for HLA-E on BM GC as 
compared with peripheral PMN in one representative MDS patient: BM GC profile (dotted 
line), PB PMN (bold plain line) and isotype control (plain line).           
 
A significant decrease of HLA-I on peripheral PMN, when compared to 
BM PMN, was observed in Low as well as in Int-1 Risk MDS patients 
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(pc<0.01 and pc<0.05, respectively) (Panel A of the Figure 5). If the patients 
were analysed according to their BM immune profile (AIP= with altered 
immune profile and NAIP= without altered immune profile), only the patients 
with an altered immune profile showed a significant decrease of HLA-I 
expression (pc<0.001) on peripheral PMN. It is worth noting that a tendency 
to present lower HLA-I levels was observed also when the AIP MDS sub-
group was compared to the healthy donors (panel B of Figure 5).  
Intriguingly, lower MHC-I expression in peripheral PMN seems to be 
strongly correlated with the occurrence of an altered BM immune profile in 
MDS patients. 
To ascertain if the presence of PMN with lower HLA-I expression in PB is 
dependent on down-modulation mechanisms occurring in the periphery or it is 
the result of immune-selection pressure favouring BM precursors carrying the 
lower HLA-I levels, we evaluated the cell distribution of GC in the BM and of 
PMN in PB. In this regards, two distinct populations with different HLA-I 
levels can be identified in GC of BM: the peripheral PMN seem to belong to 
the GC subset bearing the lower HLA-I expression (Figure 5, panel C). This 
feature significantly characterised the AIP subgroup (Figure 5, panel A). Such 
observations point to the role of CD8-dependent immune-mediated selection 
mechanisms occurring in BM. Indeed, PMN cells with lower HLA-I could be 
unable to present unknown self-antigens and, in reason of this mechanism, to 
become “targets” for autoreactive CD8 T lymphocytes. Indeed, the PMN cell 
maturation of effectors bearing lower HLA –I expression seems to be 
favoured in AIP subgroup, likely showing a deranged T cell response. 
 
 
Figure 5. HLA-I on PB and BM cells. (A) MIF graph for HLA-I expression on BM GC and 
PB PMN in Low, Int-1 AIP and NIP patients. A p value < 0.05 has been considered significant, 
(B) HLA-I levels on PB PMN of patients and controls and (C) staining profile for HLA-I in 
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one representative AIP patient: BM GC (dotted line), PB PMN (bold plain line) and isotype 
control (plain line). 
 
To investigate on the occurrence of immune-mediated selection in BM of 
MDS patients, we compared the percentage of HLA-I negative PMN cells in 
PB between healthy controls and MDS patients. A significant increase of 
HLA-I negative PMN has been observed in Int-1 patients if compared with the 
Low Risk Group (pc<0.05) and the healthy donors (pc<0.005) (Figure 3). 
When MDS patients were grouped according with their BM immune profile, 
the AIP group showed significant higher percentage of HLA-I defective PMN 
cells in comparisons with the NIP counterpart (pc<0.05) or healthy donors 
(pc<0.05).  
Such evidence, together with the observation of a lower expression of 
MHC-I on PMN in PB than on GC in BM of AIP patients (Figure 6), suggests 
the involvement of immune-mediated, HLA-I dependent mechanisms in the 
selection of PMN cells in AIP subgroup of MDS patients, characterised by low 
Treg and increased CD54 expression on CTL. 
 
Figure 6. HLA-I negative PMN in PB of MDS patients. Percentage of HLA-I negative PMN in 
PB of Low, Int-1, IP and NIP groups of MDS patients as well as in healthy donors. A p value 
<0.05 has been considered significant. 
 
In the 2013 an intriguing case of MDS patient carrying CD14(+) CD56(+) 
monocytes in bone marrow (BM), in the presence of a defective human 
leukocyte antigen (HLA)-E expression on peripheral blood (PB) cells and of 
natural killer (NK) cell expansion in PB and BM, was by us characterized. The 
defective HLA-E expression and the NK expansion were proposed to be 
relevant for the pathogenesis of myelodysplasia in those patients showing 
CD14+ CD56+ monocytes in BM (Terrazzano et al. 2013) 
 
In particular MDS patient showed a dysplastic monocytosis, characterized by 
the following features: 
1.  a significant expansion of CD14+ monocytes co-expressing the CD56 
in BM (more than 30% of monocytes) than in periphery (2% of PB 
monocytes); 
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2.  a Treg percentage and CD54 expression on both the CD4+ and CD8+ T 
Lymphocytes, similar between BM and PB, and to healthy donors; the 
Natural Killer expansion (more than 35% of lymphoid cell in BM and 
PB compartment) carried several NK receptors (CD335, CD337, 
CD244, CD158e1/e2, CD158/p70, CD94/NKG2A, CD94/NKG2C), 
suggesting that NK cells are polyclonal;   
3.  a TCR repertoire of T lymphocytes that appears to be polyclonal in 
BM and PB, without TCR-Vβ skewing (TCR polyclonal repertoire) of 
one or more T clones. 
 
Therefore, the patient showed dysplastic monocytosis (data not shown) and 
an extensive defect of HLA-E expression in both the monocytes and PMN in 
PB.  
The two PB populations evidenced only a very low staining for HLA-E 
(Figure 7A). 
 In contrast, the monocytes and PMN are positive for HLA-E in BM 
(Figure 7B). Intriguingly, the BM monocytes appear to express HLA-E as large 
distribution (see pick 2 in Figure 7B) and at higher level if compared to PMN 
(Figure 7B).  
In this regard, monocytes are divided into two subpopulations (Figure 7C): 
one expresses at lower intensity the HLA-E and is CD14+CD56−, while the 
second one shows higher level of the molecule and is CD14+CD56+. 
In addition, the expression of HLA-I on lymphocytes, monocytes, and PMN 
was similar between BM and PB (Figure 7D). The percentage of CD14+ 
monocytes co-expressing the CD56 was expanded in BM (more than 30% of 
monocytes) than in periphery (<2% of PB monocytes) (data not shown). 
Natural killer expansion (more than 35% of lymphoid cell in BM and PB 
compartment) carried several NK receptors (CD335, CD337, CD244, 
CD158e1/e2, CD158/p70, CD94/NKG2A, CD94/NKG2C), suggesting that NK 
cells are polyclonal (data not shown). 
The BM and PB NK cells were highly positive for two HLA-E receptors; in 
particular, the CD3−CD56+ cells expressing CD94/NKG2A were the 37% and 
CD94/NKG2C the 43% (data not shown). Treg percentage and CD54 
expression on both the CD4+ and CD8+ T Lymphocytes were similar to BM 
and PB, and the percentages were comparable to healthy donors (data not 
shown). Finally, the TCR repertoire of T lymphocytes appeared to be 
polyclonal in BM and PB, without TCR-Vβ skewing of one or more T clones. 
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Figure 5. Flow cytometry analysis. Panel A: surface expression of human leukocyte antigen 
(HLA)-E on polymorphonuclear cells (PMN) (1) and Monocytes (2) in peripheral blood (PB); 
Panel B: surface expression of HLA-E on PMN (1) and Monocytes (2) in bone marrow (BM); 
Panel C: surface expression of HLA-E on CD14+ CD56- (1) and CD14+CD56+ (2) Monocytes 
in bone marrow; Panel D: surface expression of HLA-I on PMN from BM (1) and PB (2) and 
on Monocytes from BM (3) and PB (4). The staining for Isotype mAb control is reported in all 
the panels (CTR). PB and BM PMN and monocyte populations were gated by FSC and SSC 
parameters and by CD45, CD14, CD33, CD56 labelling. 
 
 
Immune tolerance in chronic infectious diseases 
The aim of the study has been to investigate the immune profile of dogs 
naturally infected by L. infantum. To address the immune regulatory networks 
involved in Canine Leishmaniosis, lymphocyte T cell subsets, peripheral Treg 
levels and the presence of pro-inflammatory T cells have been assessed, in a 
cohort of 45 Leishmania infected dogs (LD), compared with 30 sex/age 
matched healthy animals, by using immune fluorescence and flow cytometry 
detection. Leishmaniotic dogs have been categorised according to their 
clinical-pathological status and their serological specific anti-Leishmania 
antibody titer. 
Figure 8 shows the analysis strategy of immune phenotype performed to 
identify the helper (CD4+ CD3+), the cytotoxic (CD8+ CD3+) T lymphocytes, 
as well as the level of theTreg sub-population. 
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Figure 8. Flow cytometry analysis strategy for phenotype studies. Panel A and B refer typical 
staining profiles for CD4+ T and CD8+ T cells obtained in a healthy control and a Leishmania 
infected animal, respectively; C–E Panels show the analysis strategy employed to identify 
CD4+Foxp3+ Treg subset in PBMC sample obtained from a control dog. As shown, T cell 
region (defined by CD3 staining as R1) has been employed to identify the CD4+ T cell subset 
(R2); in this region the presence of Foxp3 transcription factor allowed the identification of the 
CD4+Foxp3+ Treg subset. D–H Panels show a typical analysis for CD4+Foxp3+ Treg subset 
in a Leishmania infected dog. 
 
As shown in Figure 9A, Leishmania infected dogs (LD) are characterised by 
significant increase (p<0.0001) of the percentage of cytotoxic T cell effectors 
(CD8+CD3+) compared with healthy controls (67.47 ± 1.85 in LD vs 44.2 ± 2.5 
in healthy controls). This observation has been confirmed by the significant 
decrease of the percentage (31.94 ± 2.05 in LD vs 55.76 ± 2.36 in controls; 
p<0.0001) of CD4+CD3+ T cell subset (Figure 9C). No significant differences 
have been observed considering the occurrence of a High versus Low IFAT 
titer (LD-H vs LD-L) as well as by the presence of a symptomatic versus an 
asymptomatic disease (LD-S vs LD-A). Panels B and D of the Figure 9 show 
the comparison of the cell count obtained in the different animal groups. As 
shown, the significant increase in CD8+CD3+ T cells (1224 ± 135 in LD vs 
366.9 ± 17 in controls; p<0.0001) is confirmed in all the disease subgroups in 
comparison with healthy control animals (Figure 9B). The data on CD4+CD3+ 
T cells showed a significant decrease (564.5 ± 55.6 in LD vs 731 ± 26.19 in 
controls; p<0.05) of this cell subset in comparison with controls in all the LD 
animals, except the LD-A sub-group (Figure 9D) in which no significant 
differences have been observed with controls (701 ± 59 in LD-A vs 731 ± 
26.19 in healthy animals). Notably, a slight no significant increase in the 
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number of CD3+ lymphocytes have been observed in the Leishmania infected 
animal in comparison with controls (data not shown). 
Figure 9. Significant increase of CD8+ T lymphocyte subset characterises Leishmania infected 
dogs. Panel A and B refer percentage and count (106/L) of CD8+CD3+ lymphocytes in 
peripheral blood of healthy animals (CTR; white column); Leishmania infected dogs (LD; grey 
column); infected animals with an IFAT titer > 1:160 (LD-H; right striped column); infected 
animals with an IFAT titer 1:80–1:160 (LD-L left striped column); infected animals showing 
symptomatic disease (LD-S; pointed column); infected animals showing asymptomatic disease 
(LD-A cross lined column); Panel C and D refer percentage and count (106/L) of CD4+CD3+ 
lymphocytes in peripheral blood of the dogs categorised as previously indicated. Statistical 
analysis has been performed by using Mann–Whitney test. P values are indicated only for 
significant comparisons. 
 
Figure 10 shows that a significant difference (0.53 ± 0.04 in LD vs 1.83 ± 0.15 
in controls; p<0.0001) in the CD4+/CD8+ ratio characterises our cohort of 
Leishmania infected animals. This observation has been confirmed in all the 
sub-groups of Leishmania infected animals, regardless of the IFAT titer or the 
occurrence of a symptomatic versus asymptomatic disease.  
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Figure 10. CD4+/CD8+ ratio is significantly reduced in Leishmania infected dogs. Referred 
values have been observed in peripheral blood of healthy animals (CTR; white column); 
Leishmania infected dogs (LD; grey column); infected animals with an IFAT titer >1:160 (LD-
H; right striped column); infected animals with an IFAT titer 1:80–1:160 (LD-L left striped 
column); infected animals showing symptomatic disease (LD-S; pointed column); infected 
animals showing asymptomatic disease (LD-A cross-lined column); Statistical analysis has 
been performed by using Mann– Whitney test. P values are indicated only for significant 
comparisons. 
 
Figure 11 refers to the comparative analysis of Treg level in the peripheral 
blood of the pathological cohort and control group. As shown, significant 
reduction of the percentage of Treg (Fig. 11A) in the peripheral blood of the 
Leishmania infected cohort has been observed (5.39 ± 0.72 in LD vs 7.17 ± 
0.63 in controls; p<0.05). As shown, the reduced Treg percentage significantly 
correlates with the occurrence of a high IFAT titer (4.35 ± 0.95 in LD-H vs 
7.17 ± 0.63 in controls; p<0.01). Notably, when the Treg count was analysed in 
the pathological cohort versus controls (Fig. 11B), the difference appeared 
more consistent, regardless of the pathological subgroup considered (12.74 ± 
1.59 in LD vs 27.79 ± 1.94 in controls; p<0.0001; 13.28 ± 2.3 in LD-H; p < 
0.001; 11.80 ± 1.2 in LD-L; p<0.0001; 12.78 ± 2.16 in LD-S; p<0.0005; 12.77 
± 1.18 in LD-A; p<0.0001). Unlike CD4+ Treg that are largely defined by the 
expression of Foxp3, Foxp3 expression in CD8+ clones was not correlated with 
their suppressive activity (Hu et al., 2012, 2013). In this study, we checked for 
Foxp3 expression CD8+ effectors, but very faint expression was observed in 
both controls and Leishmania infected dogs (data not shown). 
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Figure 11. Significant reduction of percentage and Treg count have been observed in 
Leishmania infected dogs. Panel A and B refer percentage and count (106/L) of 
CD4+CD3+Foxp3+ (Treg) cells in healthy animals (CTR; white column); Leishmania infected 
dogs (LD; grey column); infected animals with an IFAT titer > 1:160 (LD-H; right striped 
column); infected animals with an IFAT titer 1:80–1:160 (LD-L left striped column); infected 
animals showing symptomatic disease (LD-S; pointed column); infected animals showing 
asymptomatic disease (LD-A cross-lined column); Statistical analysis has been performed by 
using Mann–Whitney test. P values are indicated only for significant comparisons. 
 
The cytokine profile has been largely described as relevant for Leishmania 
spreading control (Chamizo et al., 2005; Carillo and Moreno, 2009; Boggiatto 
et al., 2010). In order to assess whether the immunological profile by us 
described (high CD8+CD3+ T lymphocytes and reduced Treg cells), might be 
related with the induction of a specific cytokine profile in T lymphocytes, we 
analysed the IFN-γ and IL-4 production in T lymphocytes of LD animals as 
compared with healthy controls by immunofluorescence and flow cytometry 
detection. The analysis has been performed after an ON culture of PBMC, 
isolated from the peripheral blood of the animals, with Medium or PMA plus 
Ionomycin. This experimental approach is expected to allow the analysis ex 
vivo of the cytokine profile acquired by the T cells in vivo (Terrazzano et al., 
2005; Olsen and Sollid, 2013). As shown in Figure 12, the percentage of TH1 T 
cells (specifically producing IFN-γ and negative for IL-4) in LD animals is 
significantly increased as compared with controls (p<0.05) regardless of the 
grouping criteria used. No significant difference between the controls and the 
infected cohort was observed in the basal production of IFN-γ, detected in 
Medium cultures. 
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Figure 12. Significant increase of IFN-γ+IL-4-CD3+ T lymphocytes characterises Leishmania 
infected dogs. Referred values have been observed in peripheral blood of healthy animals 
(CTR; white column); Leishmania infected dogs (LD; grey column); infected animals with an 
IFAT titer > 1:160 (LD-H; right striped column); infected animals with an IFAT titer 1:80–
1:160 (LD-L; left striped column); infected animals showing symptomatic disease (LD-S; 
pointed column); infected animals showing asymptomatic disease (LD-A cross-lined column); 
Statistical analysis has been performed by using Mann–Whitney test. P values are indicated 
only for significant comparisons. 
 
The same model of natural chronic infectious disease, CL, was used to 
study whether administration of a specific pet food, supplemented with 
nutrients selected for their putative immune-modulating properties and rich in 
essential fatty acids, could modulate immunological profile of CL infected 
dogs. Thus, Lymphocytes T cell subset, peripheral Treg levels and the presence 
of pro-inflammatory T cells were evaluated at diagnosis and along a one year 
follow up in Leishmania infected dogs, submitted to standard anti-Leishmania 
pharmacological treatment alone (Group 1) or associated with the above 
specified diet (Group 2). To investigate whether diet administration during 
pharmacological anti-Leishmania treatment cold affect immunological profile 
of CL animals, analysis of CD4+/CD8+ ratio was performed. 
We analysed CD4/CD8 ratio in dogs along the 12-months of follow-up. As 
indicated in Figure 13, we confirmed the significant decrease of CD4+/CD8+ 
ratio at T0 in CL dogs when compared to healthy animals, as by us already 
described (Cortese et al., 2013). The observed increase of CD8+ T cells 
explains the decrease of CD4+/CD8+ ratio. This alteration remained 
substantially unmodified along the follow up in both Group 1 and Group 2. 
 53 
Indeed, sick dogs maintained a significant reduction of CD4+/CD8+ ratio in 
comparison to control animals at all the time points. 
Moreover, when the analysis specifically focused on CD4+/CD8+ ratio in the 
Group 1 and Group 2, significant differences between the groups were 
observed along the follow-up. As shown, an increase of CD4+/CD8+ ratio was 
revealed in Group 1 at T3 (0.81±0.09; p<0.001), while at T6 (0.58±0.08) and at 
T12 (0.31±0.02) the values substantially resembled to those observed at T0 
(0.43±0.05). At variance, the trend of increase in CD4+/CD8+ ratio at T3 
(0.73±0.08 versus 0.46±0.04) was maintained at T6 (0.71±0.08) and T12 
(0.74±0.09) in Group 2. Notably, these values remained steadily and 
significantly lower than in healthy dogs (Figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. The significant CD4/CD8 ratio reduction, observed in Leishmania sick dogs as 
compared with controls, is maintained in a one year follow up in both Group 1 and Group 2 
dogs, regardless the association of the pharmacological treatment with an immune-modulating 
diet. Values indicate the CD4/CD8 ratio observed in healthy animals (white column), in sick 
dogs at T0 (grey column), T3 (dotted column), T6 (right striped column) and T12 (crossing 
line column) in Group 1 and Group 2 animals, as indicated. Results were considered significant 
at p<0.05. 
 
As shown in Figure 14, a significant reduction in the percentage of Treg of all 
sick dogs was observed at T0. This result confirms our previous observation on 
Treg levels in CL (Cortese et al., 2013). A slight recovery of Treg percentage 
was observed only at T3 in Group 1, while this effect disappeared at T6 and 
T12. In contrast, it is worth noting that percentage of Treg became similar to 
healthy animals in Group 2 at T3, T6 and T12 (Figure 14). Indeed, the 
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differences between the Treg percentages between healthy animals and Group 
2 dogs substantially disappeared.  
 
 
Figure 14. Association of the pharmacological treatment with an immune-modulating diet 
restores Treg percentage and count in Leishmania sick dogs. Panel A and B show the 
percentage and count (x10-6/L) of Foxp3+CD4+CD3+ 18 (Treg) cells in healthy animals 
(white column) in sick dogs at T0 (grey column), T3 (dotted column), T6 (right striped 
column) and T12 (crossing line column) in Group 1 and Group 2 animals, as indicated. Results 
were considered significant at p<0.05. 
 
 
This result strongly suggests that the occurrence of a quite stable recovery of 
Treg was correlated to the immune-modulating diet administration. Similar 
results were obtained considering Treg number (data not shown). 
In addition, anti-Leishmania treatment alone was unable to modify Treg level 
in CL. At variance, the combination of drug with the potential immune-
modulating diet seems to be associated with a significant increase of Treg 
population that reaches normal values in Group 2. 
Moreover, we asked if anti-Leishmania therapy alone and/or associated with 
diet modification could affect TH1 activity in CL. As shown in Figure 15, sick 
dogs showed a significant increase of TH1 cells at T0 as compared with control 
animals, regardless the group assignment. This result is in accordance with our 
previous data on CL (Cortese et al., 2013). The comparative analysis of sick 
dogs with healthy controls revealed the occurrence of a significant decrease of 
Th1 cells from T3 to T12 in Group 1, although a trend of increase was 
observed at T6 and T12. At variance, Group 2 animals showed a progressive 
decrease of TH1 cells, whose levels became similar to healthy controls at T6 
and T12. 
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Figure 15. Association of the pharmacological treatment with an immune-modulating diet 
significantly modulates the presence of IFN-γ+ IL-4-CD3+ T lymphocytes in Leishmania sick 
dogs in a one year follow up. Values indicated the percentage of IFN- γ + IL-4-CD3+ T 
lymphocytes in healthy dogs (white column), sick dogs at T0 (grey column), T3 (dotted 
column), T6 (right striped column) and T12 (crossing line column) in Group 1 and Group 2 
animals,  as indicated. Results were considered significant at p<0.05. 
 
T cell activation and SOD1-dependent ROS modulation  
The models described above, frame two pathological conditions in which 
on the one hand we have an inflammatory microenvironment that favours the 
mechanisms of selection of pathological hematopoietic clones (PHN and MDS), 
on the other the same inflammatory condition is exploited by the physiological 
system in order to control the infection in dogs naturally infected with 
Leishmania infantum. In both cases the cells of adaptive immunity play a 
fundamental role. Thus, we focused on the role of oxidative balance regulation 
in TCR-dependent T cell activation, as a possible tool to modulate antigen-
dependent T cell activation in physiological and pathological conditions.  
Reactive oxygen species (ROS) behave as second messengers in signal 
transduction for a series of receptor/ligand interactions. A major regulatory role 
is played by hydrogen peroxide (H2O2), more stable and able to freely diffuse 
through cell membranes. Copper-zinc superoxide dismutase (CuZn-SOD)-1 is 
a cytosolic enzyme involved in scavenging oxygen radicals to H2O2 and 
molecular oxygen, thus representing a major cytosolic source of peroxides. 
Previous studies suggested that superoxide anion and H2O2 generation are 
involved in T cell receptor (TCR)-dependent signalling. To investigate whether 
cytosolic SOD-1 might be part of the molecular network involved in TCR 
triggering, the SOD-1 intracellular level and localization, as well as SOD-1 
microvesicle secretion, was analysed in TCR-triggered human T lymphocytes. 
To investigate whether antigen-dependent T cell activation induces SOD-1 
production and extracellular secretion, we measured the release of this enzyme 
in supernatants of PBMC cultured from 15 min to 18 h in presence of Medium 
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alone or with anti-CD3 mAb, that induces the TCR triggering mimicking 
antigen-dependent activation of T lymphocytes. As shown in Figure 16A, 
human PBMC cultures secreted small amount of SOD-1 that remained 
substantially stable from 15 min till to 18 h of culture. Anti-CD3 treatment 
slightly, but significantly (p<0.05), increased such basal secretion. The 
increment was detectable after 4 h of culture and reached the highest level after 
18 h of activation. This effect was independent on cell damage, always 
evaluated by PI labeling (Figure 16B) and significantly correlated with TCR 
dependent activation, as revealed by the up-regulation of the activation 
molecule CD69 (Figure 16C). Therefore, TCR-triggering was associated with 
the induction of SOD-1 secretion in human lymphocytes. 
Figure 16. SOD-1 concentration in anti-CD3 triggered cultures of human lymphocytes. (A) 
SOD-1 amount in supernatants of PBMC cultured in the presence ofMedium(black squares) or 
anti-CD3 (white squares). SOD-1 concentrations were analyzed in undiluted samples by using 
ELISA assay; results were normalized for total protein content of the tested sample. Each point 
refers mean value obtained in five independent experiments; error bars indicate SEM. * 
indicates the occurrence of statistically significant (p<0.05) higher SOD-1 concentration in 
anti-CD3 treated cultures. (B and C) PI and CD69 labeling of PBMC cultured O.N.with 
Medium or anti-CD3, as indicated. Results refer to one of five independent experiments. As 
shown (B), no significant differences have been observed in PI staining profiles of PBMC 
cultured withMediumand anti-CD3; (C) CD69 staining profile (bold line) of 
PBMCculturedwithMediumor anti-CD3, as indicated; broken line indicates isotype control; as 
shown, activated PBMCs were characterized by significant increase of the activation molecule 
CD69. 
 
To ascertain whether such secretionwas sustained by up-regulation of SOD-1 
gene transcription, we analyzed SOD-1 specific mRNA. As shown in Figure 17, 
an increase of more than 70% of SOD-1 specific mRNA has been observed in 
the cultures treated with anti-CD3 mAb as compared with resting cells. 
Therefore, antigen-dependent T cell activation induced SOD-1 secretion that 
was sustained by the increase of SOD-1 transcription in the whole PBMC 
population. 
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Figure 17. Anti-CD3 treatment induces significant increase of SOD-1mRNA in human 
lymphocytes. (A) Densitometric arbitrary units ratio between SOD-1 and beta actin in Medium 
and anti-CD3 treated cultures. Results refer one of five independent experiments. mRNA was 
measured by RT-PCR, as detailed in Material and methods section. (B) Comparative analysis 
of SOD-1 mRNA percent increase in all the five experiments performed. For each experiment 
mRNA amount in Medium cultured PBMC was considered the reference value (100) for 
calculation of percent increase in the anti-CD3 treated culture. As shown, a mean increase of 
more than 70% of SOD-1 specific mRNA has been observed in anti-CD3 treated PBMC. Error 
bars indicate SEM. Statistical analysis has been performed by using Paired t test. 
 
To evaluate whether SOD-1 export might be part of micro-vesicle production 
upon TCR triggering, we purified the micro-vesicle fraction from the 
supernatants of 18-hour cultures of PBMC and purified T cells. TCR triggering 
of PBMC was performed with anti-CD3mAb. In order to mimic costimulatory 
signals, usually mediated by accessory cells, a combination of anti-CD3/anti 
CD28 beads was used to fully activate purified T cells.  
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Figure 18. TCR-dependent T cell activation increases SOD-1 containing microvesicle 
secretion by human T lymphocytes. (A) Flow cytometry analysis of PBMC population. As 
shown, T lymphocytes (CD3+ cells) represent less than 85% of the total population; 
(B)western blot of enriched membrane vesicle fractions, isolated fromculture supernatants 
ofMedium(white column) and anti-CD3 treated PBMC (gray column), as detailed inMaterial 
and methods section. Densitometric analysis shows increased presence of SOD-1 in TCR 
triggered PBMC. Results refer one representative experiment of the six performed; (C) 
Analysis of percent increase of SOD-1 containing microvesicle in supernatants derived from 
anti-CD3 treated PBMC in six experiments. For each experiment, SOD-1 amount in Medium 
cultured PBMC was considered the reference value (100) for calculation of percent increase in 
the anti-CD3 treated culture. As shown, amean increase of 25% was observed in 
themicrovesicle enriched fraction obtained from the supernatants of anti-CD3 treated PBMC. 
(D) Flow cytometry analysis of a typical purified T cell population isolated by using negative 
selection strategy, as indicated in theMaterial and methods section. As shown, T lymphocytes 
(CD3+ cells) representmore than 98% of the total population; (E)western blot of 
enrichedmembrane vesicle fractions, isolated fromculture supernatants of Medium(white 
column) and anti-CD3/antiCD28 treated T cell cultures (gray column), as detailed inMaterial 
andmethods section. Densitometric analysis shows increased presence of SOD-1 in the sample 
obtained fromTCR triggered T cells. Results refer one representative experiment of the three 
performed; (F) analysis of percent increase of SOD-1 containing microvesicle in supernatants 
derived from anti-CD3/anti-CD28 treated T lymphocytes in three experiments. For each 
experiment, SOD-1 amount in Medium cultured T cells was considered the reference value 
(100) for calculation of percent increase in the anti-CD3/ anti-CD28 treated cultures. As shown, 
an increase of more than 120% was observed in the microvesicle enriched fraction obtained 
from the supernatants of anti-CD3/anti-CD28 treated purified T cells. Error bars indicate SEM. 
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Western blot comparative analysis of SOD-1 has been always performed on aliquots of 
enriched microvesicle fractions containing 40 µg of total proteins. Statistical analysis has been 
performed by using Paired t test. 
 
Figure 18 shows western blotting analysis of SOD-1 in the enriched membrane 
vesicle fractions. Figure 18A–B reports one representative experiment, while 
Figure 18C refers the analysis of data obtained in all the six experiments 
performed in PBMC cultures. The comparison revealed the occurrence of a 
mean 25% increase of SOD-1 content in the enriched membrane vesicle 
fraction obtained from anti-CD3 treated lymphocytes (p<0.01). As shown, in 
the enriched membrane vesicle fraction isolated from anti-CD3/anti-CD28 
treated T cells, a more consistent increase of SOD-1 content was observed 
(Figure 18D–F). Indeed, a mean increase >120% of SOD-1 content was 
evidenced in three experiments performed with purified T lymphocytes 
(p<0.05). 
To investigate whether other cell populations, present in PBMC, contribute to 
SOD-1 production and secretion in response to TCR-triggering, we analyzed 
intra-cellular SOD-1 levels in the T cell subset and in the “non-T” counterpart 
in a mixed context. This evaluation was performed by the combination of 
immune fluorescence and flow cytometry detection, to preserve the biological 
complexity of antigen-dependent T cell response and allow specific detection 
of SOD-1 in the T cell subset and in “non-T” population (Figure 19A). As 
shown (Figure 19B), very low amount of intracellular SOD-1 was observed in 
all the “resting” lymphocytes (T and non-T cells). After TCR-triggering, the 
up-regulation of SOD-1 intracellular level was observed only in T lymphocytes 
if compared to non-T cells (Region 1 versus Region 2 in Figure 19C). 
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Figure 19. Significant increase of intracellular SOD-1 and BFA-dependent SOD-1 export can 
be specifically demonstrated in anti-CD3 triggered human T cells. (A) Gating criteria for the 
identification of the “T cell subset” (R1) and of the “non-T population” (R2) in a PBMC 
culture; (B) SOD-1 staining profile of T cells (bold line) and “non-T population” (plain line) in 
O.N. Medium cultured PBMC. Dotted lines show the isotype control. As shown, similar, very 
low amount of intracellular SOD-1 characterizes both population. (C) SOD-1 staining profile 
of T cells (bold line) and “non-T population” (plain line) in anti-CD3 cultured PBMC. Dotted 
lines showthe isotype control. As shown, specific increase of SOD-1 intracellular content can 
be observed in the T cell subset (bold line) as compared with the “non-T” counterpart (plain 
line); (D) SOD-1 staining in T cell population (R1) culturedwith anti-CD3 alone (plain line) or 
in the presence of BFA (bold line). Dotted lines show the isotype control. As shown, anti-
CD3/BFA co-culture increases intracellular SOD-1 content in T cell population. (E) SOD-1 
staining in T cell population (R1) cultured with anti-CD3 alone (plain line) or in the presence 
of methylamine (bold line). Dotted lines show the isotype control. As shown, no significant 
changes in SOD-1 intracellular levels can be observed in anti-CD3/methylamine co-cultures. 
(F) SOD-1 staining profiles of “non-T population” (R2) in anti-CD3 cultures (plain line), in 
BFA/anti-CD3 co-cultures (bold line) or in methylamine/anti-CD3 cultures (broken line). 
Dotted lines show the isotype control. As shown, no significant changes in SOD-1 intracellular 
content have been observed. Results refer one of 4 independent experiments. (G–I) Column 
graphic reports the means of SOD-1 fluorescence intensities observed in 4 independent 
experiments in the whole PBMCpopulation (G), in the T cells (H) and in the “non-T” 
population (I).White columns indicate SOD-1 levels in cells, cultured as indicated; gray 
columns indicate SOD-1 in BFA co-treated cultures; striped columns refer SOD-1 in 
methylamine co-treated cultures. 
 
To investigate the pathway involved in SOD-1 secretion, we analyzed 
intracellular SOD-1 retention in T cells in the presence of BFA (Figure 19D) or 
methylamine (Figure 19E) described to block ER/Golgi intracellular network 
and cell endocytosis, respectively (Russo M. et al., 2011; Thery C. et al., 2006). 
In this regard, BFA but not methylamine treatment induced significant increase 
of the enzyme content in T cells. No significant changes in intracellular levels 
of SOD-1 were observed in “non-T” cell population, in the same experimental 
conditions (Figure 19F). Notably, none extracellular SOD-1 increase was 
detected by ELISA in anti-CD3 cultures incubated with BFA (data not shown). 
Figure 19G–I reports the statistical comparisons of SOD-1 intracellular amount 
in PBMC (Figure 19G), in T cells (Figure 19H) and “non-T” cells (Figure 19I), 
as evaluated by considering the mean fluorescence intensity (MFI) values 
obtained in all the 4 experiments performed. As shown, no significant changes 
in SOD-1 levels were observed in the absence of TCR triggering. Thus, SOD-1 
amountwas strictly dependent on antigen mediated T cell activation. Indeed, 
anti-CD3 treatment significantly increased SOD-1 intracellular level (p<0.005) 
in thewhole lymphocyte population (Figure 19G). This effect specifically 
characterized the T cell subset (p<0.005; Figure 19H), while no differences 
were observed in the “non-T” population (Figure 19I). Moreover, the block of 
ER/Golgi network, mediated by BFA treatment, was observed to mediate 
significant (p<0.05) intra-cellular SOD-1 retention only in T lymphocytes 
(Figure 19H). Similar results have been obtained by anti-CD3/anti-CD28 
triggering of purified T cells (data not shown). As control, intracellular 
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accumulation of Interferon-gamma was specifically detected in TCR triggered 
cultures treated with BFA (not shown). 
We analyzed SOD-1 and TCR cellular localization by confocal microscopy 
after 2 min of culture in the presence of Medium alone or with anti-CD3. 
Figure 20 shows TCR and SOD-1 co-staining after 2 min of culture with 
Medium alone (Figure 20A) or anti-CD3 (Figure 20B and C). As expected, the 
homogeneous surface TCR distribution observed in resting T cells (Figure 
20A) was completely changed by anti-CD3 triggering (Figure 20B and C). 
Indeed, significant TCR clustering (Figure 20B and C) characterized activated 
T cells. SOD-1 staining revealed a quite homogeneous intracellular distribution 
of the enzyme in resting T cells; staining profiles also confirmed the presence 
of SOD-1 at very low levels in human T lymphocytes (see Figure 19). Notably, 
confocal microscopy revealed that TCR triggering was able to induce a 
clustered distribution of SOD-1 enzyme (Figure 20B and C). Merged images 
clearly showed that TCR clusters have been 
recruiting intracellular SOD-1, whose localization strictly reflected TCR 
distribution (Figure 20B and C). TCR/SOD-1 co-localization disappeared 20 
min after anti-CD3 treatment (not shown). To preserve the physiological 
complexity, we chose to perform the analysis in PBMC population as a whole 
and we identified T cells by labelling with specific antibodies. In this model, 
TCR triggering is allowed by the physiological cross talk between T cells and 
autologous antigen presenting cells (APC). Notably, we never observed a TCR 
clustering decoupled from SOD-1 co-localization. No significant changes in 
SOD-1 intracellular localization were observed in “non-T” population after 
anti-CD3 triggering (not shown). Notably, SOD-1/TCR intracellular co-
clustering was observed also in anti-CD3/anti-CD28 triggered purified T cells 
(not shown). 
To investigate whether SOD-1/TCR co-localization in anti-CD3 activated T 
cells is dependent on ROS bioavailability, we performed experiments in the 
presence of the ROS scavenger NAC at 1 mM concentration. In this condition, 
TCR clustering was significantly reduced (from 70 to 95% in NAC/anti-CD3 
co-cultures). As shown, NAC significantly inhibited both TCR and SOD-1 
clustered localization (Figure 20D). Indeed, TCR was homogeneously 
distributed on cell membrane, similarly to what was observed in resting 
condition (Figure 20A). SOD-1 co-staining in anti-CD3/NAC treated 
lymphocytes also resembled basal images with the presence of small areas of 
faint cytosolic accumulation (Figure 20D). Merged images revealed a clear-cut 
distinct distribution of TCR and SOD-1 in anti-CD3/NAC treated T cells. Thus, 
ROS availability significantly affected activation-dependent TCR/SOD-1 re-
localization in human T cells. 
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Figure 20. Anti-CD3 triggering induces ROS-dependent TCR and SOD-1 co-clustering in 
activated lymphocytes. (A) Confocal microscopy image of CD3 (green) and SOD-1 (red) in 
resting T cells. A homogeneous, distinct, membrane and intracellular distribution of the TCR 
and SOD-1 can be appreciated. (B and C) After 2 min of anti-CD3 treatment a clustered 
distribution of TCR can be observed (white arrows). SOD-1 distribution becomes strongly 
clustered and resembles that of TCR (white arrows). This cell re-localization is better showed 
in panel C where a single cell has been focused. Merged images show that TCR clusters recruit 
intracellular SOD-1, whose localization strictly reflects TCR distribution (white arrows). (D) 
anti-CD3/NAC co-incubation induces a homogeneous TCR surface distribution. SOD-1 
localization also resembles basal images,with the presence of small areas of faint cytosolic 
accumulation. Merged images reveal a clear-cut distinct distribution of TCR and SOD1. 
 
To ascertain whether ROS availability might also affect the cell-to-cell 
aggregation dependent on TCR triggering, we analyzed the effect of NAC 
incubation on early cell clustering (usually detectable after 45 min of 
incubation with anti-CD3). As shown in Figure 21, anti-CD3-sitimulation was 
able to induce cell aggregation after 1 h of treatment (Figure 21C). Such effect 
became more evident after 3 h of incubation (Figure 21G). Anti-CD3/NAC 
co-treatment severely impaired anti-CD3 induced cell clustering after 1 h of 
incubation (Figure 21D). Quantification has been performed by direct 
counting of cell aggregates, identified by the presence of at least 8 clustered 
cells, in the microtiter wells. Comparative analysis showed a cell aggregate 
inhibition of 83.64 ± 1.62 in anti-CD3/NAC co-treated cultures in 6 
independent experiments; (p<0.05). This inhibition was transient and 
progressively decreased, likely mirroring the ROS scavenging activity of 
NAC. The inhibiting effect of NAC co-incubation completely disappeared 
after 6 h of anti-CD3/NAC cotreatment. NAC co-incubation was unable to 
mediate significant effects on cell viability and proliferation (not shown). 
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Figure21. NAC treatment inhibits early activation-induced aggregation of TCR triggered 
lymphocytes. Contrast phasemicroscopy images showing 1 and 3 hour cultures of PBMC 
incubated with Medium (A and E), NAC (B and F), anti-CD3 (C and G) or anti-CD3 and 
NAC (D and H). As shown, significant cell aggregation is observed in anti-CD3 triggered 
cells. Lymphocyte clustering is significantly inhibited in the anti-CD3/NAC co-treated 
cultures; (D) after 1 h of incubation. Quantification is performed by counting cell aggregates, 
identified by the presence of at least 8 clustered cells. Comparative analysis (not show) shows 
a 83.64 ± 1.62 inhibition of cell aggregates in anti-CD3/NAC co-treated cultures in 6 
independent experiments; (p b 0.05). (H) After a 3 hour period the inhibiting effect of NAC 
treatment is observed to be lowered (55.35 ± 2.23 inhibition of cell aggregates in 6 
independent experiments). Quite normal clustering of anti-CD3 treated PBMC is observed at 
longer culture time in anti-CD3/NAC co-treated cells (not shown). Results show one 
representative experiment of the six performed. 
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DISCUSSION and CONCLUSIONS  
 
Paroxysmal Nocturnal Haemoglobinuria (PNH) 
In the first work, we describe the occurrence of Treg reduction and NKTi 
increase in untreated PNH patients as well as the ability of Eculizumab 
therapy to selectively restore B and NKTi peripheral concentration without 
significant interference on NK and Treg numbers. These results confirm 
previous other and our data (Schubert et al. 1990; Alfinito et al. 1996; 
Richards et al. 1998) on the reduced number of B and NK cells in PNH also 
proposing that some of the immune alterations have to be considered as 
dependent on complement derangement. Indeed, the ability of Eculizumab to 
modify some of the alterations described in untreated patients, suggests their 
dependence on complement-mediated pathway/s. 
The correction of complement hyper activation is unable to revert the 
immune-mediated mechanisms involved in the selection and dominance of 
PNH precursors (Luzzatto et al. 1997; Karadimitris et al. 2000; Luzzatto 
2006). Indeed the size of PNH clone remains substantially unmodified in 
Eculizumab treated patients. The enhanced complement activation observed in 
PNH patients is due to absence of the GPI-linked CD55 and CD59 molecules 
cells and likely accompanied by an altered bio-availability of C3 and C5 
activation fragments (Luzzatto et al. 2010). The blockade of C5 by 
Eculizumab (Hillmen et al. 2006; Schubert et al. 2008; Luzzatto et al. 2010) 
acts on this process, probably modifying the availability of complement 
fragments. 
Interaction of C3 and C5 fragments with their cognate receptors on 
adaptive immune cells has been described to induce pleiotropic effector 
functions, (Carroll 2004b; Le Friec and Kemper 2009; Ricklin et al. 2010). 
Complement fragments regulate B cell proliferation, activation and trafficking 
(Carroll 2004a; Ottonello et al. 1999; Roozendaal and Carroll 2007) and finely 
tune T cell cytokine patterns (Longhi et al. 2006). In addition, C3 and C5 
fragments also interfere with the stromal cell-derived factor-1 (SDF-
1)/CXCR4 axis, crucial for BM homing regulation (Reca et al. 2003). Finally, 
NK and Treg alterations seem not to be influenced by Eculizumab, thus 
suggesting their independence on complement related pathways. Since similar 
alterations have been described in Aplastic Anaemia and Myelodysplastic 
Syndromes (Kiladjian et al. 2006; Kotsianidis et al. 2009; Alfinito et al. 2010), 
we can argue their involvement in the immune-mediated pathogenesis of BM 
failure disease that underlies PNH.  
Taken in all our data suggest that the unbalanced complement activation 
on the surface of GPI-defective cells mediates significant alteration of 
immune effectors in PNH patients without significant interference with the 
immune-mediated mechanisms underlying the selection/expansion of GPI-
defective haematopoiesis. Eculizumab treatment is able not only to correct the 
effect of Complement hyper-activation on red cells, but is also able to 
normalize complement-dependent alteration of immunological targets. This 
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observation suggests that changes in the immune-profile could be of some 
relevance for the amelioration of immune response in the PNH patients on 
Eculizumab treatment. 
 
MyeloDysplastic Syndromes (MDS) 
In the hypothesis that an altered immune profile might underlie the occurrence 
of CTL-dependent immune/mediated selection of the dysplastic compartment 
in MDS, the study focused on HLA-E and HLA-I molecules, as major 
elements in regulating NK and CTL recognition, respectively (Ruggiero et al. 
2009; Lanier 2005; Terrazzano et al. 2007; Zinkernagel and Doherty 1974; 
Germain 1994; Ploegh 1998; Seliger et al. 2006). 
Thus the analysis focused on granulopoietic population, as the more 
suitable compartment for studying BM selection processes. Our immune-
based sub classification of MDS patients (Alfinito et al. 2010) is dependent on 
the occurrence of lower Treg percentage, increased BM recruitment of CTL 
and high CD54 expression on CD8 T cells in a sub-group of Low/Int-1 Risk 
patients. Low/Int-1 Risk MDS patients bearing the altered immune profile are 
characterized by both the decrease in HLA-I expression and the increased 
presence of HLA-I defective cells on peripheral PMN (Alfinito et al. 2010). In 
this context, the occurrence of immune-mediated selection processes has been 
suggested by the presence of BM precursors characterised by different 
expression levels of HLA-E as well as HLA-I in MDS patients.  
We consistently found that the expression of HLA-E is lower in BM GC 
than in PB PMN population. Since HLA-E is the main inhibiting element for 
NK recognition, we hypothesise that NK could kill the lower HLA-E-
expressing PMN precursors in BM and it could consent the migration into PB 
only of those cells expressing HLA-E at higher level. The expression of NK 
ligands during BM maturation (Nowbakht et al. 2005) and the presence of 
defects in both HLA-E and CD94/NKG2 molecule, the main HLA-E-NK 
receptor,have been described, in some haematopoietic diseases (Ruggiero et al. 
2009; Majumder  et al. 2006; Warren  et al. 2003). Therefore a perturbation of 
such regulatory networks might generate the maturation of dysplastic PMN 
with significant modulation of HLA-E surface expression (Ruggiero et al. 
2009). 
Our study refers that both Low and Int-1 Risk MDS patients show 
significant decrease of HLA-I expression on peripheral PMN if compared 
with the BM counterpart. Notably, when patients were categorised according 
with their immune profile, only AIP patients significantly maintain a lower 
expression of MHC-I on peripheral PMN cells than in BM GC. This condition 
is conceivable with the hypothesis that a subpopulation of BM-PMN-
precursors, characterised by high level of MHC-I molecules, could behave as 
preferential target for a deranged autoreactive T cell response. Indeed, CTL 
are expected to be less sensitive to PMN precursors expressing low level of 
MHC-I. These cells represent the only population leaving the BM as 
peripheral PMN in AIP MDS patients. 
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HLA-I absence has been associated with escape mechanisms to CTL 
recognition (Zinkernagel and Doherty 1974; Germain 1994; Ploegh 1998; 
Seliger et al. 2006). The recognition of neo-antigens expressed by dysplastic 
cell clones and an altered self-tolerance in BM (Sloand and Rezvani 2008; 
Barrett 2004; Sloand et al. 2008 might account for our observations. The study 
evidences a significant increase of PMN lacking HLA-I in Int-1 Risk MDS 
patients. Such evidence could point to CTL-mediated mechanisms acting in 
those patients with a more advanced MDS disease stage. Notably, when 
patients were categorised according with their immune profile, the increase of 
peripheral PMN lacking HLA-I expression was preferentially observed in AIP 
patients if compared with the NIP counterpart.  
The immune-based classification criteria, by us proposed, seem to identify 
a subgroup of Low/Int-1 patients in whom CTL selection mechanisms are 
patho-genetically relevant. 
The HLA-E and HLA molecules are part of the biological mechanisms 
involved in the selection of BM precursors. Such immune-dependent selection 
processes might become pathogenetically relevant in patients in which the 
immunological activation is deranged (AIP subgroup of our patients). 
These results propose that the reduced presence of Treg in BM (Alfinito et al. 
2010) might be unable to efficiently suppress autoreactive T clones that 
preferentially recognise self-antigens on PMN precursors expressing higher 
level of MHC-I molecules. The deranged immune response could be enhanced 
by the inflammatory BM microenvironment, described in MDS (Zeng et al. 
2006). In this context, the cytotoxic activity of NK effectors that could 
recognise and kill (Lanier 20005) the PMN precursors expressing low level of 
HLA-E/MHC-I (Terrazzano et al. 2007) is not to exclude.  
A model for immune-mediated selection is hypothesised in Figure 22. 
Ideally, the immune-dependent signals, allowing the maturation and migration 
of BM precursors in PB, might depend on expression of optimal levels of both 
HLA-E and HLA-I molecules that regulate NK and CTL recognition. These 
mechanisms could preferentially affect the selection of GC in MDS patients 
with a deranged adaptive response in BM (AIP group). 
In support of our hypothesis are at least two evidences: (a) PB PMN cells 
of all patients in AIP group express higher HLA-E and lower HLA-I 
molecules (corresponding to B cell type in Figure 22); (b) we found a greater 
percentage of MHC-I negative PMN (the C cell type in our model) in Int-1, 
where the MDS progression is more advanced in respect to the Low Risk. 
Notably, when the patients have been categorised according to their immune-
profile, this feature characterised the AIP subgroup.  
This and our previous investigations over the immune alterations in MDS 
(Ruggiero et al. 2009; Alfinito et al. 2010) suggest the introduction of 
immune-based criteria in the classification of MDS patients. In particular, we 
aimed to better characterise those patients in which the immune/mediated 
mechanisms could be part of MDS pathogenesis. In this regard, it could be of 
some relevance the correlation between the expression of MHC-I/HLA-E 
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molecules and the selection of PMN dysplastic clones in MDS. Therefore, the 
expression of the activating and inhibitory receptors on NK effectors and their 
interplay with classical and non classical MHC-I molecules on haematological 
cell target need further investigation to better understand the molecular 
mechanism underlying the emergence of dysplastic clones in MDS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 . Involvement of NK and CTL in the selection of dysplastic clones. BM polyclonal 
haematopoiesis (upper panel) with at least four GC cell types (from A to D). A and D cell 
types express high level of HLA-I and represent more susceptible targets for deranged CTL 
recognising self-antigens (indicated as T in the model). B and C cell types express low level 
the HLA-I or completely lack these molecules and are spared by CTL. NK effectors recognise 
the presence of HLA-E molecules by CD94/NKG2A receptor. This mechanism likely 
mediates the clearing of C and D cell types. In the presence of a deranged CTL response (AIP 
patients), the outcome of these interactions is the result of the rescue and the preferential 
migration/expansion in PB (lower panel in the model) of the B cell type expressing low HLA-
I and high HLA-E. These conditions spare the B cell type from both NK and CTL lysis. The 
dominance of a CTL-dependent selection pressure might account the higher presence of D 
cell type in AIP group. 
 
A special case of MDS patient shows thrombocytopenia, monocytosis and 
expansion of polyclonal NK cells, and normal karyotype. These features are 
accompanied by a defect of HLA-E expression on PMN and monocytes in PB. 
Notably, despite the similarities of this MDS case with the other by us 
observed for the likely involvement of HLA-I and HLA-E in fostering the 
myelodysplasia (Terrazzano  et al. 2013), this patient seems to be substantially 
 
  
 
 
 T 
BM 
PB 
HLA-E 
MHC-I  
+ self antigen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
  
 
 Peripheral PMN 
 
 
 
 
 
 
 
 
 
 
 
 
 
(lysed) (lysed) 
 
  
 
 
 
  
 
 
 NK 
 
 
 NK 
A B C D 
 
 
TCR 
 T 
 
 T 
 
 T 
 
 T 
 
 T 
 
 T 
 
 
 NK 
 CD94/NKG2A 
 
 NK 
 
 NK 
 
 NK 
 
 NK 
 
 NK 
 T 
 
 
 
 
 
Cyt
oto
xici
ty 
Cyt
oto
xici
ty 
Cyt
oto
xici
ty Cyt
oto
xici
ty 
 
Cytotoxicity 
 
Cyt
oto
xici
ty 
 
Cyt
oto
xici
ty 
 NK 
 
Cyt
oto
xici
ty 
 
 
 
 NK 
 
 
 68 
unframed with the immunological criteria that we previously proposed 
(Alfinito et al. 2010). Indeed, the patient reveals no significant variation in the 
percentage of Treg or of expression of CD54 when compared with healthy 
controls. Nevertheless, the patient shows an intriguing analogy with previous 
patient (Ruggiero et al. 2009) for the presence of dysplastic monocytosis, 
mainly represented by CD14+CD56+HLA-E+ cells in BM, and for the 
expansion of CD94/NKG2C+ NK cells. These characteristics suggest that BM 
NK expansion, with increased expression of CD94/NKG2C, generates a 
selective pressure on hematopoietic compartments. In this regard, patient 
CD94/NKG2C+ NK cells could have exerted an efficiently killing of HLA-E+ 
myeloid precursors, thus targeting HLAE+ monocytes and HLA-E+ PMN in 
BM and sparing those cells carrying the lowest HLA-E levels. Indeed, the 
dysplastic monocytes are mainly HLAE+ CD14+CD56+ in BM and become 
HLA-E-CD14+CD56- in PB likely due to the action of NK selection. These 
evidences suggest that the action of NK in the selective pressure was exerted 
on the monocyte and PMN populations that were observed totally defective 
for HLA-E expression in PB. We could not rule out that other receptor/ligand 
pathways could have a role in regulating NK activity in this patient.  
The expression of HLA-I appears to be not involved in the selection by 
NK in this patient, as the levels of these molecules on PMN and monocytes 
are similar between PB and BM. In addition, the TCR repertoire appears to be 
unskewed, and such result could formally exclude antigen specific T-cell 
response in the patient, at least at the time of our observation.  
Taken together, the current study and the others by us published (Ruggiero 
et al. 2009; Terrazzano  et al. 2013; Alfinito et al. 2010) suggest that the 
emergence and dominance of dysplastic clones could be inferred and/or 
sustained in some MDS patients also by NK activity alone and/or as 
contribute, together with other immune-mediated mechanisms. The relevance 
for the expression of HLA-E and HLA-I on hematopoietic cells could be 
largely different, and it can range from etiopathogenetic role to some 
physiopathological aspects. This consideration makes sense when one 
considers the balance between anti-tumor immune response and the possible 
detrimental implication of immune editing in cancer (Dunn et al. 2004). 
Likewise, MDS condition is identifiable as the consequence of several clonal 
cytogenetic abnormalities conferring proliferative and surviving advantage to 
those stem cells generating dysplastic clones (Mufti 2004; Greenberg et al. 
1997). In this context, it has been proposed that inflammatory BM 
microenvironment and an altered immune response could not only represent 
huge protective reactions of the individual from disease, but also favourable 
conditions for the emergence, expansion, and dominance of dysplastic clones 
in a subgroup of MDS patients (Mufti 2004; Greenberg  et al. 1997; Malcovati 
et al. 2005; Maciejewski 2007; Sloand and Rezvani 2008; Ruggiero et al. 
2009; Terrazzano  et al. 2013; Alfinito et al. 2010). The plain significance of 
this mechanism in counteracting, causing, sustaining, or accompanying the 
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MDS is not definitively established, but it appears to be of great relevance to 
better understand the role as ‘Janus Bifront’ for immune response in MDS. 
 
Leishmania infantum infection 
In our report we describe a significant increase of CD8+CD3+ T lymphocytes 
and TH1 T cells (IFN-γ+IL-4-CD3+ lymphocytes) accompanied by a significant 
reduction of Tregs lymphocytes in a cohort of Leishmania infected dogs 
regardless of the IFAT titer or the occurrence of clinical symptomatic disease.  
Reduced percentage of CD4+ T cells has been described in CL, suggesting 
that CD8-dependent IFN-γ production and lysis of infected- macrophages can 
mediate protective immunity during the disease (Guarga et al. 2000). Increased 
number of CD8+ T effectors has been referred to preferentially characterise 
asymptomatic animals (Reis et al. 2006, 2009). In addition, higher counts of T 
lymphocytes, mainly due to increased CD8+ T lymphocytes and accompanied 
by a decreased CD4+/CD8+ ratio, were described to characterise asymptomatic 
animals with positive serology and positive molecular results (Coura-Vital et al. 
2011). Furthermore, the relevance of variations in the percentage of CD3+ and 
CD4+ T cells in mildly and severely infected dogs has been highlighted 
(Miranda et al. 2007) while prolonged allopurinol monotherapy was observed 
to improve the number of circulating CD4+ T cells, but not to restore their 
number to within the normal range (Papadogiannakis et al. 2010). 
Our results indicate that increase of CD8+ T cells, in presence of normal 
levels of T lymphocytes can be observed in CL, regardless of the IFAT titer or 
the presence of clinical signs of disease. Such observations confirm the 
relevance for CD8+ T lymphocytes in the control of intracellular-parasites 
(Guarga et al. 2000; Reis et al. 2006, 2009; Miranda et al. 2007; Coura-Vital et 
al. 2011). 
A complex network of peripheral mechanisms, co-evolved to prevent or 
dampen immune-mediated diseases, usually accounts for the regulation of the 
activation, expansion and recruitment of T cell effectors in the infected 
microenvironment. Regulatory systems include mechanisms intrinsic to the 
antigen activation and T cell differentiation as well as those mediated by 
regulatory suppressor immune-populations, as represented by the Treg subset. 
The involvement of such regulatory network is of critical relevance in the 
presence of infectious agents usually associated with chronic diseases, as 
represented by Leishmania. To investigate on such issue, we focused the 
complex network of regulatory/effector T cell populations in a cohort of 45 
Leishmania infected dogs, categorised according to their IFAT titer and the 
occurrence of a symptomatic versus asymptomatic disease. In order to analyse 
T cell behaviour, maintaining the biological complexity of the immune-
regulatory networks, we chose to analyse T cells in the whole blood samples or 
in the bulk PBMC preparations, by using immune fluorescence and multi 
parametric flow cytometry detection. Our data consistently indicate CD8+ T 
effector cells as a key effector population in CL. Thus the critical role for 
adaptive immunity in clearing intracellular parasites (Reis et al. 2006, 2009) 
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has been confirmed in our model. Moreover, our results indicate that in active 
CL an inflammatory response, characterised by increased levels of CD8+ T 
cells and TH1 T cells, might be sustained by a decrease of Treg. Thus, parasite 
persistence could maintain adaptive cytotoxic and pro-inflammatory response 
by reducing Treg-dependent mechanisms. Several observations, particularly on 
the murine cutaneous leishmaniasis model, demonstrated that TH1 and TH2 
responses via their signatory cytokines, IFN-γ, and IL-4 respectively, were 
counter-regulatory. However, later studies using gene-deficient mice have 
questioned the precise role of the TH2 response and IL-4 in regulating the TH1 
response. Depending on the parasite strain/species/host model studied the TH2 
response could either promote infection or at best be irrelevant to disease 
progression (Alexander and Brombacher, 2012). The presence of reduced 
Tregs represents a key mechanism to optimise T cell activation and effector 
functions in the presence of persistent infection. Tregs have been described to 
modulate recruitment and activation of immune effectors (Sakaguchi, 2005). 
Thus, in active CL, Treg could hamper inflammatory responses required for 
infection clearance, in such way exacerbating the risk that the unbridled 
parasite growth could lead to severe disease. On the contrary, Treg recruitment 
in infected tissues might prevent the onset of severe immune-mediated 
pathology. Such intriguing scenario could underlie immune-mediated 
pathology, likely accounting for the presence of immune-mediated auto-
immune processes, very common in this parasitic disease (Kharazmi et al. 
1982; Ferrer 1992; Terrazzano et al. 2006; Solano-Gallego et al. 2009; Cortese 
et al. 2009, 2011). These data may provide new insights into the pathogenesis 
of immune-mediated alterations associated with CL. Further studies are in 
progress in order to more specifically address such issue.  
 In the second report, we describe that a diet supplemented with 
nutraceuticals selected for their potential immune modulating properties and 
rich in essential fatty acids is able to induce an immune-modulation in dog 
chronically infected by L. infantum undergoing 12 months of treatment with 
standard pharmacological therapy. Moreover, this study addressed if the 
administration of specific nutrients could also improve the clinical response to 
the standard treatment in a model of chronic spontaneous infection, as 
represented by CL. 
 We observed that the significant reduction of Treg subset, by us previously 
associated with the occurrence of chronic CL (Cortese et al. 2013), was 
significantly restored by an immune-modulating diet. Such modification was 
maintained in a one-year follow up. Notably, Group 2 dogs also showed a 
progressive decrease of, TH1 CD4+ T cells, whose levels became similar to 
healthy dogs at T6 and T12. 
 Therefore, anti-Leishmania treatment combined with the administration of a 
specific nutraceutical pet food supplemented by nutrients selected for their 
potential immune-modulating properties and rich in essential fatty acid has 
been associated with significant changes in immune profile of sick dogs. 
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The effect of nutraceutical diet appeared to be specific for Treg, since other 
immune cells were unaffected. Indeed, CL pharmacological treatment alone or 
in the presence of specific immune modulating nutrient supplementation did 
not alter the CD4/CD8 ratio and did not affect the increase in CD8+ T cell 
effectors in sick dogs along the follow up. Notably, it is conceivable that the 
maintenance of a high percentage of T cytotoxic effectors could foster an 
effective immune response against the parasite and it is mainly correlated to the 
persistence of this chronic infection in the animals. Moreover, the increase in 
Treg percentage could have a role in reducing the immune-mediated damages 
to the tissues frequently associated with CL. In this regard, both the clinical 
outcome of the disease and the occurrence of immune-pathological 
complications have been largely associated with the anti-Leishmania immune 
response orchestration: i.e. murine cutaneous leishmaniosis model 
demonstrated that TH1 and TH2 responses are in counter regulatory dependency 
(Alexander and Brombacher, 2012). It is of note that the pharmacological-
treated dogs fed by a potential immune-modulating diet recovered the clinical 
condition in a higher percentage if compared with those animals maintained 
with standard diet (65% vs. 50%) at the end of the study. In addition, the dogs 
fed by immune-modulating diet showed a significant increase in platelet 
number all along the study. Intriguingly, our data also indicate that 
pharmacological anti-Leishmania treatment induced significant improvement 
of clinical conditions (for biochemical and haematological evaluation) in all 
CL animals, regardless the type of diet administration. 
Our data evidenced as the pharmacological treatment alone was unable to 
induce long lasting changes in pro-inflammatory response and to modulate 
Treg in sick dogs, while the combination with immune-modulating 
supplemented diet was associated with a significant restoration of Treg level. 
To this regard, it is of note that the nutraceuticals used in this study were 
previously suggested as anti-oxidants and immune-modulating substances to 
reach the physiological status in several models of disease in human (Barak et 
al, 2002; Ghanim et al, 2010) and animals (Dhasarathan et al, 2010; Buttle et al, 
2011; Halder et al, 2012; Barros et al, 2012; Kim et al, 2013). 
 Our study suggested a role for nutraceuticals as food implementation able 
to modulate the immune response. In particular, the nutraceuticals used in this 
study appear to correlate with the decrease of TH1 cells and with the increase of 
Treg in CL sick dogs. It is of some relevance that these effects seem to be not 
associated with fully changes in clinical outcome of infection in leishmaniosis, 
but the increase of Treg could have a putative role in reducing the immune-
pathological injury resulting from CL disease. 
In this context, the possibility that the occurrence of a mild inflammatory 
context accompanied by increased Treg level could ameliorate immune-
mediated pathological effects, as the immune-mediated thrombocytopenia 
(Cortese et al. 2009), appears to be of some interest and it needs to be further 
addressed. 
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 Finally, this study opens an interesting scenario on the role for metabolism 
and nutraceuticals in modifying the immune response in dogs and, as a 
perspective, in humans. 
 
Physiological model: T lymphocyte activation and SOD1 involvement 
This study revealed that SOD-1 is part of the network of molecules involved in 
antigen-dependent T cell response. SOD-1 was recruited by antigen triggered 
TCR and its intracellular content was specifically upregulated in human T cells 
after 16–18 h of anti-CD3 incubation. Moreover, SOD-1 was secreted by a 
BFA-dependent microvesicle pathway by TCR triggered T cells. These effects 
have been observed maintaining the biological complexity of antigen-
dependent T cell response and confirmed in purified T cells activated by anti-
CD3/anti-CD28 beads.  
We showed that extra-cellular SOD-1 is increased in PBMC cultures after 
anti-CD3 treatment. This effect was accompanied by both the induction of 
SOD-1 mRNA and increase of SOD-1 containing microvesicles in culture 
supernatants. Moreover, we identified the T cell population as the specific 
target for SOD-1 induction and extracellular export. Therefore, TCR-dependent 
activation behaves as a triggering element for SOD-1 production and secretion 
by human T cells.  
SOD-1 production is induced in neuroblastoma SK-N-BE cells after 
oxidative stress (Mondola et al. 1998; Mondola et al. 2003). Moreover, other 
and our data showed that cytosolic SOD-1 is secreted by many cell lines 
carrying out a paracrine modulatory role (Mondola et al. 1998; Mruk et al. 
1998; Mondola et al. 2003) and SOD-1 extracellular export was by us 
described in primary lymphoid organs (Cimini et al. 2002). Induction of extra-
cellular export of SOD-1 after TCR-triggering proposes a more complex 
physiological involvement of such enzyme in T cell activation. In this study, 
we described that a BFA-dependent secretion mechanism (Orci et al. 1991) 
characterized SOD-1 micro-vesicle intercellular trafficking upon antigen-
dependent immune response. No effect has been observed in the presence of 
methylamine that impairs cell endocytosis (Maxfield et al. 1979). Thus, a 
major involvement of endocytic recycling pathways might be excluded. Such 
mechanism, previously described in neuronal model (Mondola et al. 1998; 
Mruk et al. 1998, Ookawara et al. 1998; Turner et al. 2005; Kikuchi et al. 2006; 
Mondola et al. 2003), represents an intriguing issue for further investigations.  
SOD-1 is a cytosolic protein lacking signal peptide and consequently 
considered to be excluded from ER translocation. The small amount of wild 
type SOD-1 detected in ER–Golgi apparatus (Urushitani et al. 2008), does not 
support the direct involvement of this organelles in SOD-1 secretion. Moreover, 
the possible interference of BFA, a classical inhibitor of ER–Golgi dependent 
protein secretion, in vesicular pathways not directly involving ER–Golgi 
apparatus cannot be excluded. In this context, our data propose that SOD-1 
could be part of the micro-vesicle-dependent pathways functioning as 
secondary messenger between immune cells (Mathivanan et al. 2010; Thery et 
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al. 2009; Blanchard et al. 2002). A number of data indicate that exogenously 
added H2O2 induced signals in the absence of ligands, whereas catalase is able 
to inhibit such effect (Bae et al. 2000; Konishi et al. 1997; Sundaresan et al. 
1995). Moreover, the observations that production of catalase characterizes 
many pathogens (Wang et al. 2006) and that viral infection modulates H2O2 
production (Peterhans 1997) confirm the multiple roles played by extracellular 
H2O2 in the activation processes of lymphocytes (Kraaij et al. 2010).  
We consistently found that antigen-dependent T cell triggering mediated 
changes in the intra-cellular localization of SOD-1 that was observed to co-
localize with clustered TCR. This event was dependent on ROS availability 
since it was impaired by NAC co-treatment. 
ROS production is an essential component in signalling cascades that 
mediate actin cytoskeleton rearrangements. Small G protein Rac, a key element 
in the network assembly of actin in lamellipodia (Ridley and Hall, 1992; Hall 
1998; Heo 2011) participates in activation dependent ROS production by 
different cell types (Lambeth 2004; Bedard and Krause 2007). Moreover, Rac-
mediated ROS production results in the downmodulation of Rho activity thus 
regulating cellular morphology and migratory behavior (Nimnual et al. 2003). 
SOD-1 associates with Rac-1 regulated NADPH oxidase complexes in 
different mouse tissues and cell lines (Harraz et al. 2008). In this context, 
massive ROS scavenging is expected to disrupt ROS-dependent regulation of 
cell contractility and motility. This event could account for the TCR/SOD-1 
intracellular redistribution (Figure 20). The impairment of early cell 
aggregation in presence of anti-CD3/NAC co-treatment (Figure 21) strongly 
supports such hypothesis. Compelling evidences indicate that ROS, together 
with their essential role in innate antimicrobial defence (Fang 2004), are 
critically involved in the regulation of antigen-dependent response of adaptive 
immune effectors (Devadas et al. 2002; Kwon et al. 2003; Lee et al. 2007; 
Purushothaman and Sarin 2009; Richards and Clark 2009; Nadeau et al. 2012). 
Exposure of T cells to oxidant agents, such as pervanadate or H2O2, induces 
and/or enhances TCR signaling during T cell activation (Secrist et al. 1993; 
Cenciarelli et al. 1996; Hehner et al. 2000). TCR-dependent signaling 
generates both superoxide anion and H2O2 that selectively regulate antigen-
dependent proliferation and Fas ligand expression by T effectors (Devadas et al. 
2002). An oxidative signal  implies its tight regulation and transient character. 
Thus, in the presence of multiple intracellular ROS sources (Sena et al. 2013; 
Los et al. 1995; Jackson et al. 2004; Kwon et al. 2010), the involvement of 
multiple anti oxidant mechanisms in fine tuning of antigen-dependent T cell 
response can be hypothesized. Indeed, Mn-SOD/SOD-2 a major mitochondrial 
antioxidative enzyme has been consistently associated with T cell activation 
(Kamiński et al. 2012) and a role of catalase, glutathione and thioredoxin has 
been also proposed (Kesarwani  et al. 2013). 
In the models of ROS generation upon stimulation of receptors it has been 
shown that H2O2 is the relevant oxidant species that regulate signaling (Rhee et 
al. 2000; Reth 2002; Rhee 2006). Notably, H2O2 has a short half-life in the 
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reducing environment of the cytosol, and it acts close to its site of production. 
Thus, an important aspect of ligand dependent TCR activation might be the 
rapid translocation of receptors to a source of H2O2 or, vice versa, the 
clustering of such a source to the receptor. To this regard, our data strongly 
support the hypothesis that SOD-1 intracellular localization in antigen-
triggered T cells could provide H2O2 generation in the cell compartment 
specifically involved in tuning antigen-dependent signals. A number of data 
suggested the role for H2O2 as key modulator of protein phosphorylation on 
either serine–threonine and tyrosine residues (Fetrow et al. 1999). Indeed, all 
protein tyrosine phosphatases (PTPs) contain an essential cysteine residue in 
the signature active enzyme site motif that has been demonstrated to be target 
of specific H2O2 oxidation. 
The H2O2-mediated inhibition of PTP activity is expected to result in a shift 
of protein tyrosine kinases toward protein phosphorylation. The involvement of 
SOD-1 in such regulatory pathways has been suggested (Juarez et al. 2008). 
Our data on SOD-1 intracellular re-localization upon TCR-triggering suggests 
that SOD-1 could directly modulate kinase/phosphatase activity related to 
proximal TCR signaling. The evidence (Devadas et al. 2002) that anti-CD3 
induced ERK phosphorylation requires H2O2 but is independent on superoxide 
anion, strongly supports such hypothesis. Thus, subcellular 
compartmentalization of H2O2 generating enzymes (like SOD-1) could 
represent a relevant element in achieving the superoxide/peroxide balance 
required to optimize antigen-dependent T cell response. 
Taken in all, our data suggest that SOD-1 is part of the molecular network 
involved in antigen-dependent T cell response. At the best of our knowledge, 
this is the first observation revealing a relationship between SOD-1 
secretion/intracellular re-localization and the antigen dependent T cell 
activation. Further studies are needed to investigate on the involvement of 
SOD-1 in the regulation of TCR signalling cascades as well as in the functional 
cross talk between immune effectors. 
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a  b  s  t  r  a  c  t
Paroxysmal  Nocturnal  Haemoglobinuria  (PNH)  is  due  to  pathological  expansion  of  a  stem  progenitor  bear-
ing a  somatic  mutation  of  PIG-A  gene  involved  in  the  biosynthesis  of  the  glycosyl-phosphatidyl-inositol
(GPI)  anchor.  Numerous  data  suggest  a role  for  immune-mediated  mechanisms  in  the  selection/expansion
of  GPI-defective  clone.  Haemolytic  anaemia  in  PNH  is dependent  on the  effect  of complement  against
GPI-defective  red  cells.  Eculizumab,  an anti-C5  monoclonal  antibody,  is dramatically  effective  in  control-
ling  haemolysis  and  thrombosis,  in  reducing  fatigue  and  in improving  quality  of  life  of patients.  However,
this  therapy  presents  new  challenges  that  need  to  be  properly  faced.omplement
mmune proﬁle
mmune-regulation
mmune therapy
NH
Here, we  report  the  decrease  in  B, Natural  Killer  (NK)  and  regulatory  T  cells  (Treg),  an  altered  cytokine
proﬁle  of invariant-NKT  cells  (NKTi)  and  the  increasing  of  C-X-C  chemokine  receptor  type  4  (CXCR4)
receptor  in  PNH  patients  before  the  Eculizumab  therapy.  Treatment  signiﬁcantly  affects  some  of  these
alterations:  after  Eculizumab,  the  number  of  B  lymphocytes,  the  cytokine  secretion  of NKTi  and  CXCR4
expression  on  CD8  T cells  became  similar  to healthy  donors.  No  effects  were  observed  on NK  and  Treg.
The  amplitude  of  the  GPI-defective  compartment  remained  unchanged.ntroduction
PNH is a rare acquired clonal disorder of haematopoiesis with
n estimated prevalence in the western population around 1–5
ases per million. It is characterized by haemolytic anaemia,
hrombophilia and cytopenia resulting in serious life-threatening
omplications and early mortality (Luzzatto 2006). PNH is due to
he expansion of a stem progenitor bearing a somatic mutation
f the PIG-A gene in a context of a bone marrow failure condi-
ion. Since the PIG-A gene is required for the synthesis of the GPI
nchor, the PIG-A-defective cells do not bear those molecules need-
ng for GPI to be expressed on cell surface. The absence of the
PI-linked complement inhibitor CD55 and CD59 molecules on red
ells explains complement-mediated haemolysis in PNH patients.
Abbreviations: BM,  Bone Marrow; CXCR4, C-X-C chemokine receptor type 4; GPI,
lycosyl-phosphatidyl-inositol; IFN-, interferon-gamma; IL-4, interleukin-4; IL-17,
nterleukin-17; NKTi, invariant-NKT cells; mAb, monoclonal antibody; NK, Natural
iller; PNH, Paroxysmal Nocturnal Haemoglobinuria; Treg, regulatory T cells; SDF-1,
tromal cell-derived factor-1.
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Platelet surface activation by small amounts of complement, uroki-
nase plasminogen receptor (uPAR) deﬁciency and the release of
free haemoglobin by chronic haemolysis might explain throm-
bophilia, while the origin of the underlying bone marrow failure is
still unknown (Luzzatto 2006). The effect of the complement dys-
regulation on GPI-defective cells on the immune effectors of PNH
patients needs to be investigated.
GPI defective clones have been identiﬁed in healthy controls
and PIG-A KO murine models are unable to fully mimic a PNH syn-
drome. These observations strongly suggest that PIG-A mutation is
insufﬁcient to account for the dominance and development of PNH
clones and that some extrinsic selective pressure might favour the
preferential expansion of the GPI-defective compartment. Several
evidences suggest the involvement of T-cell-dependent autoim-
mune mechanisms in the expansion of GPI-defective progenitors
in PNH patients (Luzzatto et al. 1997; Karadimitris et al. 2000;
Luzzatto 2006). The possibility that NK cells might directly partic-
ipate in PNH pathogenesis has been also proposed (Hanaoka et al.
2006).Therapeutic approach with Eculizumab, a humanized anti-C5
monoclonal antibody, is able to inhibit the terminal complement
activation, successfully reducing intravascular haemolysis as well
as thrombosis in PNH. Several clinical trials have demonstrated that
F. Alﬁnito et al. / Immunobiolo
Table 1
Patient clinical and haematological characteristics.
Parameters [PNH patients (N = 34)] Mean ± SD
Male/female ratio 21/13
Mean age (years) 45.62 ± 16
Haemoglobin (g/dL) 9.83 ± 1.48
White blood cell count (×109/L) 3.95 ± 0.78
Neutrophil count (×109/L) 2.37 ± 0.69
Lymphocyte count (×109/L) 1.4 ± 0.6
Platelet count (×109/L) 141.6 ± 39
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NReticulocyte count (%) 4.2 ± 2.4
Neutrophil CD66b− (%) 80.87 ± 17.2
uch therapy reduces or eliminates transfusion requirement, signif-
cantly improving the quality of life in PNH patients (Hillmen et al.
006; Schubert et al. 2008).
Eculizumab mAb  binds to human C5 complement protein pre-
enting its cleavage in C5a and C5b and the subsequent formation
f the membrane attack complex. The potential consequences of
omplement inhibition are of concern, since the complement sys-
em has evolved as a key part of innate immune system and it has
 relevant role in modifying both the innate and adaptive immune
esponse (Carroll 2004a; Le Friec and Kemper 2009; Ricklin et al.
010).
Eculizumab treatment could represent an useful tool for
he study of complement-dependent immune-alterations in PNH
atients.
Here, we examined the effect of Eculizumab treatment
n innate and adaptive immune effectors in a cohort of 34
NH patients. Moreover, we investigated whether complement
nhibition might interfere with the selection/expansion of the GPI-
efective haematopoiesis.
aterials and methods
atients
The study was conducted in 34 Italian PNH patients. Clini-
al characteristics are reported in Table 1. Diagnosis was  made
ccording to International PNH Interest Group Criteria (Parker
t al. 2005). All patients showed primary haemolytic PNH with a
arge GPI-defective granulocyte population (CD66b− and/or CD59−
ranulocytes >50%). No patients showing bone marrow failure
ith emergence of PNH clones (i.e. Aplastic Anaemia/PNH syn-
rome or Hypoplastic PNH) were enrolled in the study (Brodsky
008). Notably, some of the patients were on Eculizumab treat-
ent for more than 48 months. Biological samples were collected
y venipuncture according to standard procedures and used within
he 3 h from the collection. Informed consent was obtained in
ccordance with the Declaration of Helsinki, as approved within
he study protocol by the Institutional Review Board at the Fed-
rico II University of Naples. Patients were studied at diagnosis,
efore any treatment; 17 of them were retested after at least six
onths of Eculizumab therapy; 14 patients were tested at least
hree times before and after Eculizumab treatment. None of PNH
atients received immune-suppressive therapies or other treat-
ents potentially interfering with immune responses.
mmunoﬂuorescence and ﬂow cytometry
Blood samples from patients and controls were analyzed by
mmunoﬂuorescence and ﬂow cytometry by using a two laser
quipped FACScalibur apparatus and the CellQuest analysis soft-
are (Becton Dickinson). FITC, PE, Cychrome and APC labelled
Abs against CD3, CD4, CD25, FoxP3, CD45, CD8, CD16, CD56,
KTi, CD19, CD20, CD45, Interferon (IFN)-,  Interleukin (IL)-4 andgy 217 (2012) 698– 703 699
isotype-matched controls were purchased from Becton Dickinson
PharMingen, San Jose, CA.
To analyze the production of IFN- and IL-4, puriﬁed periph-
eral blood mononuclear cells were cultured overnight in presence
of PMA  and ionomycin. Intracellular staining with the speciﬁc
mAbs was performed by a ﬁxing/permeabilization kit (Caltag,
Burlingame, CA), following manufacturer’s instructions. To avoid
extracellular cytokine export, the cultures were incubated in the
presence of 5 g/mL of Brefeldin-A (Sigma–Aldrich, St. Louis, MO),
as described (Terrazzano et al. 2005).
All phenotypes referred to ﬂow cytometry analysis of the lym-
phocyte population gated by using FSC and SSC parameters, as well
as CD45 labelling. We  choose to evaluate T, B, NK, NKTi and Treg
populations. Cytokine proﬁle (IFN-, IL-4, IL-17) was analyzed in
NKTi effectors, as major players in driving cytokine polarization. In
order to evaluate bone marrow (BM) homing of such effectors we
also evaluated their expression of CXCR4 (Pelus 2008).
Statistical analysis
Statistical evaluation of data, by using software InStat 3.0
(GraphPad Software Inc., San Diego, CA, USA), has been performed
by means of the Mann–Whitney test. Comparisons in the paired
samples were evaluated by means of the Wilcoxon matched-pairs
signed-rank test. Two-sided P values of less than 0.05 were consid-
ered to indicate statistical signiﬁcance and were not adjusted for
multiple testing.
Results
Fig. 1 shows the immune proﬁle of our cohort of PNH patients.
A signiﬁcant reduction of B lymphocytes, NK cells and Treg with
an increased number of NKTi effectors were found (Fig. 1A–D). As
shown, Eculizumab treatment signiﬁcantly modiﬁed B and NKTi
levels in patients, restoring normal values (Fig. 1A and C). No effect
was  observed on the NK and Treg subsets (Fig. 1B and D).  Using
Wilcoxon matched-pairs signed-rank test has always performed
comparison of values before and on Eculizumab therapy in the same
patients. Each reported value represents a mean of at least three
longitudinal evaluations obtained at a six month interval before and
after Eculizumab treatment. Panel E indicate the B and NK cell num-
ber observed in two  exempliﬁcative patients along the study. No
signiﬁcant differences have been observed in the peripheral white
cell count of the patients before and on Eculizumab treatment (not
shown). Percentages conﬁrmed observations on absolute numbers
for B, NK and NKTi effectors. No signiﬁcant difference in the per-
centage of Treg cells was observed between controls and patients,
before or after Eculizumab therapy (data not shown). The ability of
Treg to inhibit T lymphocytes proliferation and IFN- production
was  normal before and on therapy (data not shown).
Fig. 2 reports the analysis of cytokine production proﬁle of NKTi
effectors. As shown, NKTi cytokine secretion proﬁle was  character-
ized by a signiﬁcant decrease of IFN- and IL-17 and by an increase
of IL-4 production in the PNH cohort. On Eculizumab therapy,
the cytokine patterns became comparable with normal controls
(Fig. 2A–C).
Fig. 3 reports the analysis of the surface expression of CXCR4
molecule on NKTi, NK and CD8 T cells. As shown, signiﬁ-
cantly higher CXCR4 expression than healthy donors characterized
all these lymphocyte subsets from PNH patients. Eculizumab
treatment normalized CXCR4 expression on CD8 T cells, while
no signiﬁcant effect was  observed on NKTi and NK subsets
(Fig. 3A–D). The amplitude of the GPI-defective compartment
remained unchanged in all the patients enrolled in the study (not
shown).
700 F. Alﬁnito et al. / Immunobiology 217 (2012) 698– 703
Fig. 1. Analysis of B, NK, NKTi and Treg lymphocytes in PNH patients before and on Eculizumab treatment. As indicated, panels A–D refer comparative analysis of B, NK,
NKTi  and Treg lymphocytes in PNH patients before (BT) and on (OT) at least six months of Eculizumab treatment. The analysis has been performed by considering the values
obtained in the same patients before and after Eculizumab therapy. For the patients, each value represents a mean obtained in at least three independent evaluations before
and  after treatment. Statistical analysis has been performed by Wilcoxon matched-pairs signed-rank test. Panel E shows longitudinal evaluation of B (squares) and NK (circles)
l along
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eymphocytes in two representative patients (full and empty symbols, respectively) 
iscussion
Here, we describe for the ﬁrst time the occurrence of Treg
eduction and NKTi increase in untreated PNH patients as well
s the ability of Eculizumab therapy to selectively restore B
nd NKTi peripheral concentration without signiﬁcant interfer-
nce on NK and Treg numbers. These results conﬁrm previous the study. T0 indicates the beginning of Eculizumab treatment.
other and our data (Schubert et al. 1990; Alﬁnito et al. 1996;
Richards et al. 1998) on the reduced number of B and NK cells
in PNH.Since Eculizumab modiﬁes some of the alterations here
described in untreated patients, we  hypothesize their depen-
dence on complement-mediated pathway/s. Thus, the lack of the
GPI-linked complement regulatory proteins on the surface of the
F. Alﬁnito et al. / Immunobiology 217 (2012) 698– 703 701
Fig. 2. Analysis of cytokine proﬁle of NKTi cells in PNH patients before and on Eculizumab treatment. As indicated, panels A–C represent -IFN, IL-17 and IL-4 production in
N The an
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MKTi  cells obtained from PNH patients before (BT) and on (OT) Eculizumab therapy. 
fter  a 16–18 h culture in the presence of PMA  and Ionomycin. For each sample, a m
nalysis has been performed by Mann–Whitney test. For ﬁve of the patients, the re
PI-defective cells is able to mediate signiﬁcant quantitative alter-
tions of B and NKTi effectors.It is worth noting that the size of PNH clone remains substan-
ially unmodiﬁed in Eculizumab treated patients. This evidence
uggests that the correction of complement hyper activation is
ig. 3. Analysis of CXCR4 expression on NK, NKTi, Treg and CD8 T cells of PNH patients
xpression on NK, NKTi, Treg and CD8 T lymphocytes obtained from PNH patients befor
ann–Whitney test. For ﬁve of the patients the results have been conﬁrmed in at least thalysis has been performed by immune-ﬂuorescence and Flow Cytometry detection
m of 5000 events in the region of NKTi lymphocytes has been acquired. Statistical
ave been conﬁrmed in at least three independent experiments.
unable to revert the immune-mediated mechanisms involved in the
selection and dominance of PNH precursors (Luzzatto et al. 1997;
Karadimitris et al. 2000; Luzzatto 2006).
The absence of the GPI-linked CD55 and CD59 molecules in PNH
cells has been largely observed to mediate enhanced complement
 before and on Eculizumab treatment. As indicated, panels A–D represent CXCR4
e (BT) and on (OT) Eculizumab therapy. Statistical analysis has been performed by
ree independent experiments.
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ctivation, likely accompanied by an altered bio-availability of C3
nd C5 activation fragments (Luzzatto et al. 2010). The blockade
f C5 by Eculizumab (Hillmen et al. 2006; Schubert et al. 2008;
uzzatto et al. 2010) acts on this process, probably modifying the
vailability of complement fragments. Such altered availability of
3 and C5 activation fragments could play a major role in mediating
he effects here described.
Interaction of C3 and C5 fragments with their cognate receptors
n adaptive immune cells has been described to induce pleiotropic
ffector functions, thus translating the danger information into
eﬁned T and B cell responses (Carroll 2004b; Le Friec and Kemper
009; Ricklin et al. 2010). Complement fragments regulate B cell
roliferation, activation and trafﬁcking (Carroll 2004a; Ottonello
t al. 1999; Roozendaal and Carroll 2007) and ﬁnely tune T cell
ytokine patterns (Longhi et al. 2006). In addition, C3 and C5
ragments also interfere with the stromal cell-derived factor-1
SDF-1)/CXCR4 axis, crucial for BM homing regulation (Reca et al.
003).
In PNH patients, we observed a decreased IFN- and IL-17 pro-
uction with increased IL-4 secretion by peripheral NKTi cells.
culizumab treatment modiﬁes this cytokine proﬁle by increas-
ng IFN- and IL-17 and lowering IL-4. These data, according with
revious observations (Longhi et al. 2006; Liu et al. 2005; Heeger
t al. 2005), suggest a role for complement fragments in polariz-
ng T cell responses. Moreover, mouse model defective for CD55
Daf 1−/− mice) showed as an altered production of IFN- by T
ell is strongly dependent on functional complement system: this
lteration is reverted when Daf 1−/− mice are backcrossed with
omplement-deﬁcient mice (C3−/− mice) or treated in vivo with a
eutralizing anti-C5 antibody (Longhi et al. 2006; Liu et al. 2005;
eeger et al. 2005).
In addition, deacylated complement activated fractions could
nterfere with PNH cytokine proﬁle trough enhanced metabolic
ctivity (Cianﬂone et al. 2003).
Here, we report that CXCR4, the molecule mainly responsible for
M recruitment, was signiﬁcantly higher in untreated PNH patient
han controls on NKTi, CD8 and NK cells. Eculizumab treatment
ormalized CXCR4 expression on CD8 T cells; these changes could
e mediated by C3 and C5 cleavage fragments that have been
bserved to perturb leukocyte BM retention acting on the SDF-
/CXCR4 axis (Reca et al. 2003). In addition, the modiﬁed cytokine
roﬁle observed after Eculizumab could be involved in modulat-
ng CXCR4 expression on T cells since IFN- has been observed to
nhibit CXCR4 expression (Shirazi and Pitha 1998), while IL-4 can
nduce opposite effects (Jourdan et al. 2000).
Moreover, the ability of Eculizumab treatment to restore NKTi
eripheral levels suggests the involvement of still unknown
omplement-dependent mechanism/s for this alteration.
Finally, NK and Treg alterations seem not to be inﬂuenced by
culizumab, thus suggesting their independence on Complement
elated pathways. Since similar alterations have been described in
plastic Anaemia and Myelodysplastic Syndromes (Kiladjian et al.
006; Kotsianidis et al. 2009; Alﬁnito et al. 2010), we  can argue their
nvolvement in the immune-mediated pathogenesis of BM failure
isease that underlies PNH.
Taken in all our data suggest that the unbalanced complement
ctivation on the surface of GPI-defective cells mediates signiﬁcant
lteration of immune effectors in PNH patients without signiﬁcant
nterference with the immune-mediated mechanisms under-
ying the selection/expansion of GPI-defective haematopoiesis.
culizumab treatment is able not only to correct the effect of Com-
lement hyper-activation on red cells, but is also able to normalize
omplement-dependent alteration of immunological targets. This
bservation suggests that changes in the immune-proﬁle could be
f some relevance for the amelioration of immune response in the
NH patients on Eculizumab treatment. The effects, here described,gy 217 (2012) 698– 703
could get new insight into the investigation of PNH pathogenesis
and into the pleiotropic effects of Eculizumab therapy.
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Relevance  of  immune-dysregulation  for emergence,  dominance  and  progression  of dysplastic  clones  in
myelodysplastic  syndromes  (MDS)  was  suggested,  but valuable  or predictive  criteria  on this  involvement
are lacking.
We previously  reported  that  reduced  T-regulatory  cells  (Treg)  and  high  CD54  expression  on  T cell
identify  a sub-group  of patients  in whom  an immune-pathogenesis  might  be inferred.
Here,  we  suggest  the  occurrence  of  immune-selection  of  dysplastic  clones  in a subgroup  of MDS
patients,  with  reduced  HLA-I  and HLA-E  on  PMN,  and  propose  that  an  altered  immune  proﬁle  mighteywords:
DS
LA-I
LA-E
K
represent  a  valuable  criterion  to classify  Low/Int-1  patients  on  the  basis  of immune-pathogenesis  of
MDS.
© 2012 Elsevier Ltd. All rights reserved.TL
mmune-proﬁle
. Introduction
MDS  are haematological clonal disorders characterised by inef-
ective haematopoiesis, with a large degree of cytopenia and an
ncremental risk of leukaemia progression [1].
Emergence of the dysplastic clones in MDS  is believed to repre-
ent the consequence of several clonal cytogenetic abnormalities of
one marrow (BM) stem cells. More recently, it has been proposed
hat inﬂammatory microenvironment and an altered immune
esponse in BM could be relevant for the emergence, expansion
nd dominance of dysplastic clones in a sub-group of MDS  patients
2–6]. Dysregulation of immune response has been also suggested
n the pathogenesis of BM failure occurring in Aplastic Anaemia
AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) [4,7,8].  In
upport of immune-mediated pathogenesis is also the efﬁcacy of
mmune-suppressive therapies in MDS  [5,9,10], even if valuable
riteria to predict clinical response to such therapies are still lack-
ng.
Leukaemia risk represents one of the major criterion to classify
DS  patients according to International Prognostic Scoring System
∗ Corresponding author at: Dipartimento di Scienze, Università della Basilicata,
ia  N. Sauro, 85, 85100 Potenza, Italy. Tel.: +39 0817463059; fax: +39 0817463252.
E-mail address: terrazza@unina.it (G. Terrazzano).
145-2126/$ – see front matter ©  2012 Elsevier Ltd. All rights reserved.
ttp://dx.doi.org/10.1016/j.leukres.2012.09.015(IPSS) [11], but several reports indicates the need for a better strat-
iﬁcation of MDS  patients, especially in Low Risk group [12] and a
revised IPSS score (IPSS-R) is expected to be published [13].
The identiﬁcation of the sub-groups of MDS  patients in which
immune-mediated mechanism could be involved in the selection
of dysplastic progenitors could be of some relevance to improve
MDS  clinical management.
A complex scenario of immune-mediated mechanisms may  con-
tribute to the altered haematopoiesis in MDS: i.e., the impairment
of erythroid and granulocytic progenitors caused by CD8+ T lym-
phocytes [2],  the evidence of oligoclonal CD8+ T cells in BM [4],  the
presence of cytotoxic T cell (CTL) and Natural Killer (NK) effectors
able to recognise and kill BM precursors [6,14],  the occurrence of
immune-tolerance dysregulation [3,5] and the presence of a pro-
inﬂammatory cytokine microenvironment in BM [15].
The expression of NK ligands during BM maturation suggests
the involvement of NK in the control of haematopoiesis [16].
A major role for Human Leucocyte Antigen (HLA)-E, a non-
classical HLA molecule, in regulating NK activity was  largely
demonstrated [17]. HLA-E is expressed by a variety of immune and
non-immune cells [6,18,19] and its defects have been described in
some haematopoietic diseases [6,20].  Moreover, an altered expres-
sion of the HLA-E receptors CD94/NKG2 was  associated to chronic
NK lymphocytosis, LGL disorders and to the selection of dysplastic
progenitors in MDS  [6,21,22].
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Alteration of Regulatory T cells (Treg) was described in MDS
23–25]. In this context, the observed increasing percentage of Treg
n the High Risk patients might favour the leukaemia progression by
uppressing the immune response against dysplastic clones. Treg
efects could promote the immune-mediated clearing of healthy
M precursors by auto-reactive T cell effectors in the Low/Int-1
isk group [23–25].
We evidenced [25] that low levels of Treg and high CD54
xpression on CTL in BM identify a sub-group of Low/Int-1 risk
DS  patients in whom immune-mediated mechanisms are likely
nvolved in the emergence/dominance of the dysplastic precursors.
HLA-I represents the restriction element for CTL recognition in
hysiological and pathological conditions [26,27]. Defective HLA-I
xpression was described as a major immune escape mechanism
rom CTL recognition for virus infected and transformed cells
28,29].
Here, we investigated if the above grouping criteria (low Treg
nd high CD54 expression on CTL in BM)  could identify a subgroup
f MDS  patients in whom immune-mediated/CD8-dependent
echanisms could play a role in the emergence/expansion of dys-
lastic precursors. To analyse the selection mechanisms operating
n dysplastic BM,  we focused on PMN  and their BM precursors
nvestigating on the expression level of HLA-E and HLA-I, as major
egulating elements for NK and CTL effectors in Low/Int-1 MDS
atients.
. Design and methods
.1. Patients and controls
We  examined whole BM and peripheral blood (PB) specimens of 30 MDS
atients belonging to Low Risk and Int-1 Risk groups. BM and PB sample collec-
ion, haematological investigation, cytogenetics were performed according to the
HO  recommendations and IPSS score [11,12]. 17 patients belonged to Low Risk
roup (4 refractory anaemia, RA, 8 refractory cytopenia with multilineage dysplasia,
CMD, 2 refractory neutropenia, RN, 3 refractory thrombocytopenia, RT), and 13 to
ntermediate-1 (Int-1) Risk Group (2 RA, 8 RCMD, 3 RN). BM and PB samples from
DS  patients were obtained during routine diagnostic procedures. Informed con-
ent was  obtained from each individual patient. Local Ethical Committee approved
he  study.
None of the patients has been receiving medical treatments that could have
n  impact on their immune condition. Patients were devoid of immune-mediated
iseases and acute or chronic viral infections to avoid any interference on immune-
egulatory mechanisms. A group of 26 healthy blood donors were recruited in the
tudy as controls.
All the MDS  patients were clustered in two  sub-groups, according to their BM
reg levels and CD54 expression on BM CTL, as described [25]. Brieﬂy, 14 MDS
atients showing a Treg percentage in BM ≥ 2% of the lymphocyte population or
 ratio <10 between the mean intensity ﬂuorescence (MIF) for CD54 on BM CD8 T
ells and the control MIF  value, obtained after staining of the same cell population
ith the isotype control mAb, were considered with normal immune proﬁle (NIP).aph for HLA-E on BM GC and on PB PMN in Low, Int-1, AIP and NIP patients. A p
s compared with peripheral PMN  in one representative MDS patient: BM GC proﬁle
At variance, 16 MDS  patients showing a Treg percentage in BM < 2% of the lympho-
cyte population or a ratio ≥10 between the mean intensity ﬂuorescence (MIF) for
CD54 on BM CD8 T cells and the control MIF  value obtained after staining of the
same  cell population with the isotype control mAb, were considered with altered
immune proﬁle (AIP).
2.2. mAb, immunoﬂuorescence, and ﬂow cytometry
FITC, PE, Cychrome and APC labelled mAb against CD3, CD4, CD8, CD56, CD19,
CD10, CD25, CD45, CD54 and isotype-matched controls were purchased from
BD  PharMingen (San Jose, CA). Biotin labelled HLA-E mAb clone MEM-E/07, FITC
labelled MHC-I mAb  clone W6/32 and PE labelled avidin, were purchased from
Sigma–Aldrich, Milan, Italy. To analyse Foxp3 expression, intracellular staining was
performed by anti-human Foxp3 kit (eBioscience San Diego, USA), following the
manufacturer’s instructions. Treg subset was  identiﬁed as the high CD25 expressing
CD4+CD3+ population appearing as a tail, with a slightly but reproducible lower CD4
expression, distinct from the major CD4 population containing both the CD25 low
and  negative cells [25]. These cells were observed to express Foxp3 at a percent-
age >98%, as described [25]. All phenotypes referred to ﬂow cytometry analysis of
the lymphocyte population gated by using forward scatter (FSC) and Side Scatter
(SSC) parameters, as well as CD45 labelling. Flow cytometry and data analysis were
performed by a two laser equipped FACScalibur apparatus and CellQuest software
(Becton Dickinson).
2.3. Statistical analysis
BM and PB values were compared in the paired samples by means of the
Wilcox on matched-pairs signed-rank test. Comparisons between MDS  patients and
controls were performed by Mann–Whitney test. The corrected p value (pc) was
calculated by applying Bonferroni adjustment for multiple comparisons.
3. Results
3.1. HLA E molecule on peripheral PMN of Low and Int-1 risk
MDS patients is signiﬁcantly increased as compared with GC in
BM, regardless the immune-proﬁle
To analyse whether immune-dependent mechanisms could
affect the selection of dysplastic compartment in our cohort of Low,
Int-1 risk MDS  patients categorised according to their immune pro-
ﬁle [25], we evaluated the HLA-E expression on BM granulopoietic
compartment (GC) versus PB PMN  on paired samples. As shown
in Panel A of Fig. 1, HLA-E levels on peripheral PMN are signiﬁ-
cantly higher than on BM GC. No signiﬁcant differences have been
observed between peripheral PMN  from patients and healthy con-
trols or if the patients were grouped according with their immune
proﬁle in BM (AIP vs NIP) and with their clinical classiﬁcation (RA,
RMCD, RN, RT) (see Section 2.1) (data not shown).Higher HLA-E expression on PB PMN  could be dependent on
a speciﬁc up-regulation of the molecule on circulating PMN  or it
could derive from a preferential selection of a BM precursor show-
ing higher HLA-E expression. Thus, we analysed the staining proﬁle
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To investigate on the occurrence of immune-mediated selec-
tion in BM of MDS  patients, we compared the percentage of HLA-I
negative PMN  cells in PB of healthy controls with that observed in
our MDS  cohort. As shown in Fig. 3, signiﬁcant increase of HLA-Iig. 2. HLA-I on PB and BM cells. (A) MIF  graph for HLA-I expression on BM GC and P
B)  HLA-I levels on PB PMN  of patients and controls and (C) staining proﬁle for HL
sotype  control (plain line).
f HLA-E on BM GC. As showed in Fig. 1B, two distinct populations
ith different HLA-E expression levels are present in the BM GC.
herefore, peripheral PMN  seems to belong to the BM GC subset
ith higher HLA-E expression.
Since HLA-E molecules are believed to preferentially regulate
K-cytotoxicity [17–19],  these data suggest the involvement of NK
ffectors in the selection of PMN  in our cohort of MDS  patients.
.2. Occurrence of an altered immune proﬁle in BM is associated
ith signiﬁcant decrease of HLA-I expression on peripheral PMN
n Low and Int-1 Risk MDS  patients
Fig. 2A evidences the decrease of HLA-I on peripheral PMN,
s compared with the BM GC, in both Low and Int-1 Risk MDS
atients (pc < 0.01 and pc < 0.05, respectively). Notably, when the
atients were grouped according with their immune proﬁle in BM
AIP vs NIP, see Section 2), only AIP group demonstrated signiﬁ-
ant decrease of HLA-I expression (pc < 0.001) on PB PMN. Notably,
 tendency towards the presence of lower HLA-I was observed by
omparing AIP sub-group with controls (Fig. 2B).
Intriguingly, lower MHC-I expression in peripheral PMN  seems
o be strongly correlated with the occurrence of an altered BM
mmune proﬁle in MDS  patients.
To investigate whether the presence of PB PMN  expressing
ower HLA-I is dependent on down-modulation mechanisms occur-
ing in the periphery or it is the result of immune-selection pressure
avouring BM precursors bearing lower HLA-I levels, we analysed
he cell distribution in the cytometry staining proﬁles of BM GC
nd of PB PMN. As shown in Fig. 2C, two distinct populations with
ifferent HLA-I levels can be identiﬁed in BM GC: the PB PMN  seem
o belong to the GC subset bearing lower HLA-I expression. This
eature signiﬁcantly characterised the AIP subgroup (Fig. 2A). in Low, Int-1 AIP and NIP patients. A p value < 0.05 has been considered signiﬁcant,
one representative AIP patient: BM GC (dotted line), PB PMN  (bold plain line) and
These observations point to the role for CTL-mediated selection
mechanisms occurring in BM.  Indeed, the maturation of PMN  cells
in which the HLA-I expression is likely unable to effectively present
one (or more) unknown self-antigen to autoreactive CTL seems to
be favoured in AIP subgroup showing a deranged T cell response.
3.3. MDS patients with altered immune proﬁle in BM show
signiﬁcant increase of HLA-I negative peripheral PMNFig. 3. HLA-I negative PMN  in PB of MDS  patients. Percentage of HLA-I negative PMN
in  PB of Low, Int-1, IP and NIP groups of MDS  patients as well as in healthy donors.
A  p value < 0.05 has been considered signiﬁcant.
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Fig. 4. Involvement of NK and CTL in the selection of dysplastic clones. BM polyclonal haematopoiesis (upper panel) with at least four GC cell types (from A to D).  A and
D  cell types express high level of HLA-I and represent more susceptible targets for deranged CTL recognising self-antigens (indicated as T in the model). B and C cell types
express low level the HLA-I or completely lack these molecules and are spared by CTL. NK effectors recognise the presence of HLA-E molecules by CD94/NKG2A receptor.
This  mechanism likely mediates the clearing of C and D cell types. In the presence of a deranged CTL response (AIP patients), the outcome of these interactions is the result
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 cell type from both NK and CTL lysis. The dominance of a CTL-dependent selectio
egative PMN  was observed in Int-1 patients if compared with
he Low Risk Group (pc < 0.05) and the healthy donors (pc < 0.005).
hen MDS  patients were grouped according with their BM
mmune proﬁle, AIP group showed signiﬁcant higher percentage of
LA-I defective PMN  cells in comparisons with the NIP counterpart
pc < 0.05) or healthy donors (pc < 0.05).
Such evidence, together with the observation of a lower expres-
ion of HLA-I on PB PMN  than on BM GC of AIP patients (Fig. 2),
uggest the involvement of immune-mediated, HLA-I dependent
echanisms in the selection of PMN  cells in AIP subgroup, charac-
erised by low Treg and increased CD54 expression on CTL.
. Discussion
Our immune-based sub classiﬁcation of MDS  patients [25] is
ependent on the occurrence of lower Treg percentage, increased
M recruitment of CTL and high CD54 expression on CD8 T cells in
ub-group of Low/Int-1 Risk patients.
This study focused on the hypothesis that this altered immune
roﬁle might underlie the occurrence of CTL-dependent immune-
ediated selection of the dysplastic compartment in MDS. To
his aim, we investigated on HLA-E and HLA-I molecules, as
ajor elements in regulating NK and CTL recognition, respectively
6,17,18,26–29].
The analysis focused on granulopoietic population, as the more
uitable compartment for studying BM selection processes.
Our data indicate that both the decrease in HLA-I expression
nd the increased presence of HLA-I defective cells preferentiallyof the B cell type expressing low HLA-I and high HLA-E. These conditions spare the
sure might account the higher presence of D cell type in AIP group.
characterise the peripheral PMN  of Low/Int-1 Risk MDS  patients
bearing the altered immune proﬁle, by us described [25].
BM precursors are characterised by different expression levels
of HLA-E as well as HLA-I in MDS  patients. Our data indicate that
the recognition of both molecules could be of some relevance in the
selection mechanism for mature PMN  in MDS.
We consistently found that the expression of HLA-E is lower
in BM GC than in PB PMN  population. Since HLA-E is the main
inhibiting element for NK recognition, we hypothesise that NK
could kill the lower HLA-E-expressing PMN  precursors in BM and it
could consent the migration into PB only of those cells expressing
HLA-E at higher level. In support of this speculation is the evi-
dence over the expression of NK ligands during BM maturation
[16] and the presence of defects in both HLA-E and CD94/NKG2
molecule, the main HLA-E-NK receptor, in some haematopoietic
diseases [6,20,22].
Therefore, HLA-E dependent/NK-mediated mechanisms could
likely be part of physiological PMN  maturation processes. In addi-
tion, a perturbation of such regulatory networks might generate
the maturation of dysplastic PMN  with signiﬁcant modulation of
HLA-E surface expression [6].
This study refers that both Low and Int-1 Risk MDS  patients
show signiﬁcant decrease of HLA-I expression on peripheral PMN
if compared with the BM counterpart. Notably, when patients
were categorised according with their immune proﬁle (see Section
2.1), only AIP patients signiﬁcantly maintain a lower expression
of MHC-I on peripheral PMN  cells than in BM GC. This condi-
tion is conceivable with the hypothesis that a subpopulation of
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M-PMN-precursors, characterised by high level of MHC-I
olecules, could behave as preferential target for a deranged auto-
eactive T cell response. Indeed, CTL are expected to be less sensitive
o PMN  precursors expressing low level of MHC-I. These cells rep-
esent the only population leaving the BM as peripheral PMN  in AIP
DS  patients.
HLA-I absence has been associated with escape mechanisms to
TL recognition [26–29].  Therefore, the presence of HLA-I defective
MN suggests a correlation with the occurrence of CTL-dependent
mmune-selection processes.
Our study evidences a signiﬁcant increase of PMN  lacking
LA-I in Int-1 Risk MDS  patients. Such evidence could point to
TL-mediated mechanisms acting in those patients with a more
dvanced MDS  disease stage. The recognition of neo-antigens
xpressed by dysplastic cell clones and an altered self-tolerance in
M [5,30,31] might account for our observations. Notably, when
atients were categorised according with their immune proﬁle,
he increase of peripheral PMN  lacking HLA-I expression was
referentially observed in AIP patients if compared with the NIP
ounterpart.
The immune-based classiﬁcation criteria, by us proposed, seem
o identify a subgroup of Low/Int-1 patients in whom CTL selection
echanisms are pathogenetically relevant.
Our data are conceivable with the idea that HLA-E and HLA-
 molecules are part of the biological mechanisms involved in
he selection of BM precursors. Such immune-dependent selec-
ion processes might become pathogenetically relevant in patients
n which the immunological activation is deranged (AIP sub-
roup of our patients). In this context, it is likely that the
bserved reduced presence of Treg in BM [25] might be unable
o efﬁciently suppress autoreactive T clones that preferentially
ecognise self-antigens on PMN  precursors expressing higher level
f MHC-I molecules. This deranged immune response could be
nhanced by the inﬂammatory BM microenvironment, described
n MDS  [15]. Another component of such complex scenario is the
ytotoxic activity of NK effectors that could recognise and kill
17] the PMN precursors expressing low level of HLA-E/MHC-I
18].
A model for immune-mediated selection is hypothesised in
ig. 4. Ideally, the immune-dependent signals, allowing the mat-
ration and migration of BM precursors in PB, might depend on
xpression of optimal levels of both HLA-E and HLA-I molecules that
egulate NK and CTL recognition. These mechanisms could prefer-
ntially affect the selection of GC in MDS  patients with a deranged
daptive response in BM (AIP group).
In support of our hypothesis are at least two  evidences: (a) PB
MN  cells of all patients in AIP group express higher HLA-E and
ower HLA-I molecules (corresponding to B cell type in Fig. 4); (b)
e found a greater percentage of MHC-I negative PMN  (the C cell
ype in our model) in Int-1, where the MDS  progression is more
dvanced in respect to the Low Risk. Notably, when the patients
ave been categorised according to their immune-proﬁle, this fea-
ure characterised the AIP subgroup.
This and our previous investigations over the immune alter-
tions in MDS  [6,25] suggest the introduction of immune-based
riteria in the classiﬁcation of MDS  patients. In particular, we
imed to better characterise those patients in which the immune-
ediated mechanisms could be part of MDS  pathogenesis. In this
egard, it could be of some relevance the correlation between the
xpression of MHC-I/HLA-E molecules and the selection of PMN
ysplastic clones in MDS. Therfore, the expression of the activating
nd inhibitory receptors on NK effectors and their interplay with
lassical and non classical MHC-I molecules on haematological cell
arget need further investigation to better understand the molec-
lar mechanism on the basis of the emergence of dysplastic clones
n MDS.
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The better understanding of these aspects could provide useful
tools for the clinical management of MDS.
Conﬂict of interest statement
The authors declare no competing ﬁnancial interests.
Acknowledgements
Author’s contributions: FA coordinated the clinical management
of patients; RDP participated in the clinical management of the
patients; ATP, VR, RDP, AG participated in the design, interpre-
tation and analysis of data. FA, GT and GR planned, directed and
coordinated the research and wrote the paper. GT and FA equally
contributed to the study.
Funding: This study was supported by the Italian Ministero
dell’Università e Ricerca Scientiﬁca, PRIN grant.
References
[1] Heaney ML,  Golde DW.  Myelodysplasia. N Engl J Med  1999;340:1649–60.
[2] Baumann I, Scheid C, Koref MS,  Swindell R, Stern P, Testa NG. Autolo-
gous lymphocytes inhibit haemopoiesis in long-term culture in patients with
myelodysplastic syndrome. Exp Hematol 2002;30:1405–11.
[3] Epperson DE, Nakamura R, Saunthararaja Y, Melenhorst J, Barrett AJ, Oligoclonal
T.  cell expansion in Myelodysplastic syndrome: evidence for an autoimmune
process. Leuk Res 2001;25:1075–83.
[4] Maciejewski JP. Immune-mediated bone marrow failure syndromes of progeni-
tor and stem cells: molecular analysis of cytotoxic T cell clones. Folia Histochem
Cytochem 2007;45:5–14.
[5] Sloand EM,  Rezvani K. The role of the immune system in myelodysplasia: impli-
cations for therapy. Semin Hematol 2008;45:39–48.
[6] Ruggiero G, Sica M, Luciano L, Savoia F, Cosentini E, Alﬁnito F, et al. A case
of myelodysplastic syndrome associated with CD14(+)CD56(+) monocyto-
sis, expansion of NK lymphocytes and defect of HLA-E expression. Leuk Res
2009;33:181–5.
[7] Luzzatto L, Bessler M,  Rotoli B. Somatic mutations in Paroxysmal Nocturnal
Hemoglobinuria: a blessing in disguise? Cell 1997;88:1–4.
[8] Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic
anaemia: distinct entities or diseases linked by a common pathophysiology?
Semin Hematol 2000;37:15–29.
[9] Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, et al.
A  pilot study of antithymocyte globulin (ATG) in the treatment of patients with
‘low-risk’ myelodysplasia. Br J Haematol 2003;120:679–84.
10] Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M,  Dunbar C, et al.
Antithymocyte Globulin for treatment of the bone marrow failure associated
with Myelodysplastic Syndromes. Ann Intern Med  2002;137:156–63.
11] Greenberg F, Cox C, LeBeau MM,  Fenaux P, Morel P, Sanz G, et al. International
scoring system for evaluating prognosis in myelodysplastic syndromes. Blood
1997;89:2079–88.
12] Malcovati L, Porta MG,  Pascutto C, Invernizzi R, Boni M,  Travaglino E, et al.
Prognostic factors and life expectancy in myelodysplastic syndromes classiﬁed
according to WHO  criteria: a basis for clinical decision making. J Clin Oncol
2005;23:7594–603.
13] Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-
stratiﬁcation, and management. Am J Hematol 2012;87:693–701.
14] Sloand EM,  Mainwaring L, Fuhrer M,  Ramkissoon S, Risitano AM, Keyvana-
far K, et al. Preferential suppression of trisomy 8 compared with normal
hematopoietic cell growth by autologous lymphocytes in patients with trisomy
8  myelodysplastic syndrome. Blood 2005;106:841–51.
15] Zeng W,  Miyazato A, Chen G, Kajigaya S, Young NS, Maciejewski JP. Interferon-
gamma-induced gene expression in CD34 cells: identiﬁcation of pathologic
cytokine-speciﬁc signature proﬁles. Blood 2006;107:167–75.
16] Nowbakht P, Ionescu MC,  Rohner A, Kalberer CP, Rossy E, Mori L. Ligands for
natural killer cell-activating receptors are expressed upon the maturation of
normal myelomonocytic cells but at low levels in acute myeloid leukemias.
Blood 2005;105:3615–22.
17] Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225–74.
18] Terrazzano G, Sica M,  Gianfrani C, Mazzarella G, Maurano F, De Giulio B, et al.
Gliadin regulates the NK-dendritic cell cross-talk by HLA-E surface stabiliza-
tion. J Immunol 2007;179:372–81.
19] Marin R, Ruiz-Cabello F, Pedrinaci S, Méndez R, Jiménez P, Geraghty DE,
et  al. Analysis of HLA-E expression in human tumors. Immunogenetics
2003;54:767–75.
20] Majumder D, Bandyopadhyay D, Chandra S, Mukherjee N, Banerjee S. Lack
of  HLA-E surface expression is due to deﬁciency of HLA-E transcripts in the
malignant hematopoietic cells of leukemic patients. Leuk Res 2006;30:242–5.
21] Fischer L, Hummel M,  Burmeister T, Schwartz S, Thiel E. Skewed expression of
natural-killer (NK)-associated antigens on lymphoproliferations of large gran-
ular lymphocytes (LGL). Hematol Oncol 2006;24:78–85.
1 ia Re
[
[
[
[
[
[
[
[74 G. Terrazzano et al. / Leukem
22]  Warren HS, Christiansen FT, Witt CS. Functional inhibitory human
leucocyte antigen class I receptors on natural killer (NK) cells in
patients with chronic NK lymphocytosis. Br J Haematol 2003;121:
793–804.
23] Kordasti SY, Ingram W,  Hayden J, Darling D, Barber L, Afzali B, et al.
CD4+CD25+high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).
Blood 2007;110:847–50.
24] Kotsianidis I, Bouchliou I, Nakou, Spanoudakis E, Margaritis D, Christophoridou
AV,  et al. Kinetics, function and bone marrow trafﬁcking of CD4+CD25+FOXP3+regulatory T cells in myelodysplastic syndromes (MDS). Leukemia
2009;23:510–8.
25] Alﬁnito F, Sica M,  Luciano L, Pepa RD, Palladino C, Ferrara I, et al. Immune
dysregulation and dyserythropoiesis in MDS. Br J Haematol 2010;148:
90–8.
[
[search 37 (2013) 169– 174
26] Zinkernagel RM,  Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity
in  lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.
Nature 1974;48:701–2.
27] Germain RN. MHC-dependent antigen processing and peptide presentation:
providing ligands for T lymphocyte activation. Cell 1994;76:287–99.
28] Ploegh HL. Viral strategies of immune evasion. Science 1998;280:249–53.
29] Seliger B, Ritz U, Ferrone S. Molecular mechanisms of HLA class I anti-
gen abnormalities following viral infection and transformation. Int J Cancer
2006;118:129–38.30] Barrett AJ. Myelodysplastic syndrome: an example of misguided immune
surveillance? Leuk Res 2004;28:1123–4.
31] Sloand EM,  Wu CO, Greenberg P, Young NS, Barrett J. Factors affecting response
and survival in patients with myelodysplasia treated with immunosuppressive
therapy. J Clin Oncol 2008;26:2505–11.
CASE REPORT
Natural killer expansion, human leukocyte antigens-E
expression and CD14+ CD56+ monocytes in a
myelodysplastic syndrome patient
Giuseppe Terrazzano1,2, Valentina Rubino2, Anna Teresa Palatucci2, Angela Giovazzino2, Mariangela
Annunziatella2, Orsola Vitagliano3, Fiorella Alfinito3,*, Giuseppina Ruggiero2,*
1Department of Science, University of Basilicata, Potenza; 2Department of Translational Medical Sciences, University of Naples “Federico II”,
Naples; 3Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Naples, Italy
Abstract
Myelodysplastic syndromes (MDS) are clonal disorders characterized by ineffective hematopoiesis and
possible evolution to acute leukemia. Occurrence of stem cell defects and of immune-mediated
mechanisms was evidenced as relevant for pathophysiology of MDS. Here, we described one case of
MDS patient carrying CD14+CD56+ monocytes in bone marrow (BM), in the presence of a defective
human leukocyte antigen (HLA)-E expression on peripheral blood (PB) cells and of natural killer (NK) cell
expansion in PB and BM. The defective HLA-E expression and the NK expansion are proposed to be
relevant for the pathogenesis of myelodysplasia in those patients showing CD14+CD56+ monocytes in
BM.
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Myelodysplastic syndromes (MDS) are a heterogeneous
group of clonal disorders of stem cell characterized by
dysplasia, ineffective hematopoiesis, cytopenia, and frequent
progression to acute myeloid leukemia (AML) (1). The
International Prognostic Scoring System considers some
clinical variables (i.e., blast percentage, cytopenia, and
genetic abnormalities) to deﬁne four patient groups of risk to
develop AML: low-, intermediate-1-, intermediate-2-, and
high-risk patients (2). The needing of new grouping criteria
to better characterize the patients and to improve MDS clini-
cal management is recognized (3).
The pathophysiology of the bone marrow (BM) failure is
complex, and MDS are more than a single disease entity.
The occurrence of intrinsic stem cell defects and of immune-
mediated mechanisms has been largely suggested (1–8).
Our previous data evidenced the relevance for immune
dysregulation in MDS (7). On the different levels of BM
regulatory T cells (Treg), we identiﬁed two subgroups of
low-risk MDS patients. Intriguingly, only the subgroup with
lower Treg percentage showed a BM CD8 lymphocytes
recruitment. In addition, the different levels of the activation
marker CD54 on BM CD8 lymphocytes revealed two sub-
groups of intermediate-1-risk patients. Notably, BM recruit-
ment of CD8 lymphocytes in the low-risk group and/or the
presence of high CD54 expression on BM CD8 cells in
intermediate-1 patients are associated with more pronounced
dyserythropoiesis and erythropoietin treatment. In addition,
we suggested the occurrence of immune selection of
dysplastic clones in such subgroup of MDS patients. Indeed,
reduced human leukocyte antigens (HLA)-I and increased
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 265
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HLA-E on peripheral polymorphonuclear cells (PMN) when
compared with the BM counterpart were observed. We pro-
posed that an altered immune proﬁle might represent a valu-
able criterion to grouping low/intermediate-1 patients on the
basis of immune pathogenesis of MDS (8).
These and other desirable criteria (3) could be useful to
extend and improve the stratiﬁcation of MDS patients.
In 2009, we characterized an MDS patient showing neutro-
penia, CD14+CD56+ monocytosis, and polyclonal expansion
of natural killer (NK) expressing CD94/NKG2A and CD94/
NKG2C receptors (6). In this patient, we proposed that the
observed defective HLA-E expression on myeloid lineages,
the constitutive presence of CD178/Fas-L on CD14+CD56+
monocytes, and the expansion of CD94/NKG2A+ CD94/
NKG2C+ NK cells could be relevant for the pathogenesis of
MDS.
Expression of ligands for NK receptors during myeloid
maturation (9) highlights the NK involvement in the hemato-
poietic homeostasis. Literature suggested the role for IFN-c
secretion by large granular lymphocytes (LGL), belonging to
T or NK lineages, in hematopoietic diseases (10).
Natural killer cells are crucial for the establishment of
innate immunity and in the complex regulation of all the
immune responses (11). They express two families of HLA-
recognizing receptors: the killer immunoglobulin-like recep-
tors and the lectin-like receptors, as CD94/NKG2A and
CD94/NKG2C (12, 13). Altered expression of CD94/NKG2
receptors was correlated with chronic NK lymphocytosis
and with other LGL disorders (10, 14, 15). HLA-E, a non-
classical major histocompatibility complex class I molecule,
is expressed by several immune and non-immune cells in
healthy and pathological conditions (16, 17). The involve-
ment of HLA-E in hematopoietic diseases has been
proposed (6, 8, 10, 18). HLA-E mainly regulates NK func-
tions (11–13). In this regard, CD94/NKG2A generates an
inhibitory signal after the recognition of HLA-E, while
CD94/NKG2C binds the molecule and induces the activa-
tion of NK cells (11–13). The balance between positive and
negative signals, generated by these and other receptors,
orchestrates the NK activities.
CD56+CD14+ cells is a minor and poorly characterized
monocyte population, usually representing 0.2–3.5% of total
peripheral mononuclear cells (19). They produce a variety of
cytokines, present antigens, and could mediate regulatory
functions.
Here, we describe a peculiar case of MDS patient showing
thrombocytopenia in peripheral blood (PB), CD14+CD56+
monocytosis in BM, and polyclonal expansion of NK
expressing CD94/NKG2A and CD94/NKG2C. In addition,
we observed a defective HLA-E expression in the PB mye-
loid lineages. We speculate that the expansion of CD94/
NKG2A+ CD94/NKG2C+ NK cells is relevant for the emer-
gence/dominance of dysplastic clone(s) in those patients
showing CD14+CD56+ monocytosis in BM.
Patient and methods
Case report
An 85-year-old man presented with thrombocytopenia, whose
ﬁrst record was referred to few months before. Hb was 12.9 g/
dL, MCV 67ﬂ, white blood cell count 4.4 9 109/L with
0.15 9 109/L neutrophils, 0.096 9 109/L monocytes, and
0.166 9 109/L lymphocytes. PMN appeared hypogranular
and monocytes highly dysmorphic. Platelet count was
80 9 109/L.
BM aspirate was characterized by good cellularity with
erythroid and granulocytic dysplasia, numerous micromegak-
aryocyte and 5% of blast cells. Patient received diagnosis of
refractory cytopenia with multilineage dysplasia according to
WHO classiﬁcation (1). Microcytosis was due to beta thalas-
semia, and no organomegaly was present.
Patient showed a normal karyotype (46,XY).
Patient has been not receiving medical treatment, which
may impact his immune response. Informed consent was
obtained from the patient and the controls.
mAb, immune fluorescence and flow cytometry
Anti-CD3, -CD8, -CD4, -CD54, -CD25, -CD56, -CD14,
-CD45, -CD33, -CD127, -p140 (Q66 clone) and isotype-
matched labeled controls mAbs (Becton-Dickinson, Los
Angeles, CA, USA), anti-HLA-I (W6/32 clone) mAb
(SIGMA, Milan, Italy), anti-HLA-E mAb (MEM-E/08 clone)
(Immunological Sciences, Rome, Italy); anti-CD158e1/e2
(p58.1/2), -CD244 (2B4), -CD335 (NKp46), -CD337
(NKp30), anti-NKG2A (Z199), -Vb14, -Vb12, -Vb7.2,
-Vb20, -Vb18, -Vb7.1, -Vb22, -Vb13.2, -Vb1, -Vb17,
-Vb5.3, -Vb5.1 -Vb23, -Vb4, -Vb2, -Vb13.1, -Vb5.2, -Vb8,
-Vb9, -Vb11, -Vb3, -Vb13.6, -Vb21.3F, -Vb16 mAbs
(Beckman-Coulter, Paris, France), and -NKG2C (134591
clone) mAb (R&D System, Minneapolis, MN, USA).
Flow cytometry was performed by FACSCalibur and
CellQuest analysis software (Becton Dickinson), as
described (6–8).
Three sex- and age-matched healthy donors were used as
controls.
Statistical analysis
Statistical analysis for P calculation was performed by using
Student’s t-test. Results were considered signiﬁcant with a P
value ≤ 0.05.
Results
The patient shows dysplastic monocytosis (data not shown)
and an extensive defect of HLA-E expression in both the
monocytes and PMN in PB; indeed, the two populations
266 © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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evidenced only a very low staining for HLA-E (Fig. 1A). In
contrast, the monocytes and PMN are positive for HLA-E in
BM (Fig. 1B). Intriguingly, the BM monocytes appear to
express HLA-E as large distribution (see pick 2 in Fig. 1B)
and at higher level if compared to PMN (Fig. 1B). In this
regard, monocytes are divided into two subpopulations
(Fig. 1C): one expresses at lower intensity the HLA-E and
is CD14+CD56, while the second one shows higher level
of the molecule and is CD14+CD56+.
In addition, the expression of HLA-I on lymphocytes, mono-
cytes, and PMN is similar between BM and PB (Fig. 1D).
The percentage of CD14+ monocytes co-expressing the
CD56 is signiﬁcantly expanded in BM (more than 30% of
monocytes) than in periphery (<2% of PB monocytes) (data
not shown).
Natural killer expansion (more than 35% of lymphoid cell
in BM and PB compartment) carried several NK receptors
(CD335, CD337, CD244, CD158e1/e2, CD158/p70, CD94/
NKG2A, CD94/NKG2C), suggesting that NK cells are
frankly polyclonal (data not shown).
Intriguingly, the BM and PB NK cells are highly positive
for two HLA-E receptors; in particular, the CD3CD56+
cells expressing CD94/NKG2A are the 37% and CD94/
NKG2C the 43% (data not shown).
Treg percentage and CD54 expression on both the CD4+
and CD8+ T Lymphocytes are similar to BM and PB, and the
percentages are comparable to healthy donors (data not
shown). Finally, the TCR repertoire of T lymphocytes appears
to be polyclonal in BM and PB, without TCR-Vb skewing of
one or more T clones that, if present, could indicate a signiﬁ-
cant antigen speciﬁc T response in BM (data not shown).
Discussion
The patient here described shows thrombocytopenia, mon-
ocytosis and expansion of polyclonal NK cells, and normal
karyotype. These features are accompanied by a defect of
HLA-E expression on PMN and monocytes in PB.
Notably, despite the similarities of this MDS case with the
other by us observed patients for the likely involvement of
HLA-I and HLA-E in fostering the myelodysplasia (8), this
patient seems to be substantially unframed with the immuno-
logical criteria that we previously published (7). Indeed, the
patient reveals no signiﬁcant variation in the percentage of
Treg or of expression of CD54 when compared with healthy
controls. Nevertheless, the patient shows an intriguing anal-
ogy with previous patient (6) for the presence of dysplastic
monocytosis, mainly represented by CD14+CD56+HLA-E+
cells in BM, and for the expansion of CD94/NKG2C+ NK
cells.
Here, we suggest that BM NK expansion, with increased
expression of CD94/NKG2C, generates a selective pressure
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Figure 1 Flow cytometry analysis. Panel A: surface expression of human leukocyte antigen (HLA)-E on polymorphonuclear cells (PMN) (1) and
Monocytes (2) in peripheral blood (PB); Panel B: surface expression of HLA-E on PMN (1) and Monocytes (2) in bone marrow (BM); Panel C: sur-
face expression of HLA-E on CD14+ CD56 (1) and CD14+CD56+ (2) Monocytes in bone marrow; Panel D: surface expression of HLA-I on PMN
from BM (1) and PB (2) and on Monocytes from BM (3) and PB (4). The staining for Isotype mAb control is reported in all the panels (CTR). PB
and BM PMN and monocyte populations were gated by FSC and SSC parameters and by CD45, CD14, CD33, CD56 labelling.
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on hematopoietic compartments. In this regard, patient
CD94/NKG2C+ NK cells could have exerted an efﬁciently
killing of HLA-E+ myeloid precursors, thus targeting HLA-
E+ monocytes and HLA-E+ PMN in BM and sparing those
cells carrying the lowest HLA-E levels. Indeed, it is worth
noting that the dysplastic monocytes are mainly HLA-
E+CD14+CD56+ in BM and become HLA-E-CD14+CD56-
in PB likely due to the action of NK selection.
Moreover, the expression of HLA-I appears to be not
involved in the selection by NK in this patient, as the levels
of these molecules on PMN and monocytes are similar
between PB and BM.
These evidences suggest that the action of NK took place
as a sort of ‘customs’ that allowed to pass only certain cells
with certain characteristics from the BM toward the periph-
ery. In reason of this NK selective pressure, the monocyte
and PMN populations have been totally defective for HLA-E
expression in PB.
We could not rule out that other receptor/ligand pathways
could have a role in regulating NK activity in this patient. In
addition, the TCR repertoire appears to be unskewed, and such
result could formally exclude antigen speciﬁc T-cell response
in the patient, at least at the time of our observation.
Taken together, the current study and the others by us
published (6–8) suggest that the emergence and dominance
of dysplastic clones could be inferred and/or sustained in
some MDS patients also by NK activity alone and/or as
contribute, together with other immune-mediated mecha-
nisms. The relevance for the expression of HLA-E and
HLA-I on hematopoietic cells could be largely different, and
it can range from etiopathogenetic role to some physiopatho-
logical aspects. This consideration makes sense when one
considers the balance between anti-tumor immune response
and the possible detrimental implication of immune editing
in cancer (20). Likewise, MDS condition is identiﬁable as
the consequence of several clonal cytogenetic abnormalities
conferring proliferative and surviving advantage to those
stem cells generating dysplastic clones (1, 2). In this context,
it has been proposed that inﬂammatory BM microenviron-
ment and an altered immune response could not only repre-
sent huge protective reactions of the individual from disease,
but also favorable conditions for the emergence, expansion,
and dominance of dysplastic clones in a subgroup of MDS
patients (1–8).
The plain signiﬁcance of this mechanism in counteracting,
causing, sustaining, or accompanying the MDS is not deﬁni-
tively established, but it appears to be of great relevance to
better understand the role as ‘Janus Bifront’ for immune
response in MDS.
In conclusion, this speculation could open new insight into
the etiopathogenesis of MDS, and it could offer useful tools
to the clinical decision making and for a more accurate strat-
iﬁcation of those patients in whom the hypothesis of
immune-mediated mechanisms is conceivable.
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Canine leishmaniasis caused by the protozoan parasite Leishmania infantum is a chronic systemic disease
endemic in Mediterranean basin. The aim of the study is to investigate the immune proﬁle of dogs nat-
urally infected by Leishmania infantum. In order to address such issue, CD4+ and CD8+ lymphocyte T cell
subsets, peripheral CD4+CD3+Foxp3+ (Treg) levels and the presence of pro-inﬂammatory T cells have been
assessed, in 45 infected dogs and in 30 healthy animals, by using immunoﬂuorescence and ﬂow cytom-
etry detection. Animals were categorised according to their clinical-pathological status and their anti-
body titer at diagnosis. Results showing a signiﬁcant increase of CD8+CD3+ T lymphocytes, a reduced
percentage of the T regulatory CD4+CD3+Foxp3+ subset and a signiﬁcant increase of TH1 cells, characterise
the infected dogs, regardless of their antibody titer or the occurrence of clinical symptomatic disease.
These data may provide new insights into the pathogenesis of immune-mediated alterations associated
with canine leishmaniasis.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Canine leishmaniasis (CL), caused by the protozoan Leishmania
infantum and transmitted by the bite of phlebotomine sand ﬂy vec-
tors, is a severe zoonosis potentially fatal to humans and dogs,
which comprise the main reservoir of infection to humans. CL is
endemic in more than 70 countries in the world. It is present in re-
gions of southern Europe, Africa, Asia, South America and Central
America and has been reported also in United States of America
(Petersen and Barr, 2009). A broad range of immune responses
and clinical manifestations has been described in CL. In fact, clini-
cal appearance and evolution of leishmaniasis is the consequence
of complex interactions between the parasite and the genetic and
immunological background of the host (Baneth et al., 2008; Maia
and Campino, 2012). Leishmania infection in dogs may be mani-
fested as a subclinical infection, a self-limiting disease, or a non-
self-limiting and severe illness (Bottero et al., 2006). In dogs, the
two opposite extremes of this clinical spectrum are characterized
by a protective immunity that is mediated by CD4+ T cells by the
release of interferon-c (IFN-c), interleukin-2 (IL-2) and tumor
necrosis factor (TNF-a) that induce macrophage anti-Leishmaniaactivity, and a disease susceptibility that is associated with the pro-
duction of a marked humoral non-protective immune response
and a reduced or depressed cell mediated immunity with a mixed
T helper 1(TH1) and T helper 2 (TH2) cytokines response (Alvar
et al., 2004; Baneth et al., 2008). Within this spectrum, clinical
signs of disease can range from a mild dermatitis and alopecia,
associated with speciﬁc cellular immunity and low humoral re-
sponses (Ordeix et al., 2005) to a severe disease, characterized by
renal damage with glomerulonephritis due to immune complex
deposition, associated with a massive humoral response and high
parasite loads (Costa et al., 2003). In addition, asymptomatic vis-
ceral leishmaniasis has been consistently associated with the
induction of cellular immunity in endemic areas (Baneth et al.,
2008; Reis et al., 2009; Solano-Gallego et al., 2009; Alexandre-Pires
et al., 2010; Coura-Vital et al., 2011).
The characterization of the ongoing immune response in ani-
mals infected by L. infantum has been described to be relevant to
establish a prognosis and to predict a clinical response to treat-
ment (Papadogiannakis et al., 2010). Several studies pointed out
that lymphocyte level in sick dogs is decreased but returns to nor-
mal values after treatment (Moreno et al., 1999; Guarga et al.,
2002; Guerra et al., 2009); an increased number of CD4+T cells in
dogs with low parasitism (Reis et al., 2006) has been also referred.
Furthermore, the number of CD4+ T cells in peripheral blood wascted by
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dogs while there was no correlation between the clinical status
or response to therapy and CD4+ T cell counts (Miranda et al.,
2007). The results obtained highlight the complexity of the im-
mune response to L. infantum infection. Indeed, while low levels
of circulating B cells and monocytes have been observed to behave
as important markers of severe CL, the number of CD4+ T lympho-
cytes cannot be used alone as a prognostic marker (Miranda et al.,
2007; Alexandre-Pires et al., 2010). Increased levels of CD8+T lym-
phocytes have been referred as a mayor phenotypic feature of
asymptomatic disease (Reis et al., 2006; 2009).Treatment and
clinical recovery have been associated with improved and/or nor-
malized levels of T cells, CD4+ subset, CD4+/CD8+ ratio and anti-
gen-dependent proliferation in CL (Moreno et al., 1999; Guarga
et al., 2000, 2002; Papadogiannakis et al., 2010).The preferential
association of a pro-inﬂammatory microenvironment with a
favourable outcome of the disease has been largely suggested in
CL (Chamizo et al., 2005). Moreover, the analysis of cytokine pro-
duction in peripheral blood revealed some discrepancy (Maia and
Campino, 2012).
The occurrence in CL of immune-mediated pathological pro-
cesses that have been observed to be involved in the induction of
polyarthritis, uveitis, glomerulonephritis, (Kharazmi et al., 1982;
Ferrer, 1992; Ciaramella et al., 1997; Koutinas et al., 1999; Costa
et al., 2003; Solano-Gallego et al., 2009), as well as of antibody-de-
pend platelet abnormalities (Terrazzano et al., 2006; Cortese et al.,
2009, 2011), suggest the relevance of immune response control in
this infection. Control of the immune response in human and mur-
ine leishmaniasis has been observed to largely depend on the pro-
duction of interleukin-10 (IL-10), which can come from several
different cell types (Kaye and Scott, 2011). A key immune regula-
tory mechanism is represented by the CD4+CD25+Foxp3+ T (Tregs)
subset (Sakaguchi, 2005). Tregs are able to control the immune
effector cells in terms of clonal expansion, differentiation, cytokine
pattern and tissue migration during immune response. It is rele-
vant that Tregs control T cell priming in lymphoid organs but they
are also able to inhibit immune response in peripheral tissues
(Miller et al. 2004; Huehn and Hamman, 2005; Sakaguchi, 2005).
The role of Tregs in preventing harmful autoimmune responses
and their dynamic involvement in the modulation of immune-re-
sponse against infectious agents (Nylén and Sacks, 2007; Belkaid
and Tarbell, 2009) and transformed cells (Curiel et al., 2004) has
been consistently described. In human visceral leishmaniasis (VL)
reports on the frequency and function of Tregs are not conclusive.
Recently, Maurya et al. (2010) reported that active VL is not asso-
ciated with increased frequencies of peripheral Foxp3 Treg or accu-
mulation at the site of infection.
In veterinary medicine, Tregs have been observed to signiﬁ-
cantly increase in dog tumour models (Biller et al., 2007; Houriuchi
et al., 2009; O’Neill et al., 2009; Rissetto et al., 2010). Few studies
addressed the level of regulatory cytokines interleukin-10 (IL-10)
and the transforming growth factor beta (TGF-b) (Strauss-Ayali
et al., 2007; Boggiatto et al., 2010) in CL. The study of Treg involve-
ment in the regulation of dog immune-response against Leishmania
needs further investigation. Indeed, IL-10 producing regulatory T
cell subsets have been described to be relevant in the early phase
of visceral leishmaniasis in mouse model of L. infantum infection
(Rodrigues et al., 2009), while a reduction in lymph-node Treg
was described to signiﬁcantly correlate with immune protection
consequent to Leishmune vaccination (de Lima et al., 2010).
The aim of the present study is to investigate the immune pro-
ﬁle of dogs naturally infected by L. infantum. In order to address the
immune regulatory networks involved in CL, lymphocyte T cell
subsets, peripheral Treg levels and the presence of pro-inﬂamma-
tory T cells have been assessed, in a cohort of 45 Leishmania in-
fected dogs (LD), compared with 30 sex/age paired healthyPlease cite this article in press as: Cortese, L., et al. Regulatory T cells, Cytotox
Leishmania infantum. Res. Vet. Sci. (2013), http://dx.doi.org/10.1016/j.rvsc.2013animals, by using immune ﬂuorescence and ﬂow cytometry detec-
tion. Leishmaniotic dogs have been categorised according to their
clinical-pathological status and their serological anti speciﬁc-Leish-
mania antibody titer.
2. Materials and methods
2.1. Animals
Forty-ﬁve dogs naturally infected by L. infantum (20 males and
25 females, 5–9 years old) from the Campania region (South Italy)
were enrolled with the owner’s consent. Ten dogs were pure breed,
while 35 were mongrels. Also, 30 healthy dogs (12 males, 18 fe-
males, 5–7 years old) with no clinical signs of CL, which were also
being negative for serological, parasitological and molecular exam-
inations, were considered as healthy control group.
This work has been reviewed by Ethical Animal Care and Use
Committee of the University of Naples Federico II and received
institutional approval (Prot. 2011/0043885).
2.2. Clinical parameters and diagnostic procedure
For all dogs, the history (none of dogs received a speciﬁc treat-
ment for CL) and the clinical examination were performed. Leish-
mania infected dogs were classiﬁed according to Solano-Gallego
et al. (2009). The LD cohort has been categorised in two groups:
LD-A dogs (n = 23), presenting neither clinical signs on physical
examination nor clinical-pathological abnormalities by routine
laboratory tests (CBC, biochemical proﬁle and urinalysis) but with
a conﬁrmed L. infantum infection and LD-S dogs (n = 22) with clin-
ical leishmaniasis, presenting clinical signs and/or clinical-patho-
logical abnormalities and a conﬁrmed L. infantum infection
(Table 1). Diagnosis of CL has been conﬁrmed by detection of
amastigotes in stained cytological smears of aspirates from lymph
nodes or bone marrow, serologically by a positive indirect ﬂuores-
cent antibody test (IFATP 1:80) and by a polymerase chain
reaction (PCR). Animals presenting IFAT titersP 1:80 and positive
molecular diagnosis were included in the study as infected ani-
mals. The relevance of humoral immune response on susceptibil-
ity/resistance mechanism during ongoing canine visceral
leishmaniasis has been recognized throughout ex vivo and
in vitro investigations (Oliva et al., 2006; Reis et al., 2006). Thus,
in order to analyse the immune proﬁle in Leishmania infected ani-
mals showing different degree of speciﬁc immune activation, Leish-
mania infected dogs were further sub-classiﬁed as Low IFAT titer
animals (LD-L) when showing a IFAT titer 1:80–1:160 or High IFAT
Title animals (LD-H) when showing a IFAT titer >1:160.
Animals presenting neither clinical signs on physical examina-
tion nor clinical-pathological abnormalities by routine laboratory
tests, and with IFAT negative (61:40) and negative PCR, were con-
sidered non-infected and included as healthy control group.
Occurrence of other infectious diseases was always excluded in
all dogs. No Ehrlichia canis nor Anaplasma phagocytophilum moru-
lae, Babesia canis trophozoites and microﬁlariae were observed in
peripheral blood smears. These infections were also excluded using
IFAT and/or PCR. Finally, Diroﬁlaria immitis infection was ruled out
using the Snap Canine Combo Heartworm Antigen Antibody Test
(IDEXX).
2.3. Blood sample collection
Ten millilitres of peripheral blood was collected from the jugu-
lar vein into tubes containing ethylene diamine tetraacetic acid
(EDTA). A complete cell blood count was performed in each sample
within 30 min from the collection by using a semi-automatic cell
counter (Genius S; SEAC Radom Group, Florence, Italy). All samplesic T lymphocytes and a TH1 cytokine proﬁle in dogs naturally infected by
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Table 1
Results of diagnostic tests and clinical and laboratory ﬁndings of 45 Leishmania infected dogs.
LD – A dogs IFAT PCR Cyt CS HT% PLT 103/lL UREA mg/dL CREATININE mg/dL TPg/dL A/G
1 1/160 j j 40 470 28 0.6 7.3 0.8
2 1/320 j ND 38 223 26 0.5 6.6 1.0
3 1/320 j j 44 195 33 1.3 6.7 1.2
4 1/160 j j 40 337 24 0.6 7.2 0.9
5 1/320 j j 38 258 49 1.4 6.8 1.0
6 1/160 j N 41 452 29 0.7 6.6 0.6
7 1/160 j N 37 350 26 1.2 5.8 1.0
8 1/160 j ND 42 364 44 1.1 7.3 1.2
9 1/160 j N 38 433 46 0.9 7.4 0.7
10 1/160 j N 46 267 36 1.2 6.9 1.3
11 1/80 j j 45 482 34 0.7 7.4 0.9
12 1/160 j j 37 400 41 0.5 6.0 1.0
13 1/80 j ND 49 353 43 1.1 7.3 0.9
14 1/320 j⁄ N 40 450 17 0.8 7.0 0.8
15 1/640 j j 38 180 24 1.0 5.5 1.4
16 1/160 j N 39 181 49 1.0 7.3 0.9
17 1/640 j ND 38 236 21 0.8 6.9 1.1
18 1/80 j N 39 241 39 1.0 5.2 1.0
19 1/80 j N 42 231 23 0.5 6.8 1.2
20 1/80 j N 40 221 27 0.6 7.4 1.0
21 1/80 j ND 39 253 48 1.0 7.2 0.9
22 1/80 j N 50 177 34 0.6 7.0 1.5
23 1/80 j j 45 268 25 0.7 7.6 0.8
LD – S dogs
1 1/1280 j j j 34 123 21 0.6 6.6 1.0
2 1/1280 j j j 36 280 45 1.2 9.0 0.5
3 1/160 j j j 35 100 55 1.4 9.2 0.5
4 1/1280 j⁄ ND 48 311 57 0.7 8.7 1.0
5 1/2560 j j j 47 107 65 0.7 8.1 0.7
6 1/320 j j 38 130 22 0.9 7.1 0.8
7 1/320 j j j 45 268 27 1.0 9.4 0.5
8 1/80 j j 35 275 32 1.0 9.6 0.5
9 1/10240 j j j 33 425 35 0.9 9.4 0.5
10 1/80 j j j 40 255 40 0.6 8.1 0.5
11 1/640 j ND j 36 410 50 0.5 6.0 1.0
12 1/1280 j j j 33 216 156 3.2 8.7 0.5
13 1/1280 j j j 45 378 28 0.9 9.4 0.5
14 1/640 j j j 57 450 31 0.6 9.1 0.5
15 1/320 j ND j 42 337 34 0.8 9.0 0.5
16 1/2560 j j j 31 277 37 0.9 8.9 0.4
17 1/2560 j⁄ j j 33 200 56 0.8 10.3 0.3
18 1/10240 j j j 23 58 49 0.6 12.7 0.3
19 1/1280 j N j 41 148 61 1.5 6.1 0.3
20 1/160 j j j 41 308 38 0.8 10.2 0.4
21 1/80 j j j 34 96 21 0.7 8.0 0.7
22 1/320 j⁄ N j 43 384 41 1.0 7.2 0.7
LD – A dogs, Leishmania asymptomatic dogs; LD – S dogs, Leishmania symptomatic dogs; IFAT, indirect ﬂuorescent antibody test; PCR, polymerase chain reaction on bone
marrow (lymph node and peripheral blood ⁄, 4 dogs); Cyt, lymph nodes or bone marrow cytology; CS, Clinical signs. The squares indicate the positivity for each speciﬁc test
and the presence of any clinical sign (alopecia, dermatitis, skin ulcers, ocular lesions, conjunctivitis, onychogryphosis, weight loss and lymphadenopathy); ND, not deter-
mined; N, negative; HT, hematocrit (anemia: HT value < 37 %); PLT platelet count (thrombocytopenia: platelets count < 150 103/lL); UREA, increase of urea > 50 mg/dL;
CREATININE, increase of creatinine > 1.5 mg/dL; TP, total protein (increase of total proteins >7.7 g/dL); A/G, albumin/globulin ratio (hyperglobulinemia: A/G < 0.6).
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processing. In addition, serum aliquots were obtained from all
the dogs enrolled for the study of their biochemical proﬁle and
serological examination.
2.4. Serological diagnosis
Detection of anti-Leishmania IgG antibodies was performed by
an in-house IFAT assay using L. infantum promastigotes (WHO ref-
erence strain MHOM/TN/1980/IPT-1) as antigen and following the
protocol recommended by the Ofﬁce International des Epizooties
(Gradoni and Gramiccia, 2008). Samples were classiﬁed as positive
if promastigote cytoplasmatic or membrane ﬂuorescence was ob-
served at a serum dilution of 1:80 or higher.
2.5. Molecular diagnosis
To perform a nested-PCR assay for Leishmania spp. DNA was
obtained from bone marrow. In 4 animals, due to lack of bonePlease cite this article in press as: Cortese, L., et al. Regulatory T cells, Cytotox
Leishmania infantum. Res. Vet. Sci. (2013), http://dx.doi.org/10.1016/j.rvsc.2013marrow specimens, lymph nodes aspirates and peripheral blood
were used as DNA source for nested-PCR assay. Brieﬂy, the ﬁrst
ampliﬁcation was carried out in a 50 ll reaction containing
10 lL DNA and 40 lL PCR Master Mix (Promega) with 50 pmol
of the kinetoplastid-speciﬁc primers R221 and R332 of the
small-subunit rRNA gene (van Eys et al., 1992). For the second
ampliﬁcation, 3 lL of the ﬁrst PCR product were added to
47 lL of PCR Master Mix (Promega) containing 50 pmol of the
Leishmania-speciﬁc primers R223 and R333 of the same gene
(van Eys et al., 1992). The nested-PCR product was 358 bp. For
the E. canis nested-PCR assay, DNA was extracted from periphe-
ral blood, bone marrow and/or lymph nodal aspirate material.
Brieﬂy, the ﬁrst PCR was performed in a 25 lL reaction contain-
ing 5 lL of DNA template with 12.5 pmol of primer set of uni-
versal fD1 and Ehrlichia genus-speciﬁc EHR16SR. These primers
can amplify the ehrlichial 760 bps partial sequence of the
16SrRNA gene (Inokuma et al., 2001). For the second ampliﬁca-
tion, 5 lL of the ﬁrst PCR product were added to 20 lL of PCRic T lymphocytes and a TH1 cytokine proﬁle in dogs naturally infected by
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CANIS and GA1UR of the same gene (Inokuma et al., 2001). The
nested-PCR product was 409 bps. The ampliﬁcation products
were analysed by 1.5% agarose gel and visualized under UV light.2.6. Monoclonal antibodies, immunoﬂuorescence and ﬂow cytometry
Peripheral blood from each dog was employed as whole blood
sample to evaluate the number of CD3+CD4+, CD3+CD8+ and CD4+-
Foxp3+ T cells by immune-ﬂuorescence technique and ﬂow cytom-
etry analysis. Fluorescein isothiocyanate (FITC), Phycoerythrin (PE),
Cy-chrome and Allophycocyanin (APC) labelled monoclonal anti-
bodies (mAb) against dog CD3, CD4, CD8, and isotype-matched
controls were purchased from Serotec Ltd, London, UK. Intracellu-
lar detection of Foxp3 was performed using a cross-reactive, di-
rectly conjugated murine Foxp3 antibody (Clone FJK-16s,
eBioscience, San Diego, CA) and the permeabilisation buffer pro-
vided by the detection Kit (Foxp3 Staining Set, eBioscience), as
described (Biller et al., 2007). Foxp3 staining was carried out on
Peripheral Blood Mononuclear Cells (PBMC) puriﬁed by Ficoll (Sig-
ma–Aldrich, St. Louis, MO) density gradient centrifugation, as
described (Biller et al., 2007). CD8+ and CD4+ T cell subsets were al-
ways identiﬁed by a combination of canine speciﬁc anti-CD3 to-
gether with anti-CD4 or anti-CD8 mAbs. A typical phenotype
analysis strategy is shown in Fig. 1.
To analyze the production of IFN-c and IL-4, puriﬁed PBMC
were cultured overnight (ON) in presence of Phorbol 12-Myristate
13-Acetate (PMA) and Ionomycin, all purchased from Sigma–Al-
drich. This approach has been widely described as useful in theFig. 1. Flow cytometry analysis strategy for phenotype studies. Panel A and B refer typi
Leishmania infected animal, respectively; C–E Panels show the analysis strategy employed
shown, T cell region (deﬁned by CD3 staining as R1) has been employed to identify th
allowed the identiﬁcation of the CD4+Foxp3+ Treg subset. D–H Panels show a typical an
Please cite this article in press as: Cortese, L., et al. Regulatory T cells, Cytotox
Leishmania infantum. Res. Vet. Sci. (2013), http://dx.doi.org/10.1016/j.rvsc.2013study of established cytokine proﬁle in human and animal models
(Terrazzano et al., 2005; Papadogiannakis et al., 2009; Olsen and
Sollid, 2013). Intracellular staining with the mAbs recognising
dog IFN-c, IL-4 or isotype-matched controls (Serotec) was per-
formed by a ﬁxing/permeabilization kit (Caltag, Burlingame, CA),
following the manufacturer’s instructions. To avoid extracellular
cytokine export, the cultures were incubated in the presence of
5 lg/ml of Brefeldin-A (Sigma–Aldrich), as described (Terrazzano
et al., 2005; Papadogiannakis et al., 2009).
All phenotypes referred to ﬂow cytometry analysis of the lym-
phocyte population gated by using Forward Scatter (FSC) and Side
Scatter (SSC) parameters, as well as CD45 labelling. Flow cytometry
and data analysis were performed by using a two laser equipped
FACScalibur apparatus and the Cell Quest analysis software (Becton
Dickinson, Mountain View, CA).2.7. Statistical analysis
Statistical analysis was performed by Mann–Whitney test
(GraphPad Prism, San Diego, CA, USA). Results were considered sig-
niﬁcant at p < 0.05.3. Results
3.1. Leishmania infected dogs show a signiﬁcant increase in peripheral
CD8+ T cells
First of all, we focused our investigation on the distribution of
helper (CD4+CD3+) and cytotoxic (CD8+CD3+) T lymphocytes incal staining proﬁles for CD4+ T and CD8+ T cells obtained in a healthy control and a
to identify CD4+Foxp3+ Treg subset in PBMC sample obtained from a control dog. As
e CD4+ T cell subset (R2); in this region the presence of Foxp3 transcription factor
alysis for CD4+Foxp3+ Treg subset in a Leishmania infected dog.
ic T lymphocytes and a TH1 cytokine proﬁle in dogs naturally infected by
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to the presence (LD-S) or absence (LD-A) of clinical signs of disease
and/or clinicopathological abnormalities, as well as to the IFAT ti-
ter (1:80-1:160; LD-L or >1:160; LD-H). In order to maintain the
biological complexity of immune subsets, we used immunoﬂuores-
cence and multi-parametric ﬂow cytometry detection. Fig. 1 shows
a typical phenotype analysis strategy. The study has been per-
formed on whole blood or on the bulk of PBMC and the distinct cell
subsets have always been deﬁned by co-expression of CD3 mole-
cule, strictly dependent on the presence of a functional T cell
Receptor (TCR). As shown in Fig. 2-A, Leishmania infected dogs
(LD) are characterised by signiﬁcant increase (p < 0.0001) of the
percentage of cytotoxic T cell effectors (CD8+CD3+) compared with
healthy controls (67.47 ± 1.85 in LD vs 44.2 ± 2.5 in healthy con-
trols). This observation has been conﬁrmed by the signiﬁcant
decrease of the percentage (31.94 ± 2.05 in LD vs 55.76 ± 2.36 in
controls; p < 0.0001) of CD4+CD3+ T cell subset (Fig. 2-C). No signif-
icant differences have been observed considering the occurrence of
a High versus Low IFAT titer (LD-H vs LD-L) as well as the presence
of a symptomatic versus an asymptomatic disease (LD-S vs LD-A).
Panels B and D of the Fig. 2 show the comparison of the cell count
obtained in the different animal groups. As shown, the signiﬁcant
increase in CD8+CD3+ T cells (1224 ± 135 in LD vs 366.9 ± 17 in
controls; p < 0.0001) is conﬁrmed in all the disease subgroups in
comparison with healthy control animals (Fig. 2-B). The data on
CD4+CD3+ T cells showed a signiﬁcant decrease (564.5 ± 55.6 inCTR LD LD-H LD-L LD-S LD-A
CTR LD LD-H LD-L LD-S LD-A
p<0.0001
p<0.0001
p<0.0001
p<0.0001
p<0.0001
p<0.0001
p<0.0001
p<0.0001
p<0.0001
p<0.0001
Fig. 2. Signiﬁcant increase of CD8+ T lymphocyte subset characterises Leishmania infected
in peripheral blood of healthy animals (CTR; white column); Leishmania infected dogs (
column); infected animals with an IFAT titer 1:80–1:160 (LD-L left striped column); infec
showing asymptomatic disease (LD-A cross-lined column); Panel C and D refer percent
categorised as previously indicated. Statistical analysis has been performed by using Ma
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parison with controls in all the LD animals, except the LD-A
sub-group (Fig. 2-D) in which no signiﬁcant differences have been
observed with controls (701 ± 59 in LD-A vs 731 ± 26.19 in healthy
animals). Notably, a slight no signiﬁcant increase in the number of
CD3+ lymphocytes have been observed in the Leishmania infected
animal in comparison with controls (data not shown).
Fig. 3 shows that a signiﬁcant difference (0.53 ± 0.04 in LD vs
1.83 ± 0.15 in controls; p < 0.0001) in the CD4+/CD8+ ratio charac-
terises our cohort of Leishmania infected animals. This observation
has been conﬁrmed in all the sub-groups of Leishmania infected
animals, regardless of the IFAT titer or the occurrence of a symp-
tomatic versus asymptomatic disease.
3.2. A reduced level of regulatory T cells and an increase in interferon-c
producing T lymphocytes characterises Leishmania infected dogs
Fig. 4 refers to the comparative analysis of Treg level in the
peripheral blood of the pathological cohort and control group. As
shown, signiﬁcant reduction of the percentage of Treg (Fig. 4-A)
in the peripheral blood of the Leishmania infected cohort has been
observed (5.39 ± 0.72 in LD vs 7.17 ± 0.63 in controls; p < 0.05). As
shown, the reduced Treg percentage signiﬁcantly correlates with
the occurrence of a high IFAT titer (4.35 ± 0.95 in LD-H vs
7.17 ± 0.63 in controls; p < 0.01). Notably, when the Treg count
was analysed in the pathological cohort versus controls (Fig. 4-B),CTR LD LD-H LD-L LD-S LD-A
CTR LD LD-H LD-L LD-S LD-A
p<0.0001
p<0.0001
p<0.0001
p<0.0001
p<0.0001
p<0.05
p<0.05
p<0.05
p<0.05
dogs. Panel A and B refer percentage and count (106/L) of CD8+CD3+ lymphocytes
LD; grey column); infected animals with an IFAT titer > 1:160 (LD-H; right striped
ted animals showing symptomatic disease (LD-S; pointed column); infected animals
age and count (106/L) of CD4+CD3+ lymphocytes in peripheral blood of the dogs
nn–Whitney test. P values are indicated only for signiﬁcant comparisons.
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p<0.0001
p<0.0001
p<0.0001
p<0.0001
p<0.0001
Fig. 3. CD4+/CD8+ ratio is signiﬁcantly reduced in Leishmania infected dogs.
Referred values have been observed in peripheral blood of healthy animals (CTR;
white column); Leishmania infected dogs (LD; grey column); infected animals with
an IFAT titer > 1:160 (LD-H; right striped column); infected animals with an IFAT
titer 1:80–1:160 (LD-L left striped column); infected animals showing symptomatic
disease (LD-S; pointed column); infected animals showing asymptomatic disease
(LD-A cross-lined column); Statistical analysis has been performed by using Mann–
Whitney test. P values are indicated only for signiﬁcant comparisons.
6 L. Cortese et al. / Research in Veterinary Science xxx (2013) xxx–xxxthe difference appeared more consistent, regardless of the patho-
logical subgroup considered (12.74 ± 1.59 in LD vs 27.79 ± 1.94 in
controls; p < 0.0001; 13.28 ± 2.3 in LD-H; p < 0.001; 11.80 ± 1.2 in
LD-L; p < 0.0001; 12.78 ± 2.16 in LD-S; p < 0.0005; 12.77 ± 1.18 in
LD-A; p < 0.0001). Unlike CD4 + Treg that are largely deﬁned by
the expression of Foxp3, Foxp3 expression in CD8 + clones was
not correlated with their suppressive activity (Hu et al., 2012,
2013). In this study, we checked for Foxp3 expression CD8+ effec-
tors, but very faint expression was observed in both controls and
Leishmania infected dogs (data not shown).
The cytokine proﬁle has been largely described as relevant for
Leishmania spreading control (Chamizo et al., 2005; Carillo and
Moreno, 2009; Boggiatto et al., 2010). In order to assess whether
the immunological proﬁle by us described (high CD8+CD3+ T lym-
phocytes and reduced Treg cells), might be related with theCTR LD LD-H LD-L LD-S LD-A
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Fig. 4. Signiﬁcant reduction of percentage and Treg count have been observed in Le
CD4+CD3+Foxp3+ (Treg) cells in healthy animals (CTR; white column); Leishmania infecte
striped column); infected animals with an IFAT titer 1:80–1:160 (LD-L left striped colum
animals showing asymptomatic disease (LD-A cross-lined column); Statistical analysis
signiﬁcant comparisons.
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Leishmania infantum. Res. Vet. Sci. (2013), http://dx.doi.org/10.1016/j.rvsc.2013induction of a speciﬁc cytokine proﬁle in T lymphocytes, we ana-
lysed the IFN-c and IL-4 production in T lymphocytes of LD animals
as compared with healthy controls by immunoﬂuorescence and
ﬂow cytometry detection. The analysis has been performed after
an ON culture of PBMC, isolated from the peripheral blood of the
animals, with Medium or PMA plus Ionomycin. This experimental
approach is expected to allow the analysis ex vivo of the cytokine
proﬁle acquired by the T cells in vivo (Terrazzano et al., 2005; Ol-
sen and Sollid, 2013). As shown in Fig. 5, the percentage of TH1 T
cells (speciﬁcally producing IFN-c and negative for IL-4) in LD ani-
mals is signiﬁcantly increased as compared with controls (p < 0.05)
regardless of the grouping criteria used. No signiﬁcant difference
between the controls and the infected cohort was observed in
the basal production of IFN-c, detected in Medium cultures.4. Discussion
In our report we describe a signiﬁcant increase of CD8+CD3+ T
lymphocytes and TH1 T cells (IFN-c+IL-4-CD3+ lymphocytes)
accompanied by a signiﬁcant reduction of Tregs lymphocytes in a
cohort of Leishmania infected dogs regardless of the IFAT titer or
the occurrence of clinical symptomatic disease.
Reduced percentage of CD4+ T cells has been described in CL,
suggesting that CD8-dependent IFN-c production and lysis of in-
fected-macrophages can mediate protective immunity during the
disease (Guarga et al., 2000). Increased number of CD8+ T effectors
has been referred to preferentially characterise asymptomatic ani-
mals (Reis et al., 2006, 2009). In addition, higher counts of T lym-
phocytes, mainly due to increased CD8+ T lymphocytes and
accompanied by a decreased CD4+/CD8+ ratio, were described to
characterise asymptomatic animals with positive serology and po-
sitive molecular results (Coura-Vital et al., 2011). Furthermore, the
relevance of variations in the percentage of CD3+ and CD4+ T cells
in mildly and severely infected dogs has been highlighted (Miranda
et al., 2007) while prolonged allopurinol monotherapy was ob-
served to improve the number of circulating CD4+ T cells, but not
to restore their number to within the normal range (Papadogianna-
kis et al., 2010).
Our results indicate that increase of CD8+ T cells, in presence of
normal levels of T lymphocytes can be observed in CL, regardless of
the IFAT titer or the presence of clinical signs of disease. SuchCTR LD LD-H LD-L LD-S LD-A
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Fig. 5. Signiﬁcant increase of IFN-c+IL-4-CD3+ T lymphocytes characterises Leish-
mania infected dogs. Referred values have been observed in peripheral blood of
healthy animals (CTR; white column); Leishmania infected dogs (LD; grey column);
infected animals with an IFAT titer > 1:160 (LD-H; right striped column); infected
animals with an IFAT titer 1:80–1:160 (LD-L; left striped column); infected animals
showing symptomatic disease (LD-S; pointed column); infected animals showing
asymptomatic disease (LD-A cross-lined column); Statistical analysis has been
performed by using Mann–Whitney test. P values are indicated only for signiﬁcant
comparisons.
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control of intracellular-parasites (Guarga et al., 2000; Reis et al.,
2006, 2009; Miranda et al., 2007; Coura-Vital et al., 2011).
A complex network of peripheral mechanisms, co-evolved to
prevent or dampen immune-mediated diseases, usually accounts
for the regulation of the activation, expansion and recruitment of
T cell effectors in the infected microenvironment. Regulatory sys-
tems include mechanisms intrinsic to the antigen activation and
T cell differentiation as well as those mediated by regulatory sup-
pressor immune-populations, as represented by the Treg subset.
The involvement of such regulatory network is of critical relevance
in the presence of infectious agents usually associated with chronic
diseases, as represented by Leishmania. To investigate on such is-
sue, we focused the complex network of regulatory/effector T cell
populations in a cohort of 45 Leishmania infected dogs, categorised
according to their IFAT titer and the occurrence of a symptomatic
versus asymptomatic disease. In order to analyse T cell behaviour,
maintaining the biological complexity of the immune-regulatory
networks, we chose to analyse T cells in the whole blood samples
or in the bulk PBMC preparations, by using immune ﬂuorescence
and multi parametric ﬂow cytometry detection.
Our data consistently indicate CD8+ T effector cells as a key
effector population in CL. Thus the critical role for adaptive immu-
nity in clearing intracellular parasites (Reis et al., 2006, 2009) has
been conﬁrmed in our model. Moreover, our results indicate that
in active CL an inﬂammatory response, characterised by increased
levels of CD8+ T cells and TH1 T cells, might be sustained by a de-
crease of Treg. Thus, parasite persistence could maintain adaptive
cytotoxic and pro-inﬂammatory response by reducing Treg-depen-
dent mechanisms. Several observations, particularly on the murine
cutaneous leishmaniasis model, demonstrated that TH1 and TH2 re-
sponses via their signatory cytokines, IFN-c, and IL-4 respectively,
were counter-regulatory. However, later studies using gene-deﬁ-
cient mice have questioned the precise role of the TH2 response
and IL-4 in regulating the TH1 response. Depending on the parasite
strain/species/host model studied the TH2 response could either
promote infection or at best be irrelevant to disease progressionPlease cite this article in press as: Cortese, L., et al. Regulatory T cells, Cytotox
Leishmania infantum. Res. Vet. Sci. (2013), http://dx.doi.org/10.1016/j.rvsc.2013(Alexander and Brombacher, 2012). The presence of reduced Tregs
represents a key mechanism to optimise T cell activation and effec-
tor functions in the presence of persistent infection. Tregs have
been described to modulate recruitment and activation of immune
effectors (Sakaguchi, 2005). Thus, in active CL, Treg could hamper
inﬂammatory responses required for infection clearance, in such
way exacerbating the risk that the unbridled parasite growth could
lead to severe disease. On the contrary, Treg recruitment in in-
fected tissues might prevent the onset of severe immune-mediated
pathology. Thus, ﬁne tuning of immune regulatory networks is of
critical relevance to avoid immune pathology and protect host
against pathogens. Such intriguing scenario could underlie im-
mune-mediated pathology, likely accounting for the presence of
immune-mediated auto-immune processes, very common in this
parasitic disease (Kharazmi et al., 1982; Ferrer, 1992; Terrazzano
et al., 2006; Solano-Gallego et al., 2009; Cortese et al., 2009,
2011). These data may provide new insights into the pathogenesis
of immune-mediated alterations associated with CL. Further stud-
ies are in progress in order to more speciﬁcally address such issue.
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TCR triggeringReactive oxygen species (ROS) behave as secondmessengers in signal transduction for a series of receptor/ligand
interactions. A major regulatory role is played by hydrogen peroxide (H2O2), more stable and able to freely dif-
fuse through cell membranes. Copper–zinc superoxide dismutase (CuZn-SOD)-1 is a cytosolic enzyme involved
in scavenging oxygen radicals to H2O2 and molecular oxygen, thus representing a major cytosolic source of per-
oxides. Previous studies suggested that superoxide anion and H2O2 generation are involved in T cell receptor
(TCR)-dependent signaling. Here,we describe that antigen-dependent activation of humanT lymphocytes signif-
icantly increased extracellular SOD-1 levels in lymphocyte cultures. This effectwas accompanied by the synthesis
of SOD-1-speciﬁc mRNA and by the induction of microvesicle SOD-1 secretion. It is of note that SOD-1 increased
its concentration speciﬁcally in T cell population, while no signiﬁcant changes were observed in the “non-T” cell
counterpart. Moreover, confocal microscopy showed that antigen-dependent activationwas able tomodify SOD-
1 intracellular localization in T cells. Indeed, was observed a clear SOD-1 recruitment by TCR clusters. The ROS
scavenger N-acetylcysteine (NAC) inhibited this phenomenon. Further studies are needed to deﬁne whether
SOD-1-dependent superoxide/peroxide balance is relevant for regulation of T cell activation, as well as in the
functional cross talk between immune effectors.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
T cell activation is a complex phenomenon in which intracellular
signals, mediated by the engagement of TCR, are integrated by a variety
of ligand/receptor interactionswhose outcome is toﬁnely tune antigen-
dependent T cell response [1]. T lymphocytes play a pivotal role in the
orchestration of the immune response and TCR-mediated signaling is
a critical event to properly channeling the immune response and to ob-
tain pathogen control and self-tolerance [2].ina Clinica e Chirurgia, Università
l.: +39 081 7463225; fax: +39
cienze Mediche Traslazionali,
1 Napoli, Italy. Tel.: +39 081
uggie@unina.it (G. Ruggiero).
ights reserved.Several studies have been suggesting that TCR-dependent T cell
activation induces ROS production [3–5]. Different enzymatic sources,
such as the mitochondrial respiratory chain [6], lipooxygenases,
NADPH oxidases NOX2 and DUOX1 [7,8], have been described to con-
tribute to ROS generation upon TCR triggering. In the light of these ob-
servations, the involvement of multiple anti-oxidant enzymes in ﬁne
tuning of antigen-dependent T cell response can be hypothesized.
TCR stimulation generates both H2O2 and superoxide anion [8,10]
and antioxidant enzymes speciﬁc for H2O2 enhance and/or prolong
TCR-dependent ERK activation, while those speciﬁc for superoxide
anion have no effect [11].
ROS include oxygen superoxide, hydrogen peroxides, hydroxyl
radicals and peroxides. They represent a normal product of cellular
metabolism and play relevant roles in innate defense against pathogens
[12]. Several receptor/ligand interactions, as represented by TGF-beta
[13], insulin [14], angiotensin II [15] and EGF [16] have been correlated
to the presence of ROS. In this context, ROS appear to act as key second
messenger regulating several crucial cellular responses, as protein ki-
nase activation, gene expression and cell proliferation/apoptosis [17].
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half-life). It is electrically neutral and it can diffuse inside the cell and
freely through cell membranes. In addition, H2O2 can be rapidly gen-
erated and easily scavenged by numerous mechanisms, thus sharing
several features with well-known second messengers [18–20].
SOD molecules mediate scavenging of ROS, to H2O2 and molecular
oxygen. They belong to a large family of isoenzymes that mediate
cellular response to oxidative stress and represent the main enzy-
matic source of peroxides [21]. All mammalian cells express both
the intra-mitochondrial Mn-SOD and the cytosolic dimeric CuZn-SOD
(SOD-1), while the tetrameric extracellular CuZn-SOD isoenzyme
seems to be selectively expressed by speciﬁc cell populations
[22,23]. Hyperoxia and copper availability accelerate both the syn-
thesis and activity of Cu,Zn SOD [24]. Signiﬁcant control of ROS sig-
naling depends on its spatially restricted production at intracellular
sites, where redox-regulated signal occurs [25]. In this context, SOD-1
recruitment has been described in redox-dependent TNF-alpha and
IL-1 receptor-induced endosomes [26,27]. In addition, SOD-1 associates
with Rac-1-regulated NADPH oxidase complexes in different mouse
tissues and cell lines [28].
SOD-1 may be released in vitro by ﬁbroblasts, hepatocytes [29],
human neuroblastoma cells [30] and Sertoli cells [31]. The extracellular
release of such enzyme is related to speciﬁc stress conditions [32].
ER/Golgi involvement in SOD-1 secretion has been described
[33–36], while it is unclear how this cytosolic protein can be targeted
into the ER/Golgi network.
SOD-1 is constitutively secreted by microvesicles in some cell
lines through an ATP dependent mechanism [37]. The intracellular
increase of the enzyme can be observed in neuroblastoma SK-N-BE
cells when they are exposed to oxidative stress [37]. Recently, it
has been shown that SOD-1 secretion is induced by high level of ex-
tracellular K+ in GH3 rat pituitary cells [38] and that the enzyme in-
teracts with membrane of neuroblastoma SK-N-BE cells activating a
phospholipase/protein kinase C pathway, able to increase intracellu-
lar calcium [39,40].
Receptor–ligand interactions, involving members of hematopoietin
receptor super family and EGF, have been described to mediate extra-
cellular H2O2 generation [41,42]. Moreover, exogenously added H2O2
is able to induce signals in the absence of ligands, whereas catalase
is able to inhibit such effect [43,44]. A role for SOD-1 in modulating
ROS-dependent intra-cellular and inter-cellular signaling might be
hypothesized.
Communication between immune cells involves the secretion of
several proteins, like the cytokines, and the presence of their recep-
tors on neighboring cells. This type of intercellular “dialog”may involve
the release of membrane vesicles, like exosomes. These vesicles can
affect cell physiology inducing intracellular signaling and conferring
them new biological properties [45,46]. Peripheral blood human T
cells, T cell clones and Jurkat T cells are able to release microvesicles
in the culture medium. The microvesicle production is ﬁnely regulated
and, notably, it increases upon TCR triggering [47].
In previous papers, we showed that cytosolic SOD-1 is secreted by
several cell types [29,30,37] and it is also released in primary lym-
phoid organs, as represented by human thymus [48]. These observa-
tions suggest a paracrine role for SOD-1.
Multiple cytokines have been observed to regulate the expression
of the tetrameric form of extra-cellular SOD-1 [49], while no data are
available on the role of dimeric, cytosolic SOD-1 in functional adaptive
immune effectors. Therefore, the role for SOD-1 in ROS-dependent sig-
naling as well as in the communication between immune effectors
needs to be addressed.
This study is aimed to investigate whether cytosolic SOD-1might be
part of themolecular network involved in TCR triggering.With this pur-
pose SOD-1 intracellular level and localization, as well as SOD-1
microvesicle secretion have been investigated in TCR-triggered human
T lymphocytes.2. Material and methods
2.1. Cells
Peripheral blood mononuclear cells (PBMCs) were isolated from
10 healthy donors, after informed consent, by centrifugation of pe-
ripheral blood on Ficoll-Paque cushion (GE Healthcare, Uppsala,
Sweden) gradient. T cells have been isolated from PBMC by using a
negative isolation kit (Invitrogen Corporation, Carlsbad, CA, USA)
and following the manufacturer's instructions. PBMC or T cells
(1 × 106/ml) were cultured in 96 well ﬂat-bottomed plates (Falcon)
in RPMI 1640 medium with 2% FCS (Invitrogen, Carlsbad, CA, USA).
TCR triggering was performed by anti-CD3 mAb (Becton Dickinson,
Mountain View, CA, USA) at 5 ng/ml or by using anti-CD3/anti-
CD28 beads (Invitrogen), at 0.3 bead/cell. This activation strategy
has been largely demonstrated to mimic antigen-dependent T cell
triggering. To analyze TCR-dependent SOD-1T cell export, distinct
experiments were performed in the presence of Brefeldin-A, (BFA)
at 5 μg/ml or of 1 mM methylamine, all purchased from Sigma-
Aldrich (Milan, Italy), as described [37]. Cell viability was evaluated
by using Propidium Iodide (PI) (Sigma-Aldrich) labeling and ﬂow cy-
tometry detection [37] as well as by analyzing lactate dehydrogenase
(LDH) activity in culture supernatants by using the Roche Molecular
Biochemical LDH kit (Mannheim, Germany). Written informed con-
sent (model n. 5526 of Azienda Ospedaliera Universitaria “FEDERICO
II”) was obtained from each donor at the time of venous peripheral
blood donation. All the experiments done by using blood donations
were performed and analyzed anonymously, without any biograph-
ical reference to donors.
2.2. ELISA
The quantitative detection of human SOD-1 in medium of cultured
PBMC was carried out using the Bender Med System kit (Bender
Med System Diagnostic, Vienna, Austria), as described [37]. Results
were always normalized for total protein content of the tested sample.
SOD-1 ELISA detection has been always performed on culture superna-
tants immediately frozen at −80 °C. Protein concentrations were de-
termined according to the method of Lowry et al. [50] using BSA, as
standard.
2.3. RNA preparation, semi-quantitative RT-PCR and DNA sequencing
Analysis of SOD-1 speciﬁc RNA has been performed, as described
[51]. Brieﬂy, total RNA was extracted with High Pure RNA isolation kit
(Roche Italia, Milano, Italia), according to the manufacturer's instruc-
tions. Traces of contaminated DNA were removed with DNAse I treat-
ment. Quantiﬁcation was achieved in a single reaction by using the
housekeeping β-actin gene as internal standard. To rule out genomic
DNA contamination we performed a negative control that contained
RNA instead of cDNA. The signal intensities of PCR products were sepa-
rated on a 1.2% agarose gel and were visualized by ethidium bromide
staining. The products' signal intensitieswere determined by computer-
ized densitometric analysis using Fotoplot software. The expression of
SOD-1 was normalized to β-actin mRNA levels. To check the speciﬁcity
of the ampliﬁed products, DNA bands were eluted from the gel and pu-
riﬁed; sequence analysis was determined by the Big Dye Terminator
Cycle Sequencing method (ABI-PRISM Sequencer 310 Perkin-Elmer).
2.4. Microvesicle isolation and western blotting for SOD-1 detection
To purify the membrane microvesicle-containing fraction, superna-
tants were collected immediately after culture and treated, as described
[52]. Brieﬂy, they were sequentially centrifuged at 500 g for 15 min to
remove cellular debris and again at 10,000 g for 20 min. The obtained
supernatant was collected and further centrifuged at 100,000 g for
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the enriched membrane vesicle fraction. Western blotting analysis of
the puriﬁedmaterial was performed as previously described [37]. Com-
parative analysis of SOD-1 was performed by using 40 μg of total
proteins.
2.5. Immunoﬂuorescence and ﬂow cytometry analysis
Intracellular SOD-1 contentwas evaluated anti-SOD-1mAb and FITC
labeled anti-mouse IgG secondary antiserum (Sigma-Aldrich) staining
of permeabilized cells and immunoﬂuorescence technique. A commer-
cial ﬁxing/permeabilization kit, purchased from Becton Dickinson was
always employed, following the manufacturer's instructions. For the
analysis of SOD-1 content in distinct cell subsets and to evaluate T cell
activation after TCR triggering, co-staining with FITC, PerCP or APC la-
beled anti-CD3, anti-CD45 and anti-CD69 mAb was performed. Labeled
antibodies and isotype-matched controls were purchased from Becton
Dickinson. T cell staining and activation were performed by anti-CD3
mAb recognizing different CD3 epitopes. Cell death was always less
than 5% as evaluated by using PI (Sigma-Aldrich) staining. Immunoﬂu-
orescence, ﬂow cytometry and data analysis were performed by using a
two laser equipped Becton–Dickinson FACSCalibur ﬂow cytometer and
the Cell Quest analysis software.
2.6. Fluorescence microscopy
PBMC or puriﬁed T cells (0.5 × 106) were adhered to polylysine-
coated glass slides for 16–18 h at 37 °C.When indicated, the above pop-
ulationswere stimulated with anti-CD3mAb CLB-CD3/4E at 1:100 asci-
tes dilution or anti-CD3/anti-CD28 beads (at 0.3 bead/cell) and 1 mM
NAC [53]. Cells were incubated at 37 °C and immediately ﬁxed with
3% paraformaldehyde solution. Fixed cells were incubated with FITC la-
beled anti-CD3 and anti-human Cu,Zn SOD-1 rabbit antibody (Santa
Cruz Biotechnology, CA, USA) for 45 min in a humidiﬁed chamber,
washed three times with PBS and incubated with Alexa Fluor 594-
conjugated goat anti-rabbit secondary antibody (Molecular Probes,
Life Technologies) for additional 45 min at 37 °C in the same conditions.
After 3 washes with PBS the glass slides were mounted using a 50% so-
lution of glycerol in PBS and examined with a Zeiss LSM 510 confocal
microscope with a 63× oil immersion objective (N.A. 1,4) at room tem-
perature. Pictures were taken from selected ﬁelds of control and treated
samples.
2.7. Cell to cell aggregate evaluation
To evaluate cell aggregation, PBMCs were cultured in 96 wells ﬂat
bottomedmicrotiter plates (Falcon) in the presence of Medium, anti-
CD3 and 1 mM NAC (Sigma-Aldrich), as indicated. This NAC concen-
tration was demonstrated in preliminary experiments to completely
block ROS formation, as described [54]. Contrast phase microscopy
analysis was performed with a Leitz DIAVERT microscope with a
10× objective at room temperature. Pictures were taken from selected
ﬁelds by using a digital Nikon Coolpix Camera. NAC treatment was un-
able to signiﬁcantly affect T cell viability and proliferation, as evaluated
by PI staining after 1 to 5 h of culture and 3H thymidine incorporation
after 72 h of culture. Quantiﬁcation has been performed by counting
the number of cell aggregates (identiﬁed by the presence of at least 8
clustered cells) in the cell culture of 1 × 105 PBMC plated on the ﬂat-
bottomed microtiter wells.
2.8. Statistical analysis
Statistical evaluation of data, by InStat 3.0 software (GraphPad
Software Inc., San Diego, California, USA), has been performed by
means of the Mann–Whitney test or Paired t test, as indicated.Two-sided p values of less than 0.05 were considered to indicate sta-
tistical signiﬁcance.
3. Results
3.1. TCR triggering induces both intracellular increase and BFA-dependent
secretion of SOD-1 in human T lymphocytes
To investigate whether antigen-dependent T cell activation in-
duces SOD-1 production and extracellular secretion, we measured
the release of this enzyme in supernatants of PBMC cultured from
15 min to 18 h in presence of Medium alone or with anti-CD3 mAb,
that induces the TCR triggering mimicking antigen-dependent activa-
tion of T lymphocytes. As shown in Fig. 1A, human PBMC cultures se-
creted small amount of SOD-1 that remained substantially stable from
15 min till to 18 h of culture. Anti-CD3 treatment slightly, but signiﬁ-
cantly (p b 0.05), increased such basal secretion. The increment was
detectable after 4 h of culture and reached the highest level after 18 h
of activation. This effect was independent on cell damage, always eval-
uated by PI labeling (Fig. 1B) and signiﬁcantly correlated with TCR-
dependent activation, as revealed by the up-regulation of the activation
molecule CD69 (Fig. 1C). Therefore, TCR-triggering was associated with
the induction of SOD-1 secretion in human lymphocytes.
To ascertain whether such secretionwas sustained by up-regulation
of SOD-1 gene transcription, we analyzed SOD-1 speciﬁc mRNA. As
shown in Fig. 2, an increase of more than 70% of SOD-1 speciﬁc
mRNA has been observed in the cultures treated with anti-CD3
mAb as compared with resting cells. Therefore, antigen-dependent
T cell activation induced SOD-1 secretion that was sustained by the
increase of SOD-1 transcription in the whole PBMC population.
To evaluate whether SOD-1 export might be part of micro-vesicle
production upon TCR triggering, we puriﬁed the micro-vesicle frac-
tion from the supernatants of 18-hour cultures of PBMC and puriﬁed
T cells. TCR triggering of PBMCwas performed with anti-CD3mAb. In
order to mimic costimulatory signals, usually mediated by accessory
cells, a combination of anti-CD3/anti CD28 beads was used to fully
activate puriﬁed T cells, as described [1]. Fig. 3 shows western blot-
ting analysis of SOD-1 in the enriched membrane vesicle fractions.
Fig. 3A–B reports one representative experiment, while Fig. 3C refers
the analysis of data obtained in all the six experiments performed in
PBMC cultures. The comparison revealed the occurrence of a mean
25% increase of SOD-1 content in the enriched membrane vesicle
fraction obtained from anti-CD3 treated lymphocytes (p b 0.01). As
shown, in the enriched membrane vesicle fraction isolated from
anti-CD3/anti-CD28 treated T cells, a more consistent increase of
SOD-1 content was observed (Fig. 3D–F). Indeed, a mean increase
N120% of SOD-1 content was evidenced in three experiments per-
formed with puriﬁed T lymphocytes (p b 0.05).
To investigate whether other cell populations, present in PBMC,
contribute to SOD-1 production and secretion in response to TCR-
triggering, we analyzed intra-cellular SOD-1 levels in the T cell sub-
set and in the “non-T” counterpart in a mixed context. This evalua-
tion was performed by the combination of immune ﬂuorescence
and ﬂow cytometry detection, to preserve the biological complexity
of antigen-dependent T cell response and allow speciﬁc detection of
SOD-1 in the T cell subset and in “non-T” population (Fig. 4A). As
shown (Fig. 4B), very low amount of intracellular SOD-1 was ob-
served in all the “resting” lymphocytes (T and non-T cells).
After TCR-triggering, the up-regulation of SOD-1 intracellular level
was observed only in T lymphocytes if compared to non-T cells (Region
1 versus Region 2 in Fig. 4C).
To investigate the pathway involved in SOD-1 secretion, we ana-
lyzed intracellular SOD-1 retention in T cells in the presence of BFA
(Fig. 4D) or methylamine (Fig. 4E) described to block ER/Golgi intracel-
lular network and cell endocytosis, respectively [51,52]. In this regard,
BFA but not methylamine treatment induced signiﬁcant increase of
Fig. 1. SOD-1 concentration in anti-CD3 triggered cultures of human lymphocytes. (A) SOD-1 amount in supernatants of PBMC cultured in the presence ofMedium (black squares) or anti-
CD3 (white squares). SOD-1 concentrations were analyzed in undiluted samples by using ELISA assay; results were normalized for total protein content of the tested sample. Each point
refers mean value obtained in ﬁve independent experiments; error bars indicate SEM. * indicates the occurrence of statistically signiﬁcant (p b 0.05) higher SOD-1 concentration in anti-
CD3 treated cultures. (B and C) PI and CD69 labeling of PBMC cultured O.N. withMediumor anti-CD3, as indicated. Results refer to one of ﬁve independent experiments. As shown (B), no
signiﬁcant differences have beenobserved in PI staining proﬁles of PBMC culturedwithMediumand anti-CD3; (C) CD69 stainingproﬁle (bold line) of PBMCculturedwithMediumor anti-
CD3, as indicated; broken line indicates isotype control; as shown, activated PBMCs were characterized by signiﬁcant increase of the activation molecule CD69.
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levels of SOD-1 were observed in “non-T” cell population, in the same
experimental conditions (Fig. 4F). Notably, none extracellular SOD-1 in-
crease was detected by ELISA in anti-CD3 cultures incubated with BFA
(data not shown).
Fig. 4G–I reports the statistical comparisons of SOD-1 intracellular
amount in PBMC (Fig. 4G), in T cells (Fig. 4H) and “non-T” cells
(Fig. 4I), as evaluated by considering themean ﬂuorescence intensity
(MFI) values obtained in all the 4 experiments performed. As shown,
no signiﬁcant changes in SOD-1 levels were observed in the absence of
TCR triggering. Thus, SOD-1 amount was strictly dependent on antigen-
mediated T cell activation. Indeed, anti-CD3 treatment signiﬁcantlyFig. 2.Anti-CD3 treatment induces signiﬁcant increase of SOD-1mRNA inhuman lympho-
cytes. (A) Densitometric arbitrary units ratio between SOD-1 and beta actin in Medium
and anti-CD3 treated cultures. Results refer one of ﬁve independent experiments. mRNA
was measured by RT-PCR, as detailed in Material and methods section. (B) Comparative
analysis of SOD-1 mRNA percent increase in all the ﬁve experiments performed. For
each experiment mRNA amount in Medium cultured PBMC was considered the reference
value (100) for calculation of percent increase in the anti-CD3 treated culture. As shown, a
mean increase of more than 70% of SOD-1 speciﬁc mRNA has been observed in anti-CD3
treated PBMC. Error bars indicate SEM. Statistical analysis has been performed by using
Paired t test.increased SOD-1 intracellular level (p b 0.005) in thewhole lympho-
cyte population (Fig. 4G). This effect speciﬁcally characterized the T
cell subset (p b 0.005; Fig. 4H), while no differences were observed
in the “non-T” population (Fig. 4I). Moreover, the block of ER/Golgi
network, mediated by BFA treatment, was observed to mediate signiﬁ-
cant (p b 0.05) intra-cellular SOD-1 retention only in T lymphocytes
(Fig. 4H). Similar results have been obtained by anti-CD3/anti-CD28
triggering of puriﬁed T cells (data not shown). As control, intracellular
accumulation of Interferon-gamma was speciﬁcally detected in TCR
triggered cultures treated with BFA (not shown).
3.2. TCR and SOD-1 co-localize and cluster after TCR-triggering in human T
cells
We analyzed SOD-1 and TCR cellular localization by confocal mi-
croscopy after 2 min of culture in the presence of Medium alone or
with anti-CD3. Fig. 5 shows TCR and SOD-1 co-staining after 2 min
of culture with Medium alone (Fig. 5A) or anti-CD3 (Fig. 5B and C).
As expected, the homogeneous surface TCR distribution observed
in resting T cells (Fig. 5A) was completely changed by anti-CD3 trigger-
ing (Fig. 5B and C). Indeed, signiﬁcant TCR clustering (Fig. 5B and C)
characterized activated T cells. SOD-1 staining revealed a quite homoge-
neous intracellular distribution of the enzyme in resting T cells; staining
proﬁles also conﬁrmed the presence of SOD-1 at very low levels in
human T lymphocytes (see Fig. 4).
Notably, confocal microscopy revealed that TCR triggering was
able to induce a clustered distribution of SOD-1 enzyme (Fig. 5B
and C). Merged images clearly showed that TCR clusters have been
recruiting intracellular SOD-1, whose localization strictly reﬂected
TCR distribution (Fig. 5B and C). TCR/SOD-1 co-localization disap-
peared 20 min after anti-CD3 treatment (not shown). To preserve
the physiological complexity, we chose to perform the analysis in
PBMC population as a whole and we identiﬁed T cells by labeling
with speciﬁc antibodies. In this model, TCR triggering is allowed by
the physiological cross talk between T cells and autologous antigen
Fig. 3. TCR-dependent T cell activation increases SOD-1 containing microvesicle secretion by human T lymphocytes. (A) Flow cytometry analysis of PBMC population. As shown, T lym-
phocytes (CD3+ cells) represent less than 85% of the total population; (B) western blot of enrichedmembrane vesicle fractions, isolated from culture supernatants of Medium (white col-
umn) and anti-CD3 treated PBMC (gray column), as detailed inMaterial andmethods section. Densitometric analysis shows increased presence of SOD-1 in TCR triggered PBMC. Results
refer one representative experiment of the six performed; (C) Analysis of percent increase of SOD-1 containing microvesicle in supernatants derived from anti-CD3 treated PBMC in six
experiments. For each experiment, SOD-1 amount inMedium cultured PBMCwas considered the reference value (100) for calculation of percent increase in the anti-CD3 treated culture.
As shown, a mean increase of 25% was observed in themicrovesicle-enriched fraction obtained from the supernatants of anti-CD3 treated PBMC. (D) Flow cytometry analysis of a typical
puriﬁed T cell population isolated by using negative selection strategy, as indicated in theMaterial andmethods section. As shown, T lymphocytes (CD3+ cells) representmore than 98% of
the total population; (E)western blot of enrichedmembrane vesicle fractions, isolated from culture supernatants ofMedium(white column) and anti-CD3/antiCD28 treated T cell cultures
(gray column), as detailed inMaterial andmethods section. Densitometric analysis shows increased presence of SOD-1 in the sample obtained from TCR triggered T cells. Results refer one
representative experiment of the three performed; (F) analysis of percent increase of SOD-1 containingmicrovesicle in supernatants derived from anti-CD3/anti-CD28 treated T lympho-
cytes in three experiments. For each experiment, SOD-1 amount in Medium cultured T cells was considered the reference value (100) for calculation of percent increase in the anti-CD3/
anti-CD28 treated cultures. As shown, an increase of more than 120% was observed in the microvesicle enriched fraction obtained from the supernatants of anti-CD3/anti-CD28 treated
puriﬁed T cells. Error bars indicate SEM. Western blot comparative analysis of SOD-1 has been always performed on aliquots of enriched microvesicle fractions containing 40 μg of
total proteins. Statistical analysis has been performed by using Paired t test.
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decoupled from SOD-1 co-localization. No signiﬁcant changes in
SOD-1 intracellular localization were observed in “non-T” popula-
tion after anti-CD3 triggering (not shown). Notably, SOD-1/TCR in-
tracellular co-clustering was observed also in anti-CD3/anti-CD28
triggered puriﬁed T cells (not shown).
To investigate whether SOD-1/TCR co-localization in anti-CD3 ac-
tivated T cells is dependent on ROS bioavailability, we performed ex-
periments in the presence of the ROS scavenger NAC at 1 mM
concentration. In this condition, TCR clustering was signiﬁcantly re-
duced (from 70 to 95% in NAC/anti-CD3 co-cultures). As shown,
NAC signiﬁcantly inhibited both TCR and SOD-1 clustered localiza-
tion (Fig. 5D). Indeed, TCR was homogeneously distributed on cell
membrane, similarly to what was observed in resting condition(Fig. 5A). SOD-1 co-staining in anti-CD3/NAC treated lymphocytes
also resembled basal images with the presence of small areas of faint
cytosolic accumulation (Fig. 5D). Merged images revealed a clear-cut
distinct distribution of TCR and SOD-1 in anti-CD3/NAC treated T cells.
Thus, ROS availability signiﬁcantly affected activation-dependent
TCR/SOD-1 re-localization in human T cells.
To ascertain whether ROS availability might also affect the cell-
to-cell aggregation dependent on TCR triggering, we analyzed the ef-
fect of NAC incubation on early cell clustering (usually detectable
after 45 min of incubation with anti-CD3). As shown in Fig. 6, anti-
CD3-sitimulation was able to induce cell aggregation after 1 h of
treatment (Fig. 6C). Such effect became more evident after 3 h of in-
cubation (Fig. 6G). Anti-CD3/NAC co-treatment severely impaired
anti-CD3 induced cell clustering after 1 h of incubation (Fig. 6D).
Fig. 4. Signiﬁcant increase of intracellular SOD-1 and BFA-dependent SOD-1 export can be speciﬁcally demonstrated in anti-CD3 triggered human T cells. (A) Gating criteria for the iden-
tiﬁcation of the “T cell subset” (R1) and of the “non-T population” (R2) in a PBMC culture; (B) SOD-1 staining proﬁle of T cells (bold line) and “non-T population” (plain line) in O.N. Me-
dium cultured PBMC. Dotted lines show the isotype control. As shown, similar, very low amount of intracellular SOD-1 characterizes both population. (C) SOD-1 staining proﬁle of T cells
(bold line) and “non-T population” (plain line) in anti-CD3 culturedPBMC.Dotted lines show the isotype control. As shown, speciﬁc increase of SOD-1 intracellular content can beobserved
in the T cell subset (bold line) as comparedwith the “non-T” counterpart (plain line); (D) SOD-1 staining in T cell population (R1) culturedwith anti-CD3 alone (plain line) or in the pres-
ence of BFA (bold line). Dotted lines show the isotype control. As shown, anti-CD3/BFA co-culture increases intracellular SOD-1 content in T cell population. (E) SOD-1 staining in T cell
population (R1) cultured with anti-CD3 alone (plain line) or in the presence of methylamine (bold line). Dotted lines show the isotype control. As shown, no signiﬁcant changes in
SOD-1 intracellular levels can be observed in anti-CD3/methylamine co-cultures. (F) SOD-1 staining proﬁles of “non-T population” (R2) in anti-CD3 cultures (plain line), in BFA/anti-
CD3 co-cultures (bold line) or in methylamine/anti-CD3 cultures (broken line). Dotted lines show the isotype control. As shown, no signiﬁcant changes in SOD-1 intracellular content
have been observed. Results refer one of 4 independent experiments. (G–I) Column graphic reports the means of SOD-1 ﬂuorescence intensities observed in 4 independent experiments
in thewhole PBMCpopulation (G), in the T cells (H) and in the “non-T” population (I). White columns indicate SOD-1 levels in cells, cultured as indicated; gray columns indicate SOD-1 in
BFA co-treated cultures; striped columns refer SOD-1 in methylamine co-treated cultures.
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gates, identiﬁed by the presence of at least 8 clustered cells, in the
microtiter wells. Comparative analysis showed a cell aggregate inhi-
bition of 83.64 ± 1.62 in anti-CD3/NAC co-treated cultures in 6 inde-
pendent experiments; (p b 0.05). This inhibition was transient and
progressively decreased, likely mirroring the ROS scavenging activity
of NAC. Indeed, after 3 h of NAC/anti-CD3 incubation a percentage of
clustering inhibition of 55.35 ± 2.23 was observed in 6 independent
experiments (Supplementary Table S1). The inhibiting effect of NAC
co-incubation completely disappeared after 6 h of anti-CD3/NAC co-treatment. NAC co-incubation was unable to mediate signiﬁcant effects
on cell viability and proliferation (not shown).
4. Discussion
This study revealed that SOD-1 is part of the network of mole-
cules involved in antigen-dependent T cell response. SOD-1 was re-
cruited by antigen triggered TCR and its intracellular content was
speciﬁcally upregulated in human T cells after 16–18 h of anti-CD3
incubation. Moreover, SOD-1 was secreted by a BFA-dependent
Fig. 5. Anti-CD3 triggering induces ROS-dependent TCR and SOD-1 co-clustering in activated lymphocytes. (A) Confocal microscopy image of CD3 (green) and SOD-1 (red) in resting T
cells. A homogeneous, distinct, membrane and intracellular distribution of the TCR and SOD-1 can be appreciated. (B and C) After 2 min of anti-CD3 treatment a clustered distribution
of TCR can be observed (white arrows). SOD-1 distribution becomes strongly clustered and resembles that of TCR (white arrows). This cell re-localization is better showed in panel C
where a single cell has been focused. Merged images show that TCR clusters recruit intracellular SOD-1, whose localization strictly reﬂects TCR distribution (white arrows). (D) anti-
CD3/NAC co-incubation induces a homogeneous TCR surface distribution. SOD-1 localization also resembles basal images, with the presence of small areas of faint cytosolic accumulation.
Merged images reveal a clear-cut distinct distribution of TCR and SOD-1.
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been observed maintaining the biological complexity of antigen-
dependent T cell response and conﬁrmed in puriﬁed T cells activated
by anti-CD3/anti-CD28 beads.
We showed that extra-cellular SOD-1 is increased in PBMC cultures
after anti-CD3 treatment. This effect was accompanied by both the
induction of SOD-1 mRNA and increase of SOD-1 containing micro-
vesicles in culture supernatants. Moreover, we identiﬁed the T cell
population as the speciﬁc target for SOD-1 induction and extra-
cellular export. Therefore, TCR-dependent activation behaves as a
triggering element for SOD-1 production and secretion by human T
cells.
SOD-1 production is induced in neuroblastoma SK-N-BE cells
after oxidative stress [30,37]. Moreover, other and our data showed
that cytosolic SOD-1 is secreted by many cell lines carrying out a
paracrine modulatory role [30,31,37] and SOD-1 extracellular export
was by us described in primary lymphoid organs [48].
Induction of extra-cellular export of SOD-1 after TCR-triggering
proposes a more complex physiological involvement of such enzyme
in T cell activation. In this study, we described that a BFA-dependent
secretion mechanism [54] characterized SOD-1 micro-vesicle inter-
cellular trafﬁcking upon antigen-dependent immune response. No
effect has been observed in the presence of methylamine that im-
pairs cell endocytosis [55]. Thus, a major involvement of endocytic
recycling pathways might be excluded. Such mechanism, previously
described in neuronal model [30–34,37], represents an intriguing
issue for further investigations.
SOD-1 is a cytosolic protein lacking signal peptide and consequently
considered to be excluded from ER translocation. The small amount ofwild type SOD-1 detected in ER–Golgi apparatus [36], does not support
the direct involvement of this organelles in SOD-1 secretion. Moreover,
the possible interference of BFA, a classical inhibitor of ER–Golgi depen-
dent protein secretion, in vesicular pathways not directly involving ER–
Golgi apparatus cannot be excluded. In this context, our data propose
that SOD-1 could be part of the micro-vesicle-dependent pathways
functioning as secondary messenger between immune cells [45–47].
A number of data indicate that exogenously addedH2O2 induced sig-
nals in the absence of ligands,whereas catalase is able to inhibit such ef-
fect [42,43,56]. Moreover, the observations that production of catalase
characterizes many pathogens [57] and that viral infection modulates
H2O2 production [58] conﬁrm themultiple roles played by extracellular
H2O2 in the activation processes of lymphocytes [59].
We consistently found that antigen-dependent T cell triggering
mediated changes in the intra-cellular localization of SOD-1 that
was observed to co-localize with clustered TCR. This event was
dependent on ROS availability since it was impaired by NAC co-
treatment. ROS production is an essential component in signaling
cascades that mediate actin cytoskeleton rearrangements. Small G
protein Rac, a key element in the network assembly of actin in
lamellipodia [60–62] participates in activation-dependent ROS pro-
duction by different cell types [63,64]. Moreover, Rac-mediated
ROS production results in the downmodulation of Rho activity thus
regulating cellular morphology and migratory behavior [65]. SOD-1
associates with Rac-1 regulated NADPH oxidase complexes in different
mouse tissues and cell lines [28]. In this context, massive ROS scaveng-
ing is expected to disrupt ROS-dependent regulation of cell contractility
and motility. This event could account for the TCR/SOD-1 intracellular
redistribution (Fig. 5). The impairment of early cell aggregation in
Fig. 6. NAC treatment inhibits early activation-induced aggregation of TCR triggered lym-
phocytes. Contrast phasemicroscopy images showing1 and 3 hour cultures of PBMC incu-
batedwithMedium (A and E), NAC (B and F), anti-CD3 (C and G) or anti-CD3 and NAC (D
andH). As shown, signiﬁcant cell aggregation is observed in anti-CD3 triggered cells. Lym-
phocyte clustering is signiﬁcantly inhibited in the anti-CD3/NAC co-treated cultures; (D)
after 1 h of incubation. Quantiﬁcation is performed by counting cell aggregates, identiﬁed
by the presence of at least 8 clustered cells. Comparative analysis (see Supplementary
Table S1) shows a 83.64 ± 1.62 inhibition of cell aggregates in anti-CD3/NAC co-treated
cultures in 6 independent experiments; (p b 0.05). (H) After a 3 hour period the
inhibiting effect of NAC treatment is observed to be lowered (55.35 ± 2.23 inhibition of
cell aggregates in 6 independent experiments). Quite normal clustering of anti-CD3 treat-
ed PBMC is observed at longer culture time in anti-CD3/NAC co-treated cells (not shown).
Results show one representative experiment of the six performed.
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hypothesis.
Compelling evidences indicate that ROS, together with their essen-
tial role in innate antimicrobial defense [12], are critically involved in
the regulation of antigen-dependent response of adaptive immune
effectors [10,11,66–69]. Exposure of T cells to oxidant agents, such
as pervanadate or H2O2, induces and/or enhances TCR signaling dur-
ing T cell activation [70–72]. TCR-dependent signaling generates
both superoxide anion and H2O2 that selectively regulate antigen-
dependent proliferation and Fas ligand expression by T effectors
[10]. An oxidative signal implies its tight regulation and transient
character. Thus, in the presence of multiple intracellular ROS sources
[6–9], the involvement of multiple anti-oxidant mechanisms in ﬁne
tuning of antigen-dependent T cell response can be hypothesized. In-
deed, Mn-SOD/SOD-2 a major mitochondrial antioxidative enzyme
has been consistently associated with T cell activation [73] and a
role of catalase, glutathione and thioredoxin has been also proposed
[74].
In the models of ROS generation upon stimulation of receptors it
has been shown that H2O2 is the relevant oxidant species that regu-
late signaling [18–20]. Notably, H2O2 has a short half-life in the re-
ducing environment of the cytosol, and it acts close to its site of
production. Thus, an important aspect of ligand-dependent TCR acti-
vation might be the rapid translocation of receptors to a source of
H2O2 or, vice versa, the clustering of such a source to the receptor.
To this regard, our data strongly support the hypothesis that SOD-1
intracellular localization in antigen-triggered T cells could provide
H2O2 generation in the cell compartment speciﬁcally involved in
tuning antigen-dependent signals.
A number of data suggested the role for H2O2 as key modulator of
protein phosphorylation on either serine–threonine and tyrosineresidues [75]. Indeed, all protein tyrosine phosphatases (PTPs) contain
an essential cysteine residue in the signature active enzyme site motif
that has been demonstrated to be target of speciﬁc H2O2 oxidation.
The H2O2-mediated inhibition of PTP activity is expected to result in a
shift of protein tyrosine kinases toward protein phosphorylation. The
involvement of SOD-1 in such regulatory pathways has been suggested
[76].
Our data on SOD-1 intracellular re-localization upon TCR-triggering
suggests that SOD-1 could directly modulate kinase/phosphatase ac-
tivity related to proximal TCR signaling. The evidence [10] that anti-
CD3 induced ERK phosphorylation requires H2O2 but is independent
on superoxide anion, strongly supports such hypothesis. Thus, sub-
cellular compartmentalization of H2O2 generating enzymes (like
SOD-1) could represent a relevant element in achieving the superoxide/
peroxide balance required to optimize antigen-dependent T cell response.
Taken in all, our data suggest that SOD-1 is part of the molecular
network involved in antigen-dependent T cell response. At the best
of our knowledge, this is the ﬁrst observation revealing a relation-
ship between SOD-1 secretion/intracellular re-localization and the
antigendependent T cell activation. Further studies are needed to inves-
tigate on the involvement of SOD-1 in the regulation of TCR signaling
cascades as well as in the functional cross talk between immune
effectors.
5. Conclusion
This study reports for theﬁrst time that SOD-1, amajor physiological
regulator of cytosolic superoxide/peroxide balance, is part of themolec-
ular network involved in antigen-dependent T cell activation. Indeed,
we observed: i. mRNA induction and increased levels of extra-cellular
SOD-1 containing micro-vesicles in anti-CD3 triggered cultures; ii. in-
crease of intra-cellular SOD-1 and BFA-dependent SOD-1 microvesicle
secretion in TCR-triggered T cells; iii. TCR/SOD-1 co-localizationwas ob-
served in anti-CD3 treated T cells.
Further studies are needed to establishwhether SOD-1 is involved in
modulating ROS-dependent intra-cellular and inter-cellular signaling in
antigen triggered human T cells.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2013.10.020.
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